

CANCER CARE SERVICES



Cancer Care Services



A/Prof. Glen Kennedy
Executive Director
Cancer Care Service MNHHS

Cancer Care Services (CCS) at RBWH continues to provide expert, highly skilled, evidence-based care to patients affected by cancer and non-malignant haematological conditions, including haemophilia. As a service committed to striving for excellence, our multidisciplinary research team is an integral part of ensuring the provision of cutting edge treatment to our patients. The Cancer Care research team includes the Allied Health Professions, Cancer Nursing Professorial Precinct, Medical Oncology, Radiation Oncology, and Haematology, including the Haemophilia Centre and Bone Marrow Transplant Unit. Research is considered core business within Cancer Care, and a vehicle to the facilitation of progressive treatment for our patients.


2018 represented another year of fantastic achievement in research for Cancer Care. The annual CCS Research Retreat brought together investigators from CCS and senior hospital and district executives to enable planning to ensure that research remains at the forefront of our service both now and into the future. Initiatives in tele-trials, HIRF collaborations and multi-disciplinary care trials were highlights for our unit during the year.

A special mention and congratulations to Prof Geoff Hill, who commenced the Director of Hematopoietic Stem Cell Transplantation at the Fred Hutch / Seattle Cancer Care Alliance in July 2018. He was also awarded the Jose Carreras / E. Donnell Thomas Endowed Chair for Cancer Research. His appointment to such a prestigious position is a great achievement for one of our colleagues and staff.

Other research highlights for the year are detailed in our separate departmental reports. Of note, Dr Siok Tey was awarded a MNHHS Research Fellowship for 2019, related to her ongoing work in cellular therapies for haematological disorders. Her work will continue to be supported through a successful New Technology Grant to commence in 2019.

We look forward to 2019 to continue to strive to further expand and embed research within CCS across all patient and disease groups, incorporating new and novel approaches to care within clinical, translational and basic science research programmes and partnerships, aiming to constantly improve clinical outcomes for our patients.

Clinical Research



A/Prof. Steven Lane
Director of Clinical Research
Clinical Haematologist
Cancer Care Services RBWH

RBWH Cancer Care Services has one of the largest and most active clinical research departments on the Herston Campus. We offer a large range of clinical trials encompassing haematology and bone marrow transplant, medical oncology, radiation oncology and non-malignant diseases such as haemophilia and blood clotting disorders. We have world leading nursing and allied health research operating in parallel, enriching our overall program and providing wholistic care for our patients.

The research division continues to perform at a very high level. Stand out achievements in 2018 include chief investigator funding for NHMRC and MRFF grants, the successful application for a Queensland Genomics Health Alliance Implementation grant to sequence blood cancers and a number of philanthropic/RBWH foundation grants. Special mention should also be made of Dr Siok Tey and Dr Clare Burns, who were among the 5 recipients of the inaugural round of Metro North Research Fellowships. RBWH CCS has led publications in major international journals such as Science, Blood, The Journal of Clinical Investigation, Nature Reviews in Clinical Oncology and Clinical Cancer Research, and our clinicians have co-authored papers in the New England Journal of Medicine and contributed to international practice guidelines. Numerous presentations at national and international conferences are also noted. The volume and quality of research contributions from Cancer Care has been outstanding and I congratulate all involved in this effort. In particular, I would like to mention the work of our clinical trial coordinators who keep the research program running smoothly behind the scenes. We value your efforts, patience and organisation.

Finally, I note the extraordinary contribution by Professor Geoff Hill, Director of Research RBWH CCS for the last 3 years. He has been recruited to the Fred Hutchinson Cancer Research Centre in Seattle as Full Member, and as the Director of Hematopoietic Stem Cell Transplantation for the Seattle Cancer Care Alliance. This is an outstanding recognition of Professor Hill's leading work in BMT over the last 20+ years and will provide pathways for future clinical collaborations and trainees. Geoff has been an amazing mentor and guiding light to many, including myself. On a personal note, I would like to thank him for his leadership, wisdom and humour, and wish him good luck on the journey ahead.

Name	Role	Department	Organisation
Tracey Gilbert	Research Support Officer	Cancer Care Services	Queensland Health

Haematology and Bone Marrow Transplant



Dr Cameron Curley
A/Deputy Director
Clinical Haematology and BMT
Cancer Care Services RBWH

During 2018, the department of Haematology/BMT continued to pursue a comprehensive approach to clinical research at the RBWH and across Metro North. Disease stream leads and clinics continued to be developed with the establishment of Myeloma and Lymphoma clinical trials clinics to drive recruitment, efficiency and expertise in local investigator initiated and collaborative national and international trials for patients diagnosed with Myeloma and Lymphoma.

Major funding grants attained in 2018 include:

- NHMRC grant 2019-2021 (\$900k)
- QLD Genomics Health Alliance Implementation Grant 2019-2020 (\$800k)
- RBWH Foundation Diamond Grant 2018-2019 (\$40k).

There have been a number of notable publications, poster and oral presentations at national and international meetings during this year particularly in the areas of Novel approaches to Haploidentical allogeneic stem cell transplantation (HSCT), Graft Versus Host Disease, relapsed disease post HSCT, prediction of mortality post allogeneic BMT, impacts of mutations in AML, unique insights into the biology of graft versus leukemia effects post BMT, genetic mechanisms underlying chemo-resistance in acute leukaemia and the journey of the HSCT donor.

Notable collaborations in 2018 included a number of trials with the Australia Leukaemia and Lymphoma Group, QIMR Berghofer, UQCCR, Herston Imaging Research Facility and the department of Dietetics.

Supervised Post-Graduate Research Students

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Ashleigh Scott	MPhil, UQ (2017-2019)	Targeting translocator protein to improve diagnostic accuracy in gastrointestinal graft versus host disease	Glen Kennedy, Siok-Keen Tey
Andrea Henden	PhD, UQ (2014-2018) <i>Submitted</i>	Interferon in bone marrow transplantation	Geoff Hill
Nienke Zomerdijs	PhD, UQ (2015-2019)	The psychosocial impact of donating haematopoietic stem cells on adult related donors	Jane Turner, Geoff Hill
Rebecca Austin	PhD, UQ <i>Submitted</i>	Immune responses in leukaemia	Steven Lane
Victoria Ling	PhD, UQ	Chemotherapy resistance in leukaemia	Steven Lane
William Godfrey	Hons, UQ	Chemotherapy resistance in leukaemia	Steven Lane
Simone Minnie	PhD, UQ (2015-2018)	Immunotherapy of myeloma	Geoff Hill
Andrew Wilkinson	PhD, UQ (2015-2019)	Understanding IL-6 signalling in GVHD	Geoff Hill
Paulo Martins	PhD, UQ (2015-2018)	The immunological mechanisms of CMV reactivation after BMT	Geoff Hill
Kate Markey	MPH (Monash 2016-2018)	Clinical Research Methods	N/A

2018 Research Positions: Coordinators, Fellow, Adjunct and Honorary Positions

Name	Type of Fellowship	Research Program	University (years)
Steven Lane	<p>2017-19 Treasurer, Haematology Society of Australia and New Zealand</p> <p>2017-22 Councilor, Haematology Society of Australia and New Zealand</p> <p>2018- Metro North Research Committee</p> <p>2018- Head of Cancer Program, QIMR Berghofer Medical Research Institute</p> <p>2018- Head, Cancer Theme, Brisbane Diamantina Health Partners</p> <p>2018- RBWH Research Committee member</p> <p>2015 – 2018 RBWH Haematology Research Coordinator</p>		
Andrea Henden	2013- Senior Lecturer		The University of Queensland, Faculty of Medicine
Geoff Hill	Senior Clinical Research Fellowship		Queensland Health
Geoff Hill	Honorary Practitioner Research Fellow Level 2, Laboratory Head, Principal Research Fellow		NHMRC
Kate Markey	Junior Research Fellow	Post BMT microbiome and infectious diagnostics	Queensland Health
Robyn Western	Manager, Clinical Trials Unit	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Carolyn Little	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Jessica Kelly	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Kate Stark	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Katie Matthews	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Tricia Pusztai	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Kiara Mason	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Madonna Fuery	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Michelle deBock	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Renee Campbell	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Sinead Harvey	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Angela Wotherspoon	Clinical Trial Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Nicola Quirk	Senior Administration Officer	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Nienke Zomerdijs	Research Coordinator	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health
Sharon Milne	Senior Administration Officer	Clinical Trials Unit Haematology/Bone Marrow Transplant	Queensland Health

2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Andrea Henden	Geoff Hill, Glen Kennedy, Simon Durrant, Jason Butler, Ashish Misra, Siok Tey, Elango Subramonia-Pillai, Cameron Curley	A phase I / II study of pegylated-Interferon-2alpha for relapsed haematological malignancy after allogeneic haematopoietic progenitor cell transplantation (HPCT)
Ashleigh Scott	Glen Kennedy, Siok Tey, Paul Thomas, David Pattison	Pilot study of ¹⁸ FGE-180-PET to assess acute gastrointestinal graft <i>versus</i> host disease
Ashleigh Scott	Leo Francis	Histological features and anti-TSPO immunohistochemistry (anti-TSPO IHC) in acute gastrointestinal graft <i>versus</i> host disease (GI-GVHD)
Cameron Curley	Haem Staff	JNJ AML 2002 – clinical trial of DACOGEN (Decitabine) Plus JNJ-56022473 (Anti CD123) Versus DACOGEN (Decitabine) Alone in Patients with AML
Cameron Curley	Haem Staff	Celgene MDS-006 FUSION – clinical trial in CC-486 (Oral Azacitidine) Alone in Combination With Durvalumab (MEDI4736) in Subjects With Myelodysplastic Syndromes
Geoff Hill	Haem Staff	PCYC 1140-IM ICON Integrate – clinical trial of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)
Geoff Hill	Haem Staff	IL-17 – observational study of IL-17-related cytokines in stem cell transplantation
Geoff Hill	Haem Staff	TREG Apheresis – developing a method to generate regulatory T cells from healthy donors
Geoff Hill	Haem Staff	IR Auto – observational study of immune reconstitution in patients undergoing autologous stem cell transplantation
Geoff Hill	Haem Staff	IR Allo – Observational study of immune reconstitution following stem cell transplantation
Glen Kennedy	Haem Staff	Janssen VCAT – clinical trial of Bortezomib Consolidation (With Thalidomide and Prednisolone) Vs Thalidomide and Prednisolone Alone in Previously Untreated Subjects With Multiple Myeloma
Glen Kennedy	Haem Staff	ALLG AML M16 – clinical trial of Sorafenib in Combination with Intensive Chemotherapy for Previously Untreated Adult FLT3-ITD Positive AML
Glen Kennedy	Haem Staff	ALLG AML NBCR M18 – National Blood Cancer Registry
Glen Kennedy	Haem Staff	Amgen Onyx Endeavor – clinical trial of Carfilzomib Plus Dexamethasone vs Bortezomib Plus Dexamethasone in Patients with Relapsed Multiple Myeloma
Glen Kennedy	Haem Staff	Celgene IDHENTIFY – clinical trial of Orally Administered AG-221 Versus Conventional Care Regimens in Subjects with Isocitrate Dehydrogenase 2 Mutation Positive Acute Myeloid Leukemia
Glen Kennedy	Haem Staff	Sabrina – clinical trial of rituximab subcutaneous in combination with CHOP or CVP versus rituximab IV in combination with CHOP or CVP in follicular lymphoma
Jason Butler	Haem Staff	Acerta Ace-ly308 ECHO – clinical trial of Bendamustine and Rituximab alone Versus in Combination with Acalabrutinib in Mantle Cell Lymphoma
Jason Butler	Haem Staff	ALLG ALL NHL 29 – clinical trial of Ibrutinib, Rituximab and mini-CHOP therapy in very elderly patients with newly diagnosed DLBCL
Jason Butler	Haem Staff	Amgen Candor 275 – clinical trial of Carfilzomib, Dexamethasone, and Daratumumab to Carfilzomib and Dexamethasone for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Jason Butler	Haem Staff	Novartis REACH 2 – clinical trial of ruxolitinib vs. best available therapy in patients with corticosteroid-resistant acute graft vs. host disease after allogeneic stem cell transplantation
Kirk Morris	Haem Staff	Pomalidomide – "Real world" review of efficacy and safety of pomalidomide in Australian patients with relapsed refractory myeloma
Nick Weber	Paul Thomas, Samuel Kyle, Glen Kennedy, Kirk Morris, Simon Gray	Pilot study of ⁶⁸ Ga-Pentixafor positron emission tomography (PET) imaging in multiple myeloma
Nicholas Weber	Haem Staff	AMaRC Janssen – clinical trial of bortezomib, cyclophosphamide and dexamethasone induction (VCD) compared with VCD and daratumumab induction followed by daratumumab maintenance (VCDD) for the initial treatment of transplant ineligible patients with multiple myeloma

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Nicholas Weber	Haem Staff	Beta-lactam PK/PD in febrile neutopenia (Patient population: patients undergoing intensive chemotherapy with anticipated duration of neutropenia >7 days)
Nicholas Weber	Haem Staff	Tolerability of early enteral feeding during allogeneic haematopoietic progenitor cell transplantation: a randomized comparison with 'standard' parenteral nutritional support
Nienke Zomerdijs	Jane Turner, Geoff Hill, David Gottlieb	The psychosocial impact of HSC donation on adult related donors
Nienke Zomerdijs	Jane Turner, Geoff Hill, David Gottlieb	Evaluation of a psycho-educational resource to support adults who are donating stem cells to a family member
Simon Durrant	Haem Staff	Abbvie M14-031 BELLINI – clinical trial of Bortezomib and Dexamethasone in Combination with Either Venetoclax or Placebo in Subjects with Relapsed or Refractory Multiple Myeloma
Simon Durrant	Haem Staff	Gilead SIMPLIFY – clinical trial of Momelotinib vs Ruxolitinib in Subjects with Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Simon Durrant	Haem Staff	Pfizer Ski Extension B1871040 – ICON – Bosutinib treatment extension study for patients with chronic myeloid leukemia
Simon Durrant	Haem Staff	Novartis Response – clinical trial of JAK inhibitor INC424 tablets verSus bEst available care in Polycythemia
Simon Durrant	Haem Staff	Novartis Response 2 – clinical trial of ruxolitinib versus best available therapy in patients with polycythemia vera
Simon Durrant	Haem Staff	HELIOS CMV – clinical trial of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Simon Durrant	Haem Staff	Gilead NIAGRA 119 – clinical trial of Idelalisib (GS-1101) in Combination with Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Simon Durrant	Haem Staff	Comfort Rollover – clinical trial of patients who have completed a prior global Novartis or Incyte sponsored ruxolitinib (INC424) study and are judged by the investigator to benefit from continued treatment
Simon Durrant	Haem Staff	ROBIN BDM3502 – clinical trial of Bendamustine compared to physician's choice in the treatment of NonHodgkin's Lymphoma
Simon Durrant	Haem Staff	Amgen Blincyto 292 Verdi – clinical trial comparing Blinatumomab to Standard of Care
Simon Durrant	Haem Staff	Novartis Harmony – clinical trial of Ruxolitinib (INC424) and BKM120 in patients with Myelofibrosis
Steven Lane	Haem Staff	APML5 – clinical trial of oral arsenic in AML
Steven Lane	Haem Staff	AML M21: Sorafenib and azacitidine in AML
Steven Lane	Haem Staff	AML genomic analysis

2018 Research Awards and Achievements

Recipient	Award	Event
Ashleigh Scott	RBWH Research Postgraduate Scholarship 2018 (\$40,000)	To perform research activities in 2018
Ashleigh Scott	RBWH Research Postgraduate Scholarship 2019 (\$44,000)	To perform research activities in 2019
Nienke Zomerdijs	UQ Faculty of Medicine Travel Scholarship (\$1,600)	To support research activities in 2018
Nienke Zomerdijs	UQ HDR Candidate Development Award (\$4,000)	To support research activities in 2018
Nienke Zomerdijs	Best Oral Presentation	UQ Clinical and Public Health Symposium

2018 Research Grants – Awarded

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Ashleigh Scott	Haematology/BMT	Pilot study of ¹⁸ FGE-180-PET to assess acute gastrointestinal graft versus host disease	RBWH Foundation Diamond Care Grants	\$20,000	\$40,000 (2017-2018)
Ashleigh Scott	Haematology/BMT	Histological features and anti-TSPO immunohistochemistry (anti-TSPO IHC) in acute gastrointestinal graft versus host disease (GI-GVHD)	Pathology Queensland Study, Education and Research Committee	\$1,494	\$2978.16 (2017-2018)
Ashleigh Scott	Haematology/BMT	Using novel brain imaging to define mechanisms of persisting central nervous system toxicity ("Chemobrain") following allogeneic progenitor cell transplantation	RBWH Foundation Diamond Care Grants	\$20,000	\$40,000 (2018-2019)
Geoff Hill	Director of Research – CCS RBWH	Immunological therapies for cancer, chronic infection and autoimmunity	NHMRC Program grant: APP1071822	\$359,506	\$1,797,530 (2015-2019)
Geoff Hill	Director of Research – CCS RBWH		NHMRC senior Principal Research Fellowship	\$187,780	\$938,900 (2016-2020)
Nienke Zomerdijs	Haematology/BMT	The psychosocial impact of donating haematopoietic stem cells on adult related donors	Australian Postgraduate Award	\$26,000	\$78,000 (2015-2018)
Nienke Zomerdijs	Haematology/BMT	The psychosocial impact of donating haematopoietic stem cells on adult related donors	RBWH Foundation Diamond Cancer Care Grant	\$2,500	\$5,000 (2017-2018)
Nienke Zomerdijs	Haematology/BMT	The psychosocial impact of donating haematopoietic stem cells on adult related donors	RBWH Foundation Top Up Scholarship	\$8,000	\$16,000 (2017-2018)
Siok Tey	Haematology/BMT	The interplay between IL-6 and GVHD on anti-viral and anti-leukemic immunity	NHMRC Project Grant	\$163,125	\$489,376 (2016-2018)
Steven Lane	Haematology/BMT	Targeting Leukaemia Stem cells through inhibition of telomerase	NHMRC Project Grant	\$219,000	\$657,000 (2016-2018)
Steven Lane	Haematology/BMT	The evolution of acute myeloid leukaemia through the in-situ transformation of haematopoietic stem cells	NHMRC Project Grant	\$215,667	\$647,000 (2016-2018)
Steven Lane	Haematology/BMT	Deciphering the overlapping roles of SSB1 and SSB2 in the regulation of haematopoiesis and intestinal homeostasis	NHMRC Project Grant	\$239,750	\$959,000 (2015-2018)
Steven Lane	Haematology/BMT	Genetic modelling of MPN progression	Cancer Australia	\$100,000	\$200,000 over 2 years
Steven Lane	Haematology/BMT	Understanding Chemoresistance in AML	CSL Centenary Fellowship	\$250,000	\$1.25m over 5 years

2018 Research Publications

Journal Articles:

- Zhang, P., Raju, J., Ullah, A., Au, R., Varelias, A., Gartlan, K., Olver, S. D., Samson, L. D., Sturgeon, E., **Zomerdijs, N.**, **Avery, J.**, Gargett, T., Brown, M. P., Coin, L., Ganesamoorthy, D., **Hutchins, C.**, **Pratt, G.**, Kennedy, G.A., Morton, A.J., Curley, C., Hill, G.R., & Tey, S.K. Phase I trial of iCasp9 T cells in adult stem cell transplant demonstrates massive clonotypic proliferative potential and long-term persistence of transgenic T cells. *Clinical Cancer Research*. *Accepted 4 December 2018*
- Forsyth, C.J., Chan, W., Cook, N.C., **Lane, S.W.**, Burbury, K.L., Perkins, A.C., Grigg, A.P., & Ross, D.M. Recommendations for the use of pegylated interferon-alpha in the treatment of classical myeloproliferative neoplasms. *Internal Medicine Journal*. *Published online 8 November 2018*. doi: 10.1111/imj.14154
- Jacquelin, S., Straube, J., Cooper, L., Vu, T., Song, A., Bywater, M., Baxter, E., Heidecker, M., Wackrow, B., Porter, A., Ling, V., Green, J., Austin, R., Kazakoff, S., Waddell, N., Hesson, L.B., Pimanda, J.E., Stegelmann, F., Bullinger, L., Döhner, K., Rampal, R.K., Heckl, D., **Hill, G.R.**, & **Lane, S.W.** Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation. *Blood*. *Published online 26 October 2018*. doi: 10.1182/blood-2018-04-846220

Journal Articles: (cont):

4. **Zomerdijsk, N., Turner, JM., & Hill, GR.** Adult-related haematopoietic stem cell donor experiences and the provision of information and psychosocial support: A systematic literature review. *European Journal of Cancer Care. Published online 2 October 2018.* doi: 10.1111/ecc.12932
5. **Scott, A., Weber, N.,** Tiley, C., Taylor, K., Taper, J., Harrison, S., Chan, K.L., Stark, R., Lee, C., **Morris, K.,** Ho, P.J., Dodds, A., Ramanathan, S., Ramakrishna, R., Watson, AM., Auguston, B., Kwok, F., Quach, H., Warburton, P., Rowlings P., & Mollee, P. Real world Australian experience of pomalidomide for relapsed/refractory myeloma. *Leukemia and Lymphoma. Published online 3 June 2018.* doi: 10.1080/10428194.2017.1387911
6. Bradford, NK., Henney, R., Walker, R., Walpole, E., **Kennedy, GA.,** Nicholls, W., Pinkerton, R. Queensland Youth Cancer Service: a Partnership Model to Facilitate Access to Quality Care for Young People Diagnosed with Cancer. *Journal of adolescent and young adult oncology. Published online 1 June 2018.* doi: 10.1089/jayao.2017.0080
7. Varelias, A., Bunting, MD., Ormerod, KL., Koyama, M., Olver, SD., Straube, J., Kuns, RD., Robb, RJ., **Henden, AS.,** Cooper, L., Lachner, N., Gartlan, KH., Lantz, O., Kjer-Nielsen, L., Mak, JYW., Fairlie, DP., Clouston, AD., McCluskey, J., Rossjohn, J., **Lane, SW.,** Hugenholtz, P., & **Hill, GR.** Recipient Mucosal-Associated Invariant T Cells control GVHD within the colon. *The Journal of Clinical Investigation. Published online 9 April 2018.* doi: 10.1172/JCI91646
8. Barge, L., Pahn, G., & **Weber, N.** Transient immune-mediated agranulocytosis following *Mycoplasma pneumoniae* infection. *BMJ Case Reports. Published online 1 April 2018.* doi: 10.1136/bcr-2018-224537
9. Li, XY., Das, I., Lepletier, A., Addala, V., Bald, T., Stannard, K., Barkauskas, D., Liu, J., Aguilera, AR., Takeda, K., Braun, M., Nakamura, K., Jacquelin, S., **Lane, SW.,** Teng, MW., Dougall, WC., & Smyth, MJ. CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. *Journal of Clinical Investigation. Published online 16 March 2018.* doi: 10.1172/JCI98769
10. **Markey, KA.,** Kuns, RD., Browne, DJ., Gartlan, KH., Robb, RJ., Martins, JP., **Henden, AS.,** Minnie, SA., Cheong, M., Koyama, M., Smyth, MJ., Steptoe, RJ., Belz, GT., Degli-Esposti, MA., **Lane, SW., & Hill, GR.** Flt-3L expansion of recipients CD8a+ dendritic cells deletes alloreactive donor T cells and represents an alternative to post-transplant cyclophosphamide for the prevention of GVHD. *Clinical Cancer Research. Published online 13 March 2018.* doi: 10.1158/1078-0432.CCR-17-2148
11. **Markey, KA.,** Gartlan, KH., Kuns, RD., **Lane, SW., & Hill, GR.** Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT. *Bone Marrow Transplantation. Published online 13 March 2018.* doi: 10.1038/s41409-018-0148-y
12. **Markey, KA.,** Gartlan, KH., Kuns, RD., **Lane, SW., & Hill, GR.** Conventional dendritic cells are required for the cross-presentation of leukemia-specific antigen in a model of AML relapse post-BMT. *Bone Marrow Transplantation. Published online 13 March 2018.* doi: 10.1038/s41409-018-0148-y
13. Straube, J., Ling, YV., **Hill, GR., & Lane, SW.** The impact of age, NPM1mut and FLT3ITD allelic ratio in patients with acute myeloid leukemia. *Blood. Published online 8 March 2018.* doi: 10.1182/blood-2017-09-807438
14. Catchpoole, EM., Thirunavukarasu, CE., Varelias, A., Schlebusch, S., Olver, S., **Zomerdijsk, N.,** Osland, E., **Kennedy, GA., Tey, SK., Hill, GR., & Markey, KA.,** Early Blood Stream Infection after BMT is Associated with Cytokine Dysregulation and Poor Overall Survival. *Biology of Blood and Bone Marrow Transplantation. Published online 5 March 2018.* doi: 10.1016/j.bbmt.2018.02.025
15. **Scott, AP., Tey, SK., Butler, J., & Kennedy, GA.** Diagnostic utility of endoscopy and biopsy in suspected acute gastrointestinal graft versus host disease (GI-GVHD) following haematopoietic progenitor cell transplantation (HPCT). *Biology of Blood and Marrow Transplantation. Published online 2 February 2018.* doi: 10.1016/j.bbmt.2018.01.034.

2018 Conference Presentations – Invited Speaker, Oral and Poster

Invited Speaker:

1. **Lane SW.** Genome editing to model the progression of blood cancers. Pathology Update: the annual scientific meeting of the Royal College of Pathologists of Australasia. March 2018, Sydney
2. **Lane SW.** In vivo modeling of disease progression in MPN. Cure Cancer Australia Annual Scientific Meeting. May 2018, Sydney
3. **Lane SW.** Kanga News Dinner. Cure Cancer Australia. May 2018, Sydney
4. **Lane SW.** Genome editing to model the progression of blood cancers. Pathology Update: the annual scientific meeting of the Royal College of Pathologists of Australasia, June 2018. Sydney
5. **Henden A.** A Phase I/II study of Pegylated-Interferon 2-alpha for relapsed haematological malignancy after allogeneic progenitor cell transplantation. Blood Annual Scientific Meeting, October 2018, Brisbane
6. **Tate C, Scott AP.** Outcomes of severe aplastic anaemia post allogeneic stem cell transplant. Blood Annual Scientific Meeting, October 2018, Brisbane
7. **Thirunavukarasu CE, Scott AP.** Predictors of mortality in true positive versus discordant gastrointestinal graft versus host disease (GI-GVHD). Blood Annual Scientific Meeting, October 2018, Brisbane
8. **Admojo, L, Scott AP,** et al. A retrospective analysis of pralatrexate efficacy and tolerability in Australia. Blood Annual Scientific Meeting, October 2018, Brisbane
9. **Zomerdijsk N.** Adult related stem cell donor care – experiences and perceptions of related donors and transplant nurses. Blood Annual Scientific Meeting, October 2018, Brisbane.

Oral Presentations:

1. Vu T, **Lane SW**. Overexpression of the transcription factor Cdx2 in haematopoietic stem cells predisposes to haematologic malignancies. Travel Award. Congress of European Hematology Association. June 2018, Stockholm, Sweden
2. Vu T, **Lane SW**. Overexpression of the transcription factor Cdx2 in haematopoietic stem cells predisposes to haematologic malignancies. European Hematology Association. June 2018, Stockholm, Sweden
3. Vu T, **Lane SW**. Overexpression of the transcription factor Cdx2 in haematopoietic stem cells predisposes to haematologic malignancies. International Society of Experimental Hematology, August 2018, Los Angeles
4. Austin R... **Lane SW**. Oncogenic-Drivers Dictate Immune Responses to Control Disease Progression in Acute Myeloid Leukaemia. ASH Annual Meeting, December 2018, San Diego
5. Curtis DJ... **Lane SW**. Small-Molecule Inhibition of PRMT5 Induces Translational Stress and p53 in JAK2V617F Mutant Myeloproliferative Neoplasms. ASH Annual Meeting, December 2018, San Diego
6. **Lane SW**. Leukaemia Foundation – Current Challenges in the management of MPN, September 2018, Brisbane
7. **Henden A**. Improving graft versus leukaemia with Interferon Alpha. 27th Annual RBWH Healthcare Symposium. September 2018, Brisbane
8. **Butler J**. Improving patient outcomes: Novel agents for Chronic Lymphocytic Leukaemia (CLL) and Follicular Lymphoma (FL). Zydelig Nurses Meeting, August 2018, Brisbane
9. **Pusztai, T**. Practical patient management – Novel agents for CLL and FL. Zydelig Nurses Meeting, August 2018, Brisbane
10. **Scott AP, Tey SK, Pattison D, Kennedy GA**. Clinical Allogeneic Transplantation: Acute and Chronic GVHD, Immune Reconstitution. ASH Annual Meeting, December 2018, San Diego
11. **Yuan Y, Scott AP**. Real-World Efficacy of Anti-Fungal Prophylaxis in Patients Treated for Acute Gastrointestinal Graft-Versus-host Disease (GI-GVHD). ASH Annual Meeting, December 2018, San Diego
12. **Scott AP, Tey SK, Pattison D, Kennedy GA**. Targeted Molecular Imaging of Translocator Protein (TSPO) Using ¹⁸FGE180-PET for the Diagnosis of Gastrointestinal Graft Versus host Disease (GI-GVHD). ASH Annual Meeting, December 2018, San Diego
13. **Tate C**. Outcomes in severe aplastic anaemia post allogeneic stem cell transplant. RBWH Cancer Care Research Retreat, November 2018, Brisbane
14. **Zomerdijk N**. Being a stem cell donor for a chronically ill-family member: adult donors' experiences and unmet needs. The University of Queensland Clinical and Public Health Symposium, November 2018, Brisbane
15. **Lane SW**. Convenor: Blood_2018 (National conference of the Haematology Society of Australia and New Zealand, Thrombosis Haemostasis Society of Australia and New Zealand, Bone Marrow Transplant Society of Aust NZ, Australian and New Zealand Society of Blood Transfusion). October 2018, Brisbane.

Poster Presentations:

1. **Henden A** et al, A Phase I/II Study of Pegylated-Interferon-2Alpha For Relapsed Haematological Malignancy After Allogeneic Haematopoietic Progenitor Cell Transplantation. European Hematology Association. June 2018, Stockholm, Sweden
2. Nair AP, **Hill GR**, Ritchie D, **Butler J**, Spencer A, Wang TY, Muirhead J, Mason K, Reynolds J, Curtis D. Regression Tree-based model for predicting Non-relapse mortality in AML patients Allo-transplanted in first remission. EBMT annual Scientific Meeting. March 2018, Lisbon, Portugal
3. **Ling VY...** **Tey SK, Lane SW**. Identification of Genetic Pathways Controlling Resistance to Standard Combination Chemotherapy in Acute Myeloid Leukemia. ASH Annual Meeting, December 2018, San Diego
4. **Zomerdijk N**. Predictors of negative psychosocial outcomes among adult related stem cell donors – an Australian Multicenter study. The 20th World Congress of Psycho-Oncology and Psychosocial Academy, November 2018, Hong Kong
5. **Zomerdijk N**. Adult related stem cell donor experiences – qualitative results from an Australian Multicenter study. The 20th World Congress of Psycho-Oncology and Psychosocial Academy, November 2018, Hong Kong.

Cancer Care Nursing Professorial Precinct



Michael Smith
Acting Nursing Director
Cancer Care Services RBWH

Aims of the research group: the Cancer Care Nursing Professorial Precinct is a strategic collaboration between nurses in Cancer Care Services, Royal Brisbane and Women's Hospital and academics in the School of Nursing, Queensland University of Technology (QUT). Led by Professor Patsy Yates, the Precinct aims to build capacity for embedding research and innovation into day-to-day clinical practice, and develop a world-class academic comprehensive cancer centre that improves patient outcomes. There is a thriving culture of research that delivers continuous service improvement and evidence-based care.

Outcomes for 2018: the key areas of the Precinct's research programme have continued into 2018. This has included service delivery improvement, vascular access device management, prevention of blood stream infections, managing treatment toxicities, survivorship care and palliative care. Ongoing projects have included further growth of the vascular access devices registry, providing pro-active palliative care for people at risk of dying and research into current models of care. One of the key strengths of the Precinct is the number of high quality trials conducted investigating best practice management of vascular access devices. All research conducted in the Precinct is patient-centred and seeks to directly improve the care of patients. The broad body of work conducted will lead to improved outcomes for people living with, and beyond treatment for cancer through personalised healthcare interventions and health service innovation at a local and international level. Locally, the Evidence-Based Practice program has enabled excellence in delivery of nursing care across clinical areas. International impact continues with the ongoing dissemination of research through publications and conference presentations.

Research activities have been funded by a range of sources including the National Health and Medical Research Council, The RBWH Foundation, professional bodies (such as the Cancer Nursing Society of Australia), academic institutions and industry partners. Cancer Care Services has a strong culture of nurses pursuing post-graduate study and research higher degrees. In 2018, several nurses completed such studies and were awarded competitive scholarships. Three nurses completed higher degree research qualifications. Other highlights include members of the Precinct receiving four awards.

The key strength of the Cancer Nursing Professorial Precinct lies in the team's ability to collaborate widely. In 2018, RBWH cancer nurses worked with academic institutions including QUT, Griffith University, University of Southern Queensland, and University of Queensland. Collaborations also occurred with Princess Alexandra Hospital and Gold Coast University Hospital. These collaborations have continued to enhance the quality and impact of the research conducted in Cancer Care Services at the RBWH.

Supervised Post-Graduate Research Students

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Sarah Northfield	Master of Applied Science (Research), QUT (2014-2018)	The palliative care referral decision-making process in the acute cancer setting: Nurses' advocacy behaviours and the factors influencing these behaviours	Patsy Yates, Raymond Chan, John Rosenberg
Julie Flynn	PhD, Griffith University (2015-2018)	Decontamination of central venous catheter needleless connectors	Claire Rickard, Samantha Keogh, Li Zhang, Amanda Ullman
Nicole Gavin	PhD, Griffith University (2012-2018)	The saFety of pArenteral nutrition regarding miCrobial growth and vascular catheTer-related infection (The FACT Study)	Claire Rickard, David MacMillan, Samantha Keogh
Rae Blades	Master of Applied Science (Research), QUT (2016-2019)	A cost-effectiveness analysis of a silicone gel (StrataXRT®) for prophylaxis and management of Radiation Induced Skin Injury in head and neck cancer patients	Patsy Yates, Raymond Chan, Steven McPhail
Therese Hayes	Master of Applied Science (Research), QUT (2016-2019)	Unmet care needs in elderly patients with a haematological malignancy	Raymond Chan, Patsy Yates,
Robyn Matthews	Master of Applied Science (Research) QUT (2016-2019)	End-of-life care education and training essentials of health professionals in the acute care setting	Raymond Chan, Patsy Yates, Elise Button

Supervised Post-Graduate Research Students (cont)

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Justine Leach	Master of Applied Science (Research), QUT (2016-2019)	Nurse-led Clinics in Cancer Care Services	Raymond Chan, Patsy Yates
Natasha Roberts	PhD, QUT (2016-2019)	Patient Reported Outcomes in the Medical Oncology Setting (iPROMOs)	Monika Janda, Kimberly Alexander, David Wyld
Alison Bowers	PhD, QUT (2016-2019)	Models of care and care needs for Queensland Children Hospice	Patsy Yates, Raymond Chan
Leanne Stone	PhD, QUT (2014-2019)	Comparing the nature of nursing practice in Australian Magnet and non-Magnet hospitals	Fiona Coyer, Raymond Chan, Alexandra McCarthy
Hanan Al Yami	PhD, UQ (2016-2018)	Attributes of Quality End-of-Life Care for Advanced Cancer Patients in Critical Care Units in Saudi Arabia	Karen New, Judith McMurray, Raymond Chan
Tai-Rae Downer	MPhil, QUT (2017-2019)	Identifying patterns of care in Geriatric Oncology patients through health service usage and costs	Louise Gordon, Raymond Chan, Patsy Yates

2018 Research Positions: Coordinators, Fellow, Adjunct and Honorary Positions

Name	Type of Fellowship	Research Program	University (years)
Nicole Gavin	Co-joint nurse researcher QUT and RBWH Cancer Care Services	School of Nursing	Queensland University of Technology (2017 – current)
Elise Button	Co-joint nurse researcher QUT and RBWH Cancer Care Services	School of Nursing	Queensland University of Technology (2017 – current)
Raymond Chan	NHMRC Health Professional Research Fellowship	Development and evaluation of a tailored fatigue self-management behavioural intervention for patients with advanced cancer	Queensland University of Technology (2014-2018)
Patsy Yates	Head, School of Nursing, QUT, Professorial Precinct Lead	School of Nursing	Queensland University of Technology (ongoing)

2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Nicole Gavin	Nicole Gavin, Gillian Nasato, Nicole Marsh, Emily Larsen, Sarah Northfield, Glen Kennedy, David Wyld, Michael Smith, Krispin Hajkovicz (ID), Trent Atkinson (DMI), Barbara Hewer (VASE), Fiona Coyer (QUT), Alison Alexander, Patsy Yates, Peter Mollee (PAH)	Central Venous Access Device Registry
Nicole Gavin	Nicole Gavin, Gillian Nasato, Sarah Northfield, Shelley Kulperger (MN Consumer Engagement), Mirko Guaralda (QUT), Glen Kennedy, David Wyld, Elise Button, Michael Smith, Krispin Hajkovicz (ID), Graham Steel (EDMS), Trish Hurst (IC), Janelle Zillmann (IC), Bridget Heinemann (Comms), Alison Alexander, Jared Donovan (QUT), Glenda Caldwell (QUT), Markus Rittenbruch (QUT), Cynthia Cliff (QUT), Kaye Petherick (QUT)	Collaborative Engagement Strategy Study: Hand Hygiene
Nicole Gavin	Nicole Gavin, Amanda Ullman (GU), Tricia Kleidon (LCCH), Nicole March (CCN), Emily Larsen, Jill Campbell (Skin Integrity), Claire Rickard (GU)	Estimating the prevalence of impaired skin surrounding devices: The EPISODE Study
Nicole Gavin	Nicole Gavin, Amanda Ullman (GU), Tricia Kleidon (LCCH), Claire Rickard (GU), Li Zhang (GU), Emily Larsen	Peripherally Inserted Central Catheter Outcomes Polyurethane versus Endexo: the PICCOMPARE Trial
Nicole Gavin	Claire Rickard, Nicole Gavin, David MacMillan, Samantha Keogh, Gillian Ray-Barruel	The safety of parenteral nutrition regarding microbial growth and vascular catheter-related infection (The FACT Study)

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Nicole Gavin	Nicole Gavin, Elise Button, Rebecca Lippiatt, Emily Russell, Nicole Marsh, Emily Larsen, Julie Flynn, Glen Kennedy, David Wyld, Michael Smith, Alison Alexander, Amanda Sutherland, Jennifer O'Brien, Danielle Johanson, Kieren Barker, Tracy Glynn, David Williams, Therese Hayes, Jenni Leutenegger, Rae Blades, Barbara Hewer, Catriona Booker	Improving vascular access care in cancer care services
Julie Flynn	Claire Rickard, Samantha Keogh, Li Zhang, Amanda Ullman	Decontamination of central venous catheter needleless connectors
Rae Blades	Patsy Yates, Raymond Chan, Steven McPhail	A cost-effectiveness analysis of a silicone gel (StrataXRT®) for prophylaxis and management of Radiation Induced Skin Injury in head and neck cancer patients
Sarah Northfield	Patsy Yates, Raymond Chan, John Rosenberg	The palliative care referral decision-making process in the acute cancer setting: nurses' advocacy behaviours and the factors influencing these behaviours
Therese Hayes	Raymond Chan, Patsy Yates	Unmet care needs in elderly patients with a haematological malignancy
Justine Leach	Raymond Chan, Patsy Yates	Nurse-led Clinics in Cancer Care Services
Robyn Matthews	Raymond Chan, Patsy Yates, Elise Button	End-of-life care education and training essentials of health professionals in the acute care setting
Mary-Ellen Yarker	Carol Windsor, Jennifer Fox	The role of the oncology nurse in the decision-making process of the oncology patient
Elise Button	Elise Button, Nicole Gavin, Jason Butler, Raymond Chan, Patsy Yates	The Patient And Carer's well-being, values and preferences, living with life-threatening illness (The PACE Study)
Elise Button	Elise Button, Sarah Northfield, Nicole Gavin, Glen Kennedy, David Wyld, Gillian Nasato, Jeffrey Rowland, Rhonda Mead, Darshit Thaker, Danielle Johanson, Justine Leach, Shelley Kulperger, Carey-Ann Tanner, Gary Powell, Patsy Yates, Ray Chan, Geoff Mitchell	The Rainy-Day Care bundle: a pilot
Brighid Scanlon	Jo Durham	'Understanding barriers to health access in populations experiencing displacement'
Raymond Chan	Patsy Yates, Jane Turner, Brett Hughes, Raymond Chan	Development and evaluation of a tailored fatigue self-management behavioural intervention for patients with advanced cancer
Raymond Chan	Louisa Gordon, Adrienne Hudson, Natalie Bradford, Aaron Conway, Patsy Yates, Cherie Franks, Robyn Henderson, Richard Lakeman, Trisha Johnson, Tim Moffitt	Queensland Nurse Navigator Program Evaluation Pilot Study
Raymond Chan	Natalie Bradford, Patsy Yates, Ann Boner, Wolf Marx, Iint Douglas	Nurse-led models of care where the nurse takes a primary care role: a systematic review
Raymond Chan	Glen Kennedy, Patsy Yates, Jane Turner, Elise Button, Anthony Smith	A Multi-Centre Randomised Controlled Trial of a Nurse-led Survivorship Intervention for Empowering pAtients with HodGkin's and Non-Hodgkin's Lymphoma after trEatment: (The ENGAGE Trial)
Elise Button	Elise Button, Nicole Gavin, Jason Butler, Raymond Chan, Patsy Yates	The Patient And Carer's well-being, values and preferences, living with life-threatening illness (The PACE Study)
Elise Button	Elise Button, Sarah Northfield, Nicole Gavin, Glen Kennedy, David Wyld, Gillian Nasato, Jeffrey Rowland, Rhonda Mead, Darshit Thaker, Danielle Johanson, Justine Leach, Shelley Kulperger, Carey-Ann Tanner, Gary Powell, Patsy Yates, Ray Chan, Geoff Mitchell	The Rainy-Day Care bundle: a pilot

2018 Collaborative Research Activity involving RBWH Research Group / Department

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Emily Larsen, Nicole Marsh, Nicole Gavin, Julie Flynn, Joan Webster (Griffith University)	Nicole Gavin, Julie Flynn	C ancer ca RE: The risK factors of v enous access failu Re (CARETaKER Study)
Glen Kennedy, Patsy Yates, Jane Turner, Anthony Smith	Elise Button	A Multi-Centre Randomised Controlled Trial of a Nurse-led Survivorship Intervention for E mpoweri NG p A tients with Hod G kin's and Non-Hodgkin's Lymphoma after tr E atment: (The ENGAGE Trial)
Yates, P (Project Lead), Ash K (QUT) & Cancer Australia - collaborative lead researchers.	Northfield S – Service line researcher	The psychosexual care of women affected by gynaecological cancers: An e-learning resource for healthcare professionals (redevelopment and content update of modules)
Dr Carol Douglas	Sarah Northfield	The C are O f the D ying E valuation (CODE) Project: a survey of bereaved persons in an Australian acute care setting
Kathy Hurree	Elise Button, Nicole Gavin	Educating patients – their way: a co-design approach to develop patient education videos regarding medication administration and supportive cares
Kaye Petherick, Judith McLean, Lowanna Dunn, Deborah Anderson, Cynthia Cliff, Marisha McAuliffe (QUT)	Alison Alexander, Gillian Nasato, Michael Smith, Glen Kennedy (Cancer Care Services)	Cancer Care Information Portal for Cancer Patients in Brisbane's Metro North Area
Claire Rickard, Peter Mollee, Geoffrey Playford, Li Zhang, Sam Keogh, Andrew Hallahan, Evan Alexandrou (Griffith University)	Raymond Chan, Nicole Gavin, Emily Larsen (Cancer Care Services)	P eripherally I n S erted C entral catheter dressing and S ecurement in cancer patients: the PISCES Trial. Protocol for a 2x2 factorial, superiority randomised controlled trial
Bonnie Clough, Sonj March, Leanne Casey, Rachel Phillips R, & Michael Ireland. (University of Southern Queensland and Ipswich Hospital)	Raymond Chan (Cancer Care Services)	Psychosocial Interventions for Managing Occupational Stress and Burnout among Medical Doctors: a Systematic Review
Alexandre Chan (National University of Singapore)	Raymond Chan (Cancer Care Services)	A culturally adapted, multidisciplinary psychoeducation program for early-stage breast cancer survivors in Asia: a randomized, controlled trial
Elaine Barros Ferreira, Christiane Inocência Vasques, Rafael Gadia, Eliete Neves Silva Guerra, Luis André Mezzomo, Graziela De Luca Canto, Paula Elaine Diniz dos Reis (University of BrasíliaBrasíliaBrazil)	Raymond Chan (Cancer Care Services)	Topical interventions to prevent acute radiation dermatitis in head and neck cancer: a systematic review and meta-analysis
Natalie Bradford, Rachel Edwards (Children's Health Queensland)	Raymond Chan (Cancer Care Services)	Heparin versus 0.9% sodium chloride intermittent flushes for CVC in children and infants: a systematic review and meta-analysis
Tewodros Eyob, Terence Ng, Alexandre Chan (National University of Singapore)	Raymond Chan (Cancer Care Services)	Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies
Laisa Teleni, Alexandre Chan, Liz Isenring, Ian Vela, Warrick Inder, Debra Anderson, Alexandra McCarthy. (Bond University, National University of Singapore, and PA Hospital)	Raymond Chan (Cancer Care Services)	Dietary and exercise interventions on the quality of life, menopausal-like symptoms and metabolic risk factors in men undergoing androgen deprivation therapy for prostate cancer: a systematic review of quantitative studies

2018 Research Awards and Achievements

Recipient	Award	Event
Gavin NC	Best poster	Intravenous Nursing New Zealand
Gavin NC	Best Research Paper	Cancer Nurses' Society of Australia
Gavin NC	Winner Consumer Focus Project	QuARRIES
Button E	Third place	eHealth Hackathon

2018 Research Grants – Awarded

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Gavin NC , Curtis K, Fuller F, Jansens W	Cancer Care Services	Revision of Cancer Nurses' Society of Australia Vascular Access Device Guidelines	Cancer Nurses' Society of Australia Special Project Funding 2018	\$27,467.52	\$27,467.52 (2018)
Hurree K, Button E , Nakagaki M, Gavin NC , Adcock K, Whitfield K, Douglas C, Smith M, Wyld D, Kennedy G	Cancer Care Services	Educating patients – their way: A co-design approach to develop patient education videos regarding medication administration and supportive cares	Metro North Hospital and Health Services SEED Innovation 2018	\$41,315.50	\$82,631 (2018-2019)
Elise Button , Nicole Gavin , Jason Butler , Raymond Chan , Patsy Yates	Cancer Care Services	The Patient And Carer's well-being, values and preferences, living with life-threatening illness (The PACE Study)	RBWH Foundation Susan Suduk OneDay To Conquer Cancer Diamond Care Grants 2017	\$20,000	\$40,000 (2017-2018)
Raymond Chan , Alex Molassiotis, Patsy Yates , Gillian Nasato , Teresa Brown , Elise Button , Andrea Marshall, I Isenring, David Wyld , Melissa Eastgate , Nicole Gavin	Cancer Care Services	A Patient-family-Centered intervention to promote Nutrition In Advanced Cancer patients	RBWH Foundation Susan Suduk OneDay To Conquer Cancer Diamond Care Grants 2017	\$20,000	\$40,000 (2017-2018)
David Wyld , Matthew Burge , Raymond Chan , Jane Turner, Patsy Yates , Rachel Neale, Vanessa Beesley	Cancer Care Services	Towards improved support of patients with pancreatic cancer and their families	RBWH Foundation Susan Suduk OneDay To Conquer Cancer Diamond Care Grants 2017	\$20,000	\$40,000 (2017-2018)
Patsy Yates , Raymond Chan , David Wyld	Cancer Nursing Professorial Precinct; Cancer Care Services	A sequential multiple assignment randomized trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy	NHMRC	\$237,418	\$713,418 (2017-2020)
Elise Button , Sarah Northfield , Nicole Gavin , Glen Kennedy , David Wyld , Gillian Nasato , Jeffrey Rowland, Rhonda Mead, Darshit Thaker , Danielle Johanson , Justine Leach , Shelley Kulperger, Carey-Ann Tanner, Gary Powell , Patsy Yates , Ray Chan , Geoff Mitchell	Cancer Care Services	The Rainy-Day Care bundle: a pilot	State-wide End of Life Strategy SEED funding	\$60,000	\$120,000 (2017-2018)
Rae Blades	Cancer Care Services	A cost-effectiveness analysis of a silicone gel (StrataXRT®) for prophylaxis and management of Radiation Induced Skin Injury in head and neck cancer patients	RBWH Foundation	\$36,863.96	\$36,863.96 (2018)

2018 Research Publications

Journal Articles:

1. **Button E, Gavin NC, Chan R, Chambers S, Butler J, Yates P.** (2018) Clinical indicators that identify risk of deteriorating and dying in people with a haematological malignancy: a case-control study with multivariable analysis. *J Palliative Medicine*. 21(12): 1729-1740.
2. Tuffaha H, Marsh N, Brynes J, Webster J, **Gavin NC, Cooke M & Rickard C** (2018) Cost of vascular access devices in public hospitals in Queensland. *Australian Health Review*. <https://doi.org/10.1071/AH18102>
3. Takashima M, **Gavin NC, Larsen EN, Northfield S, Mihala G, Corley A, Ziegenfuss M, Rickard CM.** (2018). Building a central vascular access device registry in an adult intensive care unit: feasibility study. *Vascular Access*, 2018, 4(1) 1-9
4. **Gavin NC, McMillan D, Keogh S, Choudhury MA, Ray-Barruel G, Rickard C** (2018) Effect of delaying replacement of parenteral nutrition intravenous administration sets: preclinical experiments and a dynamic laboratory model of microbial colonization. *Journal of Parenteral and Enteral Nutrition* 42(7) 987-997 doi:10.1002/jpen.1039
5. **Gavin NC, Button E, Castillo MI, Ray-Barruel G, Keogh S, McMillan D & Rickard C.** (2018) Does a dedicated lumen for parenteral nutrition administration reduce the risk of catheter-related blood stream infections? A systematic literature review. *Journal of Infusion Nursing* 41(2) 122-130 DOI: 10.1097/NAN.0000000000000270
6. **Gavin NC, McMillan D, Keogh S, Choudhury MA, Ray-Barruel G & Rickard CM.** (2018) Pre-clinical laboratory experiments and a dynamic laboratory model to investigate the effect of hang time of intravenous administration sets for the delivery of parenteral nutrition containing intravenous fat emulsions on the risk of fluid colonisation. *Journal of Parenteral and Enteral Nutrition*. DOI: 10.1002/jpen.1039
7. **Webster, J., Northfield, S., Larsen, E. N., Marsh, N., Rickard, C. M., & Chan, R. J.** (2018). Insertion site assessment of peripherally inserted central catheters: inter-observer agreement between nurses and inpatients. *The Journal of Vascular Access*. DOI: 10.1177/1129729818757965
8. **Flynn, J., Slater, K., Cooke, M., & Rickard, C. M.** (2018). Needleless connector decontamination: to use, or not to use, chlorhexidine? *American journal of infection control*.

2018 Conference Presentations – Invited Speaker, Oral and Poster

Oral Presentations:

1. **Button, E.** The Rainy-Day Care projects. State-wide Strategy for Care at the End of Life Forum, March 2018
2. **Flynn, J.** Decontamination of the needleless connector: an in vitro study. Rotorua, New Zealand
3. **Button E.** When do people with a haematological malignancy first show signs of risk of deteriorating and dying? International Conference on Cancer Nursing, Auckland. September 2018
4. **Gavin NC & Barrie JM.** Co-designed and situated consumer engagement: the hand hygiene InstaBooth project. Health Consumers Queensland. June 2018
5. **Northfield S, Chan RJ, Rosenberg J, Yates P.** Factors associated with patient access to specialist palliative care services in an acute cancer setting. Palliative Care Nurses Australia (PCNA) conference. May 2018
6. **Northfield S, Chan RJ, Rosenberg J, Yates P.** Identifying the factors that influence cancer nurses advocating for patient referrals to specialist palliative care services: a national survey. Palliative Care Nurses Australia (PCNA) conference. May 2018
7. **Coyne E, Northfield S, Ash K, Brown-West L, Miles C, Munton K, Barratt C.** A review of literature to provide evidence for best practice administering chemotherapy to enable optimum patient outcomes and nurse safety. (Oral presentation – Coyne E). CNSA 21st Annual Congress, Brisbane
8. **Gavin NC, Northfield S, Larsen E, Mihala G, Marsh N, Ray-Barruel G, Rickard CM.** Central venous access device Registry: Improving outcomes for patients diagnosed with cancer. (Oral presentation – Gavin NC). CNSA 21st Annual Congress, Brisbane
9. **Button E, Gavin NC, Chan R, Connell S, Butler J, Yates P.** Clinical indicators that identify risk of deteriorating and dying in people with a haematological malignancy. CNSA 21st Annual Congress, Brisbane
10. **Bates B, Button E, Wyld D, Nasato G, Fennelly E, Northfield S, Yates P, Gavin N, Leutenegger J, Smith M.** RBWH Cancer Care Services Model of Care: Working to Reduce Avoidable Emergency Presentations and Hospitalisation. CNSA 21st Annual Congress, Brisbane
11. **Roberts N, Janda M, Alexander K, Wyld D.** Facilitators and Barriers to Implementing Patient Reports Outcome Measures (PROMs) in Routine Oncology Nursing Care. CNSA 21st Annual Congress, Brisbane
12. **Gavin NC, Northfield S, Somerville M, Lippiatt R, Larsen E, Marsh N, Rickard C.** Central venous access device Registry: Improving outcomes for patients diagnosed with cancer. CNSA 21st Annual Congress, Brisbane
13. **Rickard C, Marsh N, Larsen E, Runnegar N, Gavin NC, Mihala G, Playford G, Webster J.** Administration sets/infusion tubing: how often should they be replaced to prevent infection? CNSA 21st Annual Congress, Brisbane
14. **Gavin NC, Kulperger S, Nasato G, Northfield S, Lippiatt R, Guaralda M, Carolli L, Barrie JM, Colquhoun J & Wharton C.** Hands up for hand hygiene in cancer care. Royal Brisbane and Women's Hospital QuARRIES 2018
15. **Gavin NC, Kulperger S, Nasato G, Northfield S, Lippiatt R, Guaralda M, Carolli L, Barrie JM, Colquhoun J & Wharton C.** Hands up for hand hygiene in cancer care. Royal Brisbane and Women's Hospital Symposium 2018
16. **Gavin NC, Northfield S, Somerville M, Lippiatt R, Larsen E, Marsh N & Rickard C.** CVAD Registry: improving outcomes for patients diagnosed with cancer. International Conference on Cancer Nursing, Auckland. September 2018
17. **Button E.** When do people with a haematological malignancy first show signs of risk of deteriorating and dying? International Conference on Cancer Nursing, Auckland. September 2018

Oral Presentations: (cont):

18. Coyne E, **Northfield S**, Ash K, Brown-West L, Barratt C, Miles C, Munton K. Building evidence to inform position statement development: integrative review of chemotherapy education and safety standards. International Conference on Cancer Nursing, Auckland, September 2018
19. **Northfield S**, Button E, Wyld D, Gavin N, Nasato G, Yates P. Taking care of our own: a narrative review of cancer care services-led models of care providing emergent care to patients with cancer. Cancer Care Services Research Retreat, Brisbane
20. Rickard C, Marsh N, Larsen E, Runnegar N, **Gavin NC**, Mihala G, Playford G, Webster J. Administration sets/infusion tubing: how often should they be replaced to prevent infection? CNSA 21st Annual Congress, Brisbane
21. Rickard C, Marsh N, Larsen E, Runnegar N, **Gavin NC**, Mihala G, Playford G, Webster J. Administration sets/infusion tubing: how often should they be replaced to prevent infection? CNSA 21st Annual Congress, Brisbane.

Poster Presentations:

1. **Gavin NC, Northfield S**, Larsen E, Mihala G, **Marsh N, Ray-Barruel G, Rickard CM**. CVAD Registry: improving outcomes for cancer care patients. IntraVenous Nursing New Zealand (IVNNZ), March 2018
2. **Northfield S**, Chan RJ, Rosenberg J, **Yates P**. Factors that influence palliative care referrals for hospitalised patients with advanced cancer: an integrative review. Royal Brisbane and Women's Hospital Symposium 2018
3. **Fernandes J, Gavin NC & Button E**. Urokinase versus alteplase for the management of occluded central venous access devices: a systematic review. Royal Brisbane and Women's Hospital Symposium 2018
4. **Wong L & Gavin NC**. Does a clinical sepsis pathway improve outcomes in cancer patients? A systematic review. Royal Brisbane and Women's Hospital Symposium 2018
5. **Percival V & Gavin NC**. Post-dural puncture headache following lumbar puncture and intrathecal chemotherapy, how long should patients remain recumbent? A systematic review. Royal Brisbane and Women's Hospital Symposium 2018
6. **Barker K, Sutherland A**. Two Person Medication Administration Compliance. CNSA 21st Annual Congress, Brisbane
7. **Northfield S**, Button E, Wyld D, Gavin N, Nasato G, Yates P. Models of care for reducing the use of emergency departments by adult cancer patients: a narrative review. Cancer Care Services Research Retreat, Brisbane
8. **Matthews R**, Yates P, Chan R. Education and training for healthcare professionals to deliver end-of-life care in the acute care setting: A literature review. CNSA 21st Annual Congress, Brisbane
9. **Turner T**, Button E, Gavin NC, Dyer I, Leutenegger J. How should we manage oncology infusion related reactions? A clinical guideline reviews. CNSA 21st Annual Congress, Brisbane
10. Fernandes J, **Gavin NC**, Button. Urokinase versus alteplase for the management of occluded Central Venous Access Devices: a systematic review. CNSA 21st Annual Congress, Brisbane
11. **McCurry T**, Wallace A, Leonard S, Lear V. Working in partnership to meet the demands and challenges of a shared Clinical Nurse Consultant/Cancer Care Coordinator role. CNSA 21st Annual Congress, Brisbane
12. **Scanlon B**, A literature review on the efficacy of increasing the tobacco excise within Australia. CNSA 21st Annual Congress, Brisbane.

Medical Oncology



A/Prof David Wyld

Director Medical Oncology

Deputy Director of Clinical Research
Cancer Care Services RBWH

The Cancer Care Services Medical Oncology (MO) Department provides clinical services to the Metro North HHS district through its staff managing patients at RBWH, North Lakes, TPC and Caboolture. The unit continued to expand its research portfolio in 2018, with progress in a number of different areas. Below are a few selected highlights from the department in 2018.

Offering individuals with cancer access to new therapies as part of a clinical trial is recognised as an essential part of any academic oncology unit. The MO department has a very active clinical trials program which continues to be recognised for its conduct of high quality clinical research, which is a credit to all involved. 2018 was a very busy year, with 121 studies active in 2018. 267 new patients were recruited to studies in 2018, with 591 patients in total on study at some point in 2018.

A highlight in this area include the national MONNARCC Study in metastatic colorectal cancer commencing recruitment this year, with Dr Matthew Burge as the national chief investigator – a concept he developed and he now leads for the Australasian Gastrointestinal Trials Group. And this year A/Prof Brett Hughes and Dr Elizabeth Ahern, in conjunction with Prof Mark Smyth at QIMR have developed and obtained funding to conduct an innovative project evaluating anti-PD1 checkpoint inhibition combined with RANKL blockade in operable NSCLC. This project, led by RBWH, will be conducted at RBWH, TPC and two other Qld sites, and has a major translational component which will be undertaken by Prof. Smyth at QIMR.

Departmental staff continue to increase the number of collaborative research projects they undertake with external partners – including HIRF, QUT, The University of Queensland and multiple groups within QIMR, as well as researchers from a variety of other institutions both locally, national and internationally as demonstrated in the collaborative project list below.

The number of conference presentations and publications from the department continues to grow each year. Highlights include several publications in high impact journals in 2018, as well as oral presentations by several departmental staff at both national and international meetings.

With a focus over the last few years on encouraging trainees in Medical Oncology to undertake higher degrees, it is exciting to see two recent RBWH medical oncology fellows – Elizabeth Ahern and Rahul Ladwa nearing completion of their PhD and MPhil respectively. In addition, Natasha Roberts, a Medical Oncology research nurse coordinator, will also complete her PhD in early 2019. We congratulate them and look forward to each of them developing their own research programs in oncology in Brisbane in the coming years.

Supervised Post-Graduate Research Students

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Ali Dulfikar	PhD QUT	Pilot feasibility study of exercise in grade II, III and IV glioma while receiving radiation therapy with or without chemotherapy	Zarnie Lwin , Fiona Naumann, Mark Pinkham, Elizabeth Pinkham, Gabriel Siqueira Trajano
Dr Elizabeth Ahern	PhD UQ 2015-	Targeting RANK/RANKL in combination immunotherapy using murine and translational models of melanoma, prostate and other solid organ malignancies	Mark Smyth, Michele Teng, David Wyld
Natasha Roberts	PhD QUT 2016-2019	Patient Reported Outcomes in a Medical Oncology Setting	Monika Janda, Kim Alexander, David Wyld
Dr Rahul Ladwa	MPhil UQ 2017-	Predictors of dosimetry and response to peptide receptor radionuclide therapy	David Wyld , Stephen Rose, Nicholas Dowson
Dr Darshit Thaker	MPhil UQ 2017-	Implementation of Comprehensive Geriatric assessment (CGA) for patients older than 70 years in medical oncology clinic to facilitate decision making and provision of supportive management	David Wyld , Sunil Lakhani

2018 Research Positions: Coordinators, Fellow, Adjunct and Honorary Positions

Name	Type of Fellowship	Research Program	University (years)
Dr Anna Kuchel	Research Fellow	Medical Oncology	Queensland Health
Annette Cubitt	Manager, Clinical Trials Unit	Clinical Trials Unit Medical Oncology	Queensland Health
Jenny Campbell	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Amy Ives	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Andrea McKenzie	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Wendy Pritchard	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Megan Ward	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Natasha Roberts	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Gel Bolanos	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Diana Lewis	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Andrea Junghans	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Leah Hingston	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Jenna Peckston	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Jasmine Brady	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Krystal Perera	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Lourdes Pamposa	Clinical Trial Coordinator	Clinical Trials Unit Medical Oncology	Queensland Health
Jennifer Lonton	Research Development Officer	Clinical Trials Unit Medical Oncology	Queensland Health
Danni Church	Research Administration Officer	Clinical Trials Unit Medical Oncology	Queensland Health
Denise Flynn	Research Administration Officer	Clinical Trials Unit Medical Oncology	Queensland Health

2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
David Wyld, Matthew Burge	Rachel Neale, Vanessa Beesley	PRO-NET: patient reported outcomes in people with neuroendocrine tumours
Natasha Roberts, David Wyld	Monika Janda, Kim Alexander	Patient Report Outcomes (PROs) in a medical oncology setting: a low risk project to identify staff perceptions about the use of PRO data in a clinical setting
Zarnie Lwin	Alex Broom	Cultural biographies, medical knowledges: a sociological study at the intersection of cancer and culture
Matthew Burge	Euan Walpole	Prospective evaluation of FOLFIRINOX for metastatic or locally advanced Pancreatic Cancer
Melissa Eastgate	David Wyld, Darshit Thaker, Monica Dumbrava, Teresa Brown	Dietary patterns and preferences/attitudes of cancer patients regarding sources of information about the diet during cancer treatment
David Wyld	Rahul Ladwa, Paul Klages, Monica Dumbrava, Timothy Kalas	Dose intensity in adjuvant chemotherapy in women over 65 with breast cancer
Melissa Eastgate	Lindy Jeffree, Kelly McGrath, Shu Fen Lee	Audit of outcomes of melanoma patients undergoing neurosurgery
Rahul Ladwa	David Wyld, Matthew Burge, David Pattison	Assessing response to Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumours: case series of pseudoprogression
Aneta Suder, Andrew Schmidt	Brett Hughes, Zarnie Lwin, Michael Allen	Exploring the rate of hospital admissions due to immune therapy toxicities in two tertiary cancer centres
David Wyld	Louisa Gordon, John Leyden, Kate Wakelin, Michael Michael, Nick Pavlakis	F-NET Project: financial Outcomes in people with Neuro-Endocrine Tumours
Matthew Burge	Paul Thomas, David Wyld, Melissa Eastgate, Stephen Rose, Nick O'Rourke, Davis Cavallucci Richard Bryant	Imaging the CXCR-4 Chemokine receptor with a novel PET tracer in pancreatic cancer

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Matthew Burge	Paul Thomas, Andrew Stevenson, David Wyld (CCS), Melissa Eastgate , Stephen Rose, David Clark, Craig Harris, Damien Petersen, David Taylor, Carina Chow, Paul Tesar, Michelle Grogan	A pilot study of CXCR-4 PET scanning in operable rectal cancer
David Wyld	Matthew Burge , Raymond Chan , Jane Turner, Patsy Yates, Melissa Eastgate , Rachael Neale, Vanessa Beesley	PREPARES: Patients and Relatives affected by Pancreatic cancer: Referral, Education and Support feasibility trial
Matthew Burge	Melissa Eastgate , David Wyld , Shu Lee	Analysis of prospectively collected pancreatic cancer patients given folfinrox at RBWH
David Wyld	Julie Moore, Mark Wan	Neuroendocrine Tumours: Epidemiologic trends in Queensland
Brett Hughes	Elizabeth Ahern , Bill Dougall, Mark Smyth	Pre-operative evaluation of anti-PD1 checkpoint inhibition (Nivolumab) with RANKL blockade (Denosumab) in patients with operable stage I-III NSCLC
Natasha Roberts (Cancer Care Services/Queensland University of Technology)	Monika Janda, Kim Alexander, David Wyld	Patient Reported Outcomes in the Medical Oncology Setting (IPROMOS)
Melissa Eastgate	Anna Kuchel , David Wyld	Medical Oncology Clinical Activity Review
David Wyld	David Chan (Sydney), S Singh, A Thawer, C Fingrut, R Yelamanchila (Canada)	Understanding the Barriers to the Development of a Shared Care Model for the Treatment of Patients with Neuroendocrine Tumours (NETs): Optimization of care between NET Speciality Centres and General/Local/Community Oncologist
Melissa Eastgate	Anna Kuchel	Financial planning concerns in patients with advanced melanoma – a research study into patient and clinician perspectives
David Wyld	Julie Moore, Nancy Tran, Michael Wyld	Neuroendocrine Neoplasms in the Paediatric, Adolescent and Young Adult Population in Queensland, Australia
David Wyld	Julie Moore, Nancy Tran, Ben Lawrence, Kate Parker, Sharon Pattison	Neuroendocrine neoplasms in the paediatric adolescent and young adult population – comparing New Zealand and Queensland Australia
Natasha Roberts	Haryana Dhillon, Phillip Parente, Craig Gedy, Australia New Zealand Urogenital and Prostate Cancer Trials Group	Patient Experience of Participating in a Clinical Trial
Natasha Roberts	Medical Oncology, Radiation Oncology, Haematology Cancer Care Services, RBWH	Poster Project: a study to describe oncology patient perceptions of research
Natasha Roberts (Cancer Care Services/Queensland University of Technology)	Medical Oncology, Cancer Care Services, RBWH	Poster Project: a pilot study to describe medical oncology patient perceptions of research
Melissa Eastgate	Geoffrey Bryant, Mathew Burge , Darshit Thaker , David Wyld	Colorectal cancer patient reported outcomes: putting theory into practice
Brett Hughes (Cancer Care Services), Elizabeth Ahern (Cancer Care Services/Queensland Institute of Medical Research Berghofer),	Martin Batstone, Mark Smyth and Bill Dougall	Expression of novel immune markers in mucosal head and neck squamous cell carcinoma (HNSCC) specimens
Melissa Eastgate, Elizabeth Ahern (Cancer Care Services/Queensland Institute of Medical Research Berghofer Anna Kuchel	Ailin Lepetier, Jason Madore, Mark Smyth	Multiplex immunofluorescence assessment of melanoma biopsies and response to immunotherapy
Brett Hughes, Elizabeth Ahern (Cancer Care Services/Queensland Institute of Medical Research Berghofer)	Martin Batstone, Mark Smyth and Bill Dougall	Immune Biomarker Evaluation in Oral Mucosal Squamous Cell Carcinoma: a prospective tissue collection
Clare Senko	Brett Hughes , Zarnie Lwin	Evaluating the prognostic significance of significant weight loss in patients with stage III non-small cell lung cancer undergoing definitive chemoradiation

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Matthew Burge	David Wyld , David Pattison, Fiona Paxton-Hall , Kathy You	Outcome and toxicity of salvage therapy with 177 Lu-dotatate in patients with metastatic neuroendocrine tumours
David Wyld	Julie Moore, Nathan Dunn, Nancy Tran	Small Intestinal Neuroendocrine neoplasms in Qld: 2001-2015. Stage at diagnosis and survival

2018 Collaborative Research Activity involving RBWH Research Group / Department

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	INTEGRATE II A Randomised Phase III Double Blind Placebo Controlled Study of regorafenib in Refractory Advanced Gastroesophageal Cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	ACTICCA-1 study: Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial)
Australasian Gastrointestinal Trials Group	David Wyld (Cancer Care Services)	CONTROL NETS: Phase II multi-arm, randomised open label trial of Lutetium-177 Octreotate peptide receptor radionucleotide therapy, capecitabine/temozolamide chemotherapy, or the combination in the first or second line treatment of low to intermediate grade gastroenteropancreatic neuroendocrine tumours
Walter and Eliza Hall Institute, Colorectal Translational Oncology Group	Matthew Burge (Cancer Care Services)	ctDNA in Pancreatic Cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	DOCTOR: a Randomised Phase II Trial of Pre-Operative Cisplatin, 5 Fluorouracil and Docetaxel or Cisplatin, 5 Fluorouracil, Docetaxel plus Radiotherapy based on poor early response to standard chemotherapy for resectable adenocarcinoma of the oesophagus and/or OG Junction
Ludwig Institute for Cancer Research	Matthew Burge (Cancer Care Services)	Circulating Tumour DNA as a Sensitive and Specific Marker of Response to Therapy and of Occult Disease in Colorectal Cancer – for resectable CRC liver mets pts
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	GAP: Phase II study of pre-operative Gemcitabine and Abraxane for resectable Pancreas cancer
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	DYNAMIC: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage II Colon Cancer
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	Evaluation of temporal dynamics of RAS Mutation emergence in Cell Free DNA (cfDNA) in response to first-line cetuximab anti-EGFR therapy in Patients with Metastatic Colorectal Cancer
Centre for Medical Psychology and Evidence Based Decision Making	Matthew Burge (Cancer Care Services)	CHALLENGE: a Phase III study of the impact of a Physical Activity program on Disease-Free Survival in patients with high risk Stage II or Stage III Colon Cancer: a randomised controlled trial (CO.21)
Australasian Gastrointestinal Trials Group/National Cancer Centre, Singapore	Melissa Eastgate (Cancer Care Services)	ASCOLT: Aspirin for Dukes C and high-risk Dukes B Colorectal Cancers – an international, multi-centre, double blind, randomised placebo controlled Phase III trial (AGITG)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	ctDNA as a Marker of Complete Pathological Response and Long-Term Outcome for Locally Advanced Rectal Cancer Treated with Pre-operative Chemoradiotherapy
Ludwig Institute for Cancer Research	Matthew Burge (Cancer Care Services)	Circulating Tumour DNA as a Marker of Occult Disease in Stage II Colorectal Cancer and Response to Therapy in Metastatic Colorectal Cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	AGITG SCOT Trial: Short Course Oncology Therapy – a Study of Adjuvant Chemotherapy in Colorectal Cancer
Australasian Gastrointestinal Trials Group/European Organization for Research and Treatment of Cancer	Matthew Burge (Cancer Care Services)	PETACC6 – preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	MODULATE: modulation of the tumour microenvironment using either vascular disrupting agents or STAT3 inhibition in order to synergise with PD1 inhibition in microsatellite stable, refractory colorectal cancer. (AGITG)

2018 Collaborative Research Activity involving RBWH Research Group / Department (cont)

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Australasian Gastrointestinal Trials Group/ Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	DYNAMIC-III: Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study (AGITG, WEHI)
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	VELIA (M13-694): a Phase 3 Placebo Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and continuous Maintenance Veliparib in Subjects with Previously Untreated Stages III or IV High Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Australia New Zealand Gynaecological Oncology Group	Alison Hadley (Cancer Care Services)	OUTBACK: a PHASE III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone
Australia New Zealand Gynaecological Oncology Group	Jeff Goh (Cancer Care Services)	PARAGON: a study to assess the activity of anastrozole, an aromatase inhibitor, in women with oestrogen receptor and/or progesterone receptor positive (ER/PR+ve) and therefore potentially hormone responsive recurrent or metastatic gynaecological cancers
Australia New Zealand Gynaecological Oncology Group	Jeff Goh (Cancer Care Services)	OVAR 2.21: a prospective randomized Phase III trial of carboplatin/ gemcitabine/ bevacizumab vs. carboplatin/pegylated liposomal doxorubicin/ bevacizumab in patients with platinum-sensitive recurrent ovarian cancer
Australia New Zealand Gynaecological Oncology Group	Jeff Goh (Cancer Care Services)	ICON 8: an international trial comparing weekly chemotherapy with 3 weekly chemotherapy for women with ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Australia New Zealand Gynaecological Oncology Group	Jeff Goh (Cancer Care Services)	OVAR 16 – a Phase III study to evaluate the efficacy and safety of Pazopanib monotherapy versus placebo in women who have not progressed after first line chemotherapy for epithelial ovarian, fallopian tube or primary peritoneal cancer
Australia New Zealand Urogenital and Prostate Cancer Trials Group	David Wyld (Cancer Care Services)	Phase III BEP Trial: a randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Aneta Suder (Cancer Care Services)	ENZAMET Trial: a randomised phase 3 trial of enzalutamide in first line androgen deprivation therapy for metastatic prostate cancer
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	ACED: randomised phase II study of acetazolamide plus dexamethasone versus dexamethasone alone for management of cerebral oedema in recurrent or progressive high-grade gliomas
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	VERTU – Veliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma: A Randomised Phase II study of veliparib + radiotherapy (RT) with adjuvant temozolomide (TMZ) + veliparib versus standard RT + TMZ followed by TMZ in newly diagnosed glioblastoma (GBM) with unmethylated O (6)-methylguanine-DNA methyltransferase
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	INTELLANCE 2 - ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group
Cooperative Trials Group for Neuro-oncology	Po-Ling Inglis (Cancer Care Services)	CATNON: Phase III trial comparing no adjuvant chemotherapy versus adjuvant therapy until progression for anaplastic glioma without 1p/19q loss. An EORTC/NCI-C/RTOG/MRC/HUB/ intergroup study
Australia New Zealand Breast Cancer Trials Group	Michelle Nottage (Cancer Care Services)	PALbociclib CoLLaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer. PALLAS
Australia New Zealand Breast Cancer Trials Group	Po-Ling Inglis (Cancer Care Services)	Penelope B: Phase III study evaluating palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in patients with hormone-receptor-positive, HER2-normal primary breast cancer with high relapse risk after neoadjuvant chemotherapy
Kathleen Houston, Sunshine Coast Oncology Research Group	Michelle Nottage (Cancer Care Services)	TAPS: Gabapentin for taxane acute pain syndrome – a phase III randomised, placebo-controlled, crossover trial
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	TEXT-Bone: a substudy of the TEXT trial to evaluate serial bone markers for bone remodeling, serial growth factors, and bone mineral density
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	TEXT: a Phase III Trial Evaluating the Role of Exemestane plus GnRH analogue as Adjuvant Therapy for premenopausal women with endocrine responsive breast cancer

2018 Collaborative Research Activity involving RBWH Research Group / Department (cont)

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	An International multi-centre study of tamoxifen vs. Anastrozole in postmenopausal women with hormone sensitive ductal carcinoma in situ (DCIS) IBIS II
Australia New Zealand Breast Cancer Trials Group/ECOG-ACRIN	Po-Ling Inglis (Cancer Care Services)	TAILORx Program for the Assessment of Clinical Cancer Tests (PACCT-1): trial Assigning Individualized Options for Treatment: the TAILORx Trial
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	Suppression of Ovarian Function Trial (SOFT) A Phase III Trial Evaluating the Role of Ovarian function Suppression and the Role of Exemestane as Adjuvant therapies for premenopausal women with Endocrine responsive breast cancer
Australia New Zealand Breast Cancer Trials Group/Breast International Group	Michelle Nottage (Cancer Care Services)	A phase III study to evaluate Letrozole as adjuvant endocrine therapy for postmenopausal women with receptor (ER and/or PgR) positive tumours (BIG-1-98)
Walter and Eliza Hall Institute	Matthew Burge (Cancer Care Services)	Pancreatic cancer: understanding Routine Practice and Lifting End results (PURPLE) A Prospective Pancreatic Cancer clinical registry
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	KEYPAD: proposed phase 2 trial of pembrolizumab and denosumab in advanced clear-cell renal cell carcinoma (ccRCC) progressing after a VEGF-TKI
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	UNISO – anzUp Nivo->Ipi+Nivo Sequential Non-clear cell – Proposed Phase II Sequential Cohort Trial Of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab In Metastatic Or Unresectable Non-Clear Cell Renal
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Jeffrey Goh (Cancer Care Services)	TheraP: a randomised phase 2 trial of 177 Lu-PSMA617 theranostic versus cabazitaxel in men with progressive metastatic castration resistant prostate cancer
Australia New Zealand Urogenital and Prostate Cancer Trials Group	Natasha Roberts (Cancer Care Services)	The Patient Experience of Participating in a Clinical Trial
Cooperative Trials Group for Neuro-oncology	Zarnie Lwin (Cancer Care Services)	NUTMEG: a Randomized Phase II Study of Nivolumab and TeMozolomide vs Temozolomide in newly diagnosed Elderly Glioblastoma
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	LIBERATE – phase II study evaluating liquid biopsies to profile metastatic colorectal cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	PIT STUDY: an open label Phase IB/II, non-randomised, dose-escalating, safety, tolerability and pharmacokinetic study of first line Panitumumab, Irinotecan, Trifluridine/tipiracil in RAS wild type patients with metastatic colorectal cancer
Australasian Gastrointestinal Trials Group	Matthew Burge (Cancer Care Services)	A randomised phase 2 study of Panitumumab monotherapy versus fluoropyrimidine and bevacizumab as first line therapy for RAS wild type metastatic colorectal cancer. (MONARCC study)
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	Phase II clinical trial of the PARP inhibitor, olaparib, in HR-deficient metastatic breast and relapsed ovarian cancer in patients without germline mutations in BRCA1 and BRCA2: the EMBRACE study
Australia New Zealand Gynaecological Oncology Group/ United Kingdom Medical Research Council	Jeffrey Goh (Cancer Care Services)	ICON 9: to assess the efficacy, safety and tolerability of maintenance cediranib in combination with olaparib therapy compared to single agent cediranib maintenance in women with relapsed platinum sensitive ovarian, fallopian tube or primary peritoneal cancer. (ANZGOG/UK MRC)
Australia New Zealand Gynaecological Oncology Group	Jeffrey Goh (Cancer Care Services)	iPRIME: a phase II study of durvalumab and tremilumumab in combination with carboplatin and paclitaxel, as neoadjuvant treatment for newly diagnosed, advanced high grade serous ovarian cancer (ANZGOG)
Australia and New Zealand Melanoma Trials Group	Melissa Eastgate (Cancer Care Services)	A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma. (ANZMTG 01.15.) CHARLI
Australian Lung Cancer Trials Group	Brett Hughes (Cancer Care Services)	NIVORAD – a randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy
Australian Lung Cancer Trials Group/ European Thoracic Oncology Platform	Brett Hughes (Cancer Care Services)	STIMULI: small cell lung carcinoma trial with nivolumab and Ipilimumab in Limited disease. A randomised open-label phase II trial of consolidation with nivolumab and ipilimumab in limited-stage SCLC after chemo-radiotherapy. (ALTG, ETOP)

2018 Collaborative Research Activity involving RBWH Research Group / Department (cont)

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Melbourne Health	Alison Hadley (Cancer Care Services)	NOMINATOR: GENOMIC MATCHING TREATMENT FOR RARE CANCERS Feasibility of performing genomic testing of rare cancers to match the cancer to treatment
QIMR Berghofer Medical Research Institute Bryan Day (QIMR),	Po Ling Inglis (Cancer Care Services) Rosalind Jeffree (Neurosurgery)	Novel Therapies for Brain Cancer
Rebecca Mercieca-Bebber (University of Sydney)	Natasha Roberts (Cancer Care Services/ Queensland University of Technology)	Quality of life end-points in clinical trials
Quan Tran, (Cancer Care Services, The Prince Charles Hospital)	Brett Hughes, Zarnie Lwin (Cancer Care Services), David Smith, Andrew Schmidt (The Prince Charles Hospital)	Identifying perceived barriers to physical activity in patients with lung cancer at two Brisbane-based institutions
Andrew Schmidt (Cancer Care Services, The Prince Charles Hospital)	Brett Hughes, Zarnie Lwin, Michael Allen (Cancer Care Services)	Exploring the rate of hospital admissions due to immune therapy toxicities in two tertiary cancer centres
Kate Roberts (Princess Alexandra Hospital), Ken O'Byrne (Queensland University of Technology),	Brett Hughes, Zarnie Lwin (Cancer Care Services)	A multi-institutional retrospective audit of patients with metastatic malignancy treated with nivolumab through the Open Access Scheme at the Princess Alexandra Hospital, the Royal Brisbane and Womens' Hospital, and The Prince Charles Hospital
Lisa Guccione (PMCC), Penelope Schofield (Swinburne University), Michael Michael (PMCC), Mustafa Khasraw (RNSH), Timothy Price (TQEH), Nick Pavlakis (RNSH), Megan Rogers (PMCC), Karla Gough (PMCC), Grace Kong (PMCC), Simone Leyden (Unicorn Foundation), John Leyden (Unicorn Foundation)	David Wyld (Cancer Care Services)	DEFINING NETs – defining the supportive care needs and psychological morbidity of patients with Functioning versus Non-Functioning Neuroendocrine Tumours (NETs)
Manoj Bhatt (Nuc Med)	David Wyld, Matthew Burge, Rahul Ladwa (Cancer Care Services), Peter Garcia, David Pattison, Kevin Lee, Samuel Kyle, Nicholas Dowson, Jye Smith (Nuclear Medicine), Steven Goodman, Stephen Rose	Pilot project to assess liver metastases by comparing novel, dynamic and static functional imaging, and also morphological imaging with standard of care in WHO Grade I and Grade II Neuroendocrine Tumour (NET)
Claudia Rutherford (Quality of Life Office, University of Sydney)	Natasha Roberts (Cancer Care Services/Queensland University of Technology)	Systematic Review of Quality of Life Measures
University of New South Wales	David Wyld (Cancer Care Services), Robert Henderson (Neurology)	Peripheral Neuropathy in Chemotherapy-treated Patients: Predictors, Assessment strategies and Functional Outcomes IN FOCUS Study (Identifying Neurological and Functional Outcomes in Cancer Survivors Study)
Olivia Newton-John Cancer Research Institute	Po-Ling Inglis (Cancer Care Services)	A phase I safety and bioimaging trial of KB004 in patients with glioblastoma
International Society for Quality of Life	Natasha Roberts (Cancer Care Services)	Proxy reported patient reported outcomes measures
Amanda Love (Endocrinology), Marianne Elston (NZ), Richard Carrol (NZ), Eva Segelov (Monash)	David Wyld (Cancer Care Services)	Assessment of hypopituitarism rates following peptide receptor radionuclide therapy for neuroendocrine tumours
John Clouston, Roger Bain (Medical Imaging)	Melissa Eastgate (Cancer Care Services)	The Metro North Interventional Oncology database: a prospective observational cohort study examining outcomes for interventional oncology procedures
Sunil Lakhani (University of Queensland), Amy Reed (UQCCR), Christopher Pyke (Mater), Cameron Snell (Mater), Nicole McCarthy (Wesley), Ken O'Byrne (PAH), Valentine Hyland (Pathology), Owen Ung (Surgery), Natasha Woodward (Mater), Euan Walpole (PAH), Peter Simpson (UQ), Stephen Rose (CSIRO), Fares Al-Ejeh (QIMR)	Po-Ling Inglis, Ben Green (Cancer Care Services)	High risk breast cancer genomic sequencing project platform Queensland wide

2018 Collaborative Research Activity involving RBWH Research Group / Department (cont)

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Claudia Rutherford, Madeleine King, (Quality of life office, University of Sydney)	Natasha Roberts (Cancer Care Services)	Patient reported outcomes in clinical practice
Patsy Yates (Palliative Care)	David Wyld (Cancer Care Services), Kimberly Alexander, Christine Miaskowski, Raymond Chan, Alexandra McCarthy, Steven McPhail, Helen Skerman	A Sequential Multiple Assignment Randomised Trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy

2018 Research Awards and Achievements

Recipient	Award	Event
Brett Hughes	Best oral presentation	CCS Research Retreat 8 November 2018
David Wyld	Best of the best gastrointestinal abstract	COSA 45 th Annual Scientific Meeting 13-15 November 2018
Zarnie Lwin	2018 Most Outstanding Poster Presentation	Cooperative Trials Group for Neuro-Oncology 11 th Annual Scientific Meeting 7-9 October 2018 Brisbane.

2018 Research Grants – Awarded

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Patsy Yates , Kimberly Alexander, Christine Miaskowski, Raymond Chan, Alexandra McCarthy, Steven McPhail, David Wyld , Helen Skerman	Medical Oncology	A sequential multiple assignment randomised trial (SMART) of nursing interventions to reduce pain associated with chemotherapy induced peripheral neuropathy	NHMRC APP1129532	\$178,355	\$713,418.20 (2017-2020)
Alex Broom, Emma Kirby, Renata Kokanovic; Jonathan Adams; Zarnie Lwin ; David Wyld ; Eng-Siew Koh; Paul de Souza; Lisa Woodland	Medical Oncology	Cultural Biographies, Medical Knowledge: a sociological study	Australian Research Council Linkage Grant	\$342,320	\$210,000 [ARC contribution] + [\$816,962 cash/ in-kind partner contributions] (2016-2018)
Benjamin Chua , Bryan Day, Stephen Rose, Paul Thomas , Rosalind Jeffree , Yi Chieh Lim, Po-Ling Inglis , Z Lwin , Jacqui Keller	Medical Oncology, Radiation Oncology	Using molecular-guided PET/MRI imaging to target hypoxia in glioblastoma: a preclinical study to identify novel pathways and define molecular signatures associated with hypoxia and poor patient outcome	Herston Imaging Research Facility Seed Funding	\$66,498	\$66,498 (2018)
Matthew Burge , Paul Thomas , David Wyld , Stephen Rose, Melissa Eastgate , Nick O'Rourke, David Cavalluchi, Richard Bryant	Medical Oncology	A study to look at a new way of detecting the spread of pancreas cancer	Herston Imaging Research Facility Seed Funding	\$58,014	\$58,014 (2018)
Matthew Burge , Paul Thomas , David Wyld , Stephen Rose, Melissa Eastgate , Nick O'Rourke , David Cavalluchi, Richard Bryant	Medical Oncology	A Pilot Study of CXCR-4 PET scanning in operable rectal cancer	Herston Imaging Research Facility Seed Funding	\$23,760	\$23,760 (2018)
Matthew Burge	Medical Oncology	MONARCC Study: a randomised Phase 2 study of panitumumab monotherapy versus panitumumab and 5 Fluorouracil as first line treatment for RAS and RAF wild type metastatic colorectal cancer (mCRC)	Australian Gastro-Intestinal Group Innovation Fund	\$33,333	\$100,000 (2017-2019)

2018 Research Grants – Awarded (cont)

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Medical Oncology Clinical Trials Unit	Medical Oncology	Clinical Trials Data Management Grant	Queensland Cancer Fund	\$54,000	\$54,000 (2018)
Melissa Eastgate, David Wyld, Matthew Burge, Vicki Whitehall	Medical Oncology	Genomic landscape of BRAF mutant colorectal cancers	RBWH Diamond Cancer Care Grant 2017	\$18,000	\$36,000 (2017-2018)
David Wyld, Matthew Burge, Ray Chan, Jane Turner, Rachael Neale, Vanessa Beesley, Patsy Yates	Medical Oncology	PREPARES: patients and relatives affected by pancreatic cancer: referral, Education and Support Feasibility trial	RBWH Diamond Cancer Care Grant 2017	\$19,618	\$39,236 (2017-2018)
Matthew Burge, Wyld D, Eastgate M, Ahern E, Whitehall V, Dougall B, Smyth B, Teng M	Medical Oncology, QIMR	Mapping immune infiltrates in colorectal cancer	RBWH Diamond Cancer Care Grant 2017	\$19,320	\$38,640 (2017-2018)
Chan R, Molassiotis A, Yates P, Nasato G, Brown T, Button E, Marshall A, Isenring L, Wyld D, Eastgate M, Gavin N	Medical Oncology	A Patient-family-Centered intervention to promote Nutrition In advanced Cancer patients: a pilot randomised controlled trial	RBWH Diamond Cancer Care Grant 2017	\$20,000	\$40,000 (2017-2018)
Manoj Bhatt (Nuc Med), David Wyld (CCS), Matthew Burge (CCS), Rahul Ladwa (CCS), Peter Garcia (Nuc Med), David Pattison (Nuc Med), Kevin Lee (Nuc Med), Samuel Kyle, Nicholas Dowson, Jye Smith (Nuc Med), Steven Goodman, Stephen Rose	Nuclear Medicine, Medical Oncology, Herston Imaging Research Facility	Pilot project to assess liver metastases by comparing novel, dynamic and static functional imaging, and also morphological imaging with standard of care in WHO Grade I and Grade II Neuroendocrine Tumour (NET)	Herston Imaging Research Facility Seed Funding	\$19,250	\$38,500 (2017-2018)
David Wyld (CCS), Gillian Nasato (CCS)	Medical Oncology	RBWH neuroendocrine tumour Nurse Coordinator	Ipsen Pty Ltd Aust	\$22,500	\$45,000 (2017-2018)
Brett Hughes, Elizabeth Ahern, Bill Dougall, Mark Smyth	Medical Oncology	Pre-operative evaluation of anti-PD1 checkpoint inhibition (Nivolumab) with RANKL blockade (Denosumab) in patients with operable stage I-III NSCLC	Amgen	\$470,185	\$940,370 (697,000 US\$) (2018-2019)
Natasha Roberts (CCS/QUT)	Medical Oncology	Patient Reported Outcomes in a Medical Oncology Setting	Royal Brisbane and Women's Hospital Scholarship	\$36,864	\$36,863.96 (2018)
Geoff Bryant, Melissa Eastgate, David Wyld, Matt Burge	Medical Oncology	Structured symptom reporting for patients with colorectal cancer undergoing chemotherapy	Metro North Hospital and Health Service SEED Grant	\$63,385	\$126,770 (2018 – 2019)
Andrew Scott, Anna Nowak, Hui Ganet, Zarnie Lwin et al	Medical Oncology	The role of FET-PET in glioblastoma	2018 Medical Research Future Fund Grant	\$1,520,000	\$1,520,000 (2018)

2018 Research Publications

Journal Articles

- Ahern E**, Harjunpää H, O'Donnell JS, Allen S, Dougall WC, Teng MWL, Smyth MJ. RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. *Oncoimmunology* [Internet]. 2018 Feb 14;7(6): e1431088. doi: 10.1080/2162402X.2018.1431088. eCollection 2018
- Ahern E**, Smyth MJ, Dougall WC, Teng MWL. Roles of the RANKL-RANK axis in antitumour immunity – implications for therapy. *Nat Rev Clin Oncol*. 2018 Nov;15(11):676-693
- Beesley VL, **Burge M**, Dumbra M, Callum J, Neale RE, **Wyld DK**. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. *Support Care Cancer*. 2018 Sep 26(9), 3153-3161
- Blagden SP, Hamilton AL, Mileskin L, Wong S, Michael A, Hall M, **Goh JC**, Lisyanskaya AS, DeSilvio M, Frangou E, Stronach EA, Gopalakrishna P, Meniawy TM, Gabra H. Phase IB Dose-Escalation and Expansion Study of AKT kinase inhibitor Afuresertib with Carboplatin and Paclitaxel in Recurrent Platinum-Resistant Ovarian Cancer. *Clin Cancer Res*. [Internet] 2018 Dec 18. doi: 10.1158/1078-0432.CCR-18-2277

Journal Articles (cont):

5. Broom A, Kenny K, Kirby E, **Lwin Z**. The collective/affective practice of cancer survivorship. *Br J Sociol*. [Internet] 2018 Nov 8. Doi: 10.1111/1468-4446.12616
6. Brown T, Banks M, **Hughes BGM**, Lin C, Kenny L, Bauer J. Comparison of nutritional and clinical outcomes in patients with head and neck cancer undergoing chemoradiotherapy utilising proactive versus reactive nutrition support approaches. *J Acad Nutr Diet*. 2018; 118 (4): 627-636
7. **Burge M**, Semira C, Lee B, Lee M, Kosmider S, Wong R, Shapiro J, Ma B, Dean AP, Zimet AS, Steel SA, Lok SW, Torres J, Eastgate M, Wong HL, Gibbs P. Previous Bevacizumab and Efficacy of Later Anti-Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: results from a Large International Registry. *Clin Colorectal Cancer*, 2018 Sep 01; 17(3): 593-599
8. Dumbrava MI, Burmeister EA, **Wyld D**, Goldstein D, O'Connell DL, Beesley VL, Gooden HM, Janda M, Jordan SJ, Merrett ND, Payne ME, Waterhouse MA, Neale RE. Chemotherapy in patients with unresected pancreatic cancer in Australia: a population-based study of uptake and survival. *Asia Pac J Clin Oncol*. 2018 Aug;14(4): 326-336
9. Friedlander M, Shannon C, **Goh J**, Scott C, Mileschkin L. Practical considerations for clinicians for transitioning patients on maintenance therapy with olaparib capsules to the tablet formulation of olaparib. *Asia Pac J Clin Oncol*. 2018 Dec;14(6):459-464
10. Gibson AF, Broom A, Kirby E, **Wyld DK, Lwin Z**. '... My biggest worry now is how my husband is going to cope': women's relational experiences of cancer 'care' during illness. *Journal of Gender Studies*. 2018; 27 (8): 901-913
11. Harjunpää H, Blake SJ, **Ahern E**, Allen S, Liu J, Yan J, Lutzky V, Takeda K, Aguilera AR, Guillerey C, Mittal D, Li XY, Dougall WC, Smyth MJ, Teng MWL. Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. *Oncoimmunology*. [Internet] 2018 Mar 26;7(7): e1445949. Doi: 10.1080/2162402X.2018.1445949. eCollection 2018
12. Hill AG, Findlay MP, **Burge ME**, Jackson C, Alfonso PG, Samuel L, Ganju V, Karthaus M, Amatu A, Jeffery M, Di Bartolomeo M, Bridgewater J, Covelev AL, Hidalgo M, Kapp AV, Sufan RI, McCall BB, Hanley WD, Penuel EM, Pirzkall A, Tabernero T. Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) versus cetuximab in combination with FOLFIRI in second line RAS wild-type metastatic colorectal cancer. *Clin Cancer Res*. 2018 May; 24(10):2276-2284
13. Kawamata F, Patch AM, Nones K, Bond C, McKeone D, Pearson SA, Homma S, Liu C, Fennell L, Dumenil T, Hartel G, Kobayasi N, Yokoo H, Fukai M, Nishihara H, Kamiyama T, **Burge ME**, Karapetis CS, Taketomi A, Leggett B, Waddell N, Whitehall V. Copy number profiles of paired primary and metastatic colorectal cancers. *Oncotarget*. 2017 Dec 15;9(3):3394-3405. doi: 10.18632/oncotarget.23277. eCollection 2018 Jan 9
14. Kirby E, **Lwin Z**, Kenny K, Broom A, Birman H, Good P. "It doesn't exist...": negotiating palliative care from a culturally and linguistically diverse patient and caregiver perspective. *BMC Palliat Care*. 2018 Jul 2;17(1):90
15. Kondrashova O, Topp M, Nesic K, Lieschke E, Ho GY, Harrell MI, Zapparoli GV, **Hadley A**, Holian R, Boehm E, Heong V, Sanij E, Pearson RB, Krais JJ, Johnson N, McNally O, Ananda S, Alsop K, Hutt KJ, Kaufmann SH, Lin KK, Harding TC, Traficante N, Australian Ovarian Cancer Study (AOCS), 33ultice A, McNeish IA, Bowtell DD, Swisher EM, Dobrovic A, Wakefield MJ, Scott CL. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. *Nat Commun*. 2018 Sep 28;9(1):3970
16. Ladwa R, Hong HW, **Wyld D**, Pattison DA, **Burge M**. Tumor Cystic Necrosis Following Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors. *Clinical Nuclear Medicine*. 2018 Mar 1; 43(3):186-187
17. Ladwa R, Kalas T, Pathmanathan S, Woodward N, **Wyld D**, Sanmugarajah J. Maintaining Dose Intensity of Adjuvant Chemotherapy Qin Older Patients With Breast Cancer. *Clin Breast Cancer*. 2018 Oct;18(5), e1181-e1187
18. Lassman AB, van den Bent MJ, Gan HK, Reardon DA, Kumthekar P, Butowski N, **Lwin Z**, Mikkelsen T, Nabors LB, Papadopoulos KP, Penas-Prado M, Simes J, Wheeler H, Walbert T, Scott AM, Gomez E, Lee HJ, Roberts-Rapp L, Xiong H, Ansell PJ, Bain E, Holen KD, Maag D, Merrell R. Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I Multicentre trial. *Neuro Oncol*. [Internet] 2018 Jul 5. Doi:10.1093/neuonc/noy091
19. **Lee SF, Burge M, Eastgate M**. Metastatic colorectal cancer during pregnancy: a tertiary center experience and review of the literature. *Obstetric Medicine*. [Internet] 2018 Mar 19; DOI: 10.1177/1753495X18755958
20. Liede A, Hernandez RK, Wade SW, Bo R, Nussbaum NC, **Ahern E**, Dougall WC, Smyth MJ. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. *Oncoimmunology*. [Internet] 2018 Sep 5;7(12):e1480301. Doi: 10.1080/2162402X.2018.1480301
21. Lindemann K, Beale PJ, Rossi E, **Goh JC**, Vaughan D, Tenney ME, Martyn JK, Sommeijer D, Iglesias JL, Kremmidiotis G, Simpson J, Doolin L, Lavranos TC, Leske A, Veillard AS, Espinoza D, Stockler MR, Rischin D; For ANZGOG and HCRN Collaborative Groups. Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103). *Cancer Chemother Pharmacol*. [Internet] 2018 Oct 27. Doi: 10.1007/s00280-018-3706-5
22. **Lwin Z**, Broom A, Sibbritt D, Francis K, Karapetis CS, Karikios D, Harrup R. The Australian Medical Oncologist Workforce Survey: The profile and challenges of medical oncology. *Semin Oncol*. 2018 Oct;45(5-6):284-290
23. McKeage M, Kotasek D, Markman B, Hidalgo M, Millward M, Jameson M, Harris D, Stagg R, Kapoun A, Xu L, **Hughes BGM**. A phase 1b study of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as 1st line treatment of patients with metastatic non-squamous NSCLC. *Targ Oncol* 2018; 13:89-98. Doi 10.1007/s11523-017-0543-0
24. Mercieca-Bebber R, Douglas W, Langford A, Rutherford L, **Roberts N**, Roydhouse J, Wilson M, Tinsley M, King M, Vodicka E, Devine B. A systematic review of the Australian New Zealand Clinical Trials Registry for trials with patient-reported outcomes endpoints. *Quality of Life Research*. 2018 Oct;27(10):2581-2591
25. Metaxas Y, Rivalland G, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, **Hughes BG**, Bouchaab H, Rothschild S, Pavlakakis N, Wolleb S, Petrusch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, Mauti L, John T. Brief Report: Pembrolizumab as palliative immunotherapy in malignant pleural mesothelioma. *J Thorac Oncol*. 2018; 13(11):1784-1791. Doi: 10.1016/j.jtho.2018.08.007
26. Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, **Hughes BGM**, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsí J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. *N Engl J Med*. 2018; 379(4):341-351. Doi:10.1056/NEJMoa1805131

Journal Articles (cont):

27. Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, Kenny L, Chua B, **Hughes BGM**. Helical IMRT with concurrent chemotherapy for oropharyngeal SCC: a prospective investigation of acute swallowing and toxicity patterns. *Head & Neck*. 2018; 40(9):955-1966. Doi:10.1002/hed.25182
28. Moroney LB, Helios J, Ward EC, Crombie J, Burns CL, Yeo SQ, Pelecanos A, Spurgin AL, Blake C, Kenny L, Chua B, **Hughes BGM**. Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. *Support Care Cancer*. [Internet] 2018 Jul 17; Doi: 10.1007/s00520-018-4352-5. Forthcoming 2019 Feb
29. Payne M, Burmeister EA, Waterhouse M, Jordan SJ, O'Connell DL, Merrett ND, Goldstein D, **Wyld D**, Beesley VL, Gooden H, Janda M, Neale RE. Biliary Stenting in Patients With Pancreatic Cancer: Results From a Population-Based Cohort Study. *Pancreas*. 2018 Jan;47(1):80-86. Doi: 10.1097/MPA.0000000000000960
30. Price TJ, Tang M, Gibbs P, Haller DG, Peeters M, Arnold D, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, **Burge M**, Shapiro J. Targeted therapy for metastatic colorectal cancer. *Expert Rev Anticancer Ther*. 2018 Oct;18(10):991-1006. doi: 10.1080/14737140.2018.1502664
31. Semira C, Tran B, **Burge M**, Lipton L, Gibbs P Et al. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence? *Internal medicine Journal*. [Internet]2018 Sep19. doi.org/10.1111/imj.14115
32. Singh S, Moody L, Chan DL, Metz DC, Strosberg J, Asmis T, Bailey DL, Bergsland E, Brendtro K, Carroll R, Cleary S, Kim M, Kong G, Law C, Lawrence B, McEwan A, McGregor C, Michael M, Pasieka J, Pavlakis N, Pommier R, Soulen M, **Wyld D**, Segelov E; Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group. Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors. *JAMA Oncol*. 2018Nov 1; 4(11), 1597-1604 doi:10.1001/jamaoncol.2018.2428
33. Tang M, Price TJ, Shapiro J, Gibbs P, Haller DG, Arnold D, Peeters M, Segelov E, Roy A, Tebbutt N, Pavlakis N, Karapetis C, **Burge M**. Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis Published online: 01 Mar 2018. Expert Review of Anticancer Therapy. 2018 Apr;18(4):339-349. Doi:10.1080/14737140.2018.1444481
34. Tie J, Cohen JD, Wang Y, Li L, Christie M, Simons K, Elsahle H, Kosmider S, Wong R, Yip D, Lee M, Tran B, Rangiah D, **Burge M**, Goldstein D, Singh M, Skinner I, Faragher I, Croxford M, Bampton C, Haydon A, Jones IT, Karapetis CS, Price T, Schaefer MJ, Ptak J, Dobbryn L, Silliman N, Kinde I, Tomasetti C, Papadopoulos N, Kinzler K, Volgestein B, Gibbs P. Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study. *GUT- BJM [Internet]*. 2018 Feb 2. pii: gutjnl-2017-315852. doi: 10.1136/gutjnl-2017-315852
35. Wann A, Tully P, Barnes L, **Lwin Z**, Jeffree L, Drummond K, Gan H, Khasraw M. Outcomes after second surgery for recurrent glioblastoma: A retrospective case-control study. *J Neuro-Oncol*. 2018 Apr;137(2):409-415. doi: 10.1007/s11060-017-2731-2
36. Wong, W T, Broom A, Kirby E, **Lwin Z**. What lies beneath? Experiencing emotions and caring in oncology. *Health (London)*. [Internet] 2018 Sep 24. Doi:10.1177/1363459318800168
37. Wong T, Kirby E, Broom A, Sibbritt D, Francis K, Karapetis C, Karikios D, Harrup R, **Lwin Z**. A mixed methods analysis of experiences and expectations among early career medical oncologists in Australia. *Asia Pac J Clin Oncol*. [Internet] 2018 Jan 26;14(5): e521-e527 Doi: 10.1111/ajco.12844
38. Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiet S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Fivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgürö-lu M; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med* 2018; 379:2342-2350 DOI: 10.1056/NEJMoa1809697 (**Hughes B**)
39. Block MS, Vierkant RA, Rambau PF, Winham SJ, Wagner P, Traficante N, Tołoczko A, Tiezzi DG, Taran FA, Sinn P, Sieh W, Sharma R, Rothstein JH, Ramón Y Cajal T, Paz-Ares L, Oszurek O, Orsulic S, Ness RB, Nelson G, Modugno F, Menkiszak J, McGuire V, McCauley BM, Mack M, Lubiński J, Longacre TA, Li Z, Lester J, Kennedy CJ, Kalli KR, Jung AY, Johnatty SE, Jimenez-Linan M, Jensen A, Intermaggio MP, Hung J, Herpel E, Hernandez BY, Hartkopf AD, Harnett PR, Ghatage P, García-Bueno JM, Gao B, Fereday S, Eilber U, Edwards RP, de Sousa CB, de Andrade JM, Chudecka-Glaz A, Chenevix-Trench G, Cazorla A, Brucker SY; Australian Ovarian Cancer Study Group, Alsop J, Whittemore AS, Steed H, Staebler A, Moysich KB, Menon U, Koziak JM, Kommoss S, Kjaer SK, Kelemen LE, Karlan BY, Huntsman DG, Högdall E, Gronwald J, Goodman MT, Gilks B, García MJ, Fasching PA, de Fazio A, Deen S, Chang-Claude J, Candido Dos Reis FJ, Campbell IG, Brenton JD, Bowtell DD, Benítez J, Pharoah PDP, Köbel M, Ramus SJ, Goode ELN. MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. *Mayo Clin Proc*. 2018;93(3):307-320 (**Wyld D**)
40. Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J. Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. *Journal of Clinical Oncology*. [Internet] 2018 April20; 36(19): JCO2017764258 DOI: 10.1200/JCO.2017.76.4258 (**Nottage M**)
41. Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE Jr, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM; SOFT and TEXT Investigators and the International Breast Cancer Study Group. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. *N Engl J Med*. 2018 Jul 12;379(2):122-137 (**Nottage M**)
42. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A, Gebiski V, Van Buskirk M, Zhao H, van Hazel G; SIRFLOX and FOXFIRE Global Trial Investigators. Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. *Clin Colorectal Cancer*. [Internet] 2018 Dec;17(4):e617-e629. doi: 10.1016/j.clcc.2018.06.001 (**Burge M**)
43. Horn L, Mansfield AS, Szczesna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinnavar F, Lin W, Sandler A, Liu SV; Impower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl J Med*. 2018 Dec 6;379(23):2220-2229. (**Hughes B, Inglis PL, Lwin Z**)
44. Iveson TJ, Kerr RS, Saunders MP, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Scudder C, Boyd KA, Briggs A, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan HS, Pau J. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. *Lancet Oncol* 2018; 19: 562–78 (**Burge M**)

Journal Articles (cont):

45. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S, Powles T, Donskov F, Neiman V, Kollmannsberger CK, Salman P, Gurney H, Hawkins R, Ravaud A, Grimm MO, Bracarda S, Barrios CH, Tomita Y, Castellano D, Rini BI, Chen AC, Mekan S, McHenry MB, Wind-Rotolo M, Doan J, Sharma P, Hammers HJ, Escudier B, for the CheckMate 214 Investigators*. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. *N Engl J Med* 2018Apr 5; 378:1277-1290 DOI: 10.1056/NEJMoa1712126 (**Goh J**)
46. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodríguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *Journal of Clinical Oncology*. 2018 Aug; 36(24):2465-2472. JCO2018789909. doi: 10.1200/JCO.2018.78.9909 (**Inglis P**)
47. Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, Rodríguez-Abreu D, Moro-Sibilot D, Thomas CA, Barlesi F, Finley G, Kelsch C, Lee A, Coleman S, Deng Y, Shen Y, Kowanetz M, Lopez-Chavez A, Sandler A, Reck M; Impower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *N Engl J Med*. 2018 Jun 14;378(24):2288-2301. (**Hughes B**)
48. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, Song C, Wu H, Eng-Wong J, Kim K, Kang YK. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study. *Lancet Oncol*. 2018 Oct;19(10):1372-1384 (**Burge M**).

2018 Conference Presentations – Invited Speaker, Oral and Poster

Invited Speaker:

1. **Ahern E**. Pre-operative PD1 checkpoint blockade and RANKL inhibition in Non-Small Cell Lung Cancer (POPCORN) – Metro North Research Retreat 2018. Brisbane, Australia
2. **Ahern E**. Pre-operative PD1 checkpoint blockade and RANKL inhibition in Non-Small Cell Lung Cancer (POPCORN) – Brisbane Diamantina Health Partners Cancer Theme Seminar – Lung Cancers 2018. Brisbane, Australia
3. **Hughes B**. Advances in systemic therapy of head and neck cancer. Brisbane Cancer Care Conference 2018. Brisbane, Australia
4. **Lwin Z**. Palliative care in the context of cultural and linguistic diversity: the role of the interpreter. Society of Neuro-oncology Annual Scientific Meeting 2018. New Orleans, USA
5. **Lwin Z**. Role of biomarkers in new WHO classification of glioma. COGNO Consumer Advisory Panel Workshop. Co-operative Trials Group of Neuro-oncology Annual Scientific Meeting 2018, Brisbane, Australia
6. **Lwin Z**. Cardio-oncology: the Oncologist's perspective. Cardiac Society of Australia-New Zealand Annual Scientific Meeting 2018. Brisbane, Australia
7. **Lwin Z**. The changing landscape of cancer survivorship. Cancer Care Services, RBWH Cancer Research Monthly Forum 2018. Brisbane
8. **Lwin Z**. Travelling with Cancer. Grand rounds, Royal Brisbane and Women's Hospital. 2018 Brisbane, Australia
9. **Lwin Z**. Travel advice for cancer patients South East Queensland Oncology Group meeting. 2018. Brisbane, Australia
10. **Lwin Z**. The role of the informal carer in glioma. Asian Society of Neuro Oncology Annual Scientific Meeting, Beijing, China Oct 2018
11. **Wyld D**. Epidemiology – ENETS Meets East and West – Asian Pacific Perspective. European Neuroendocrine Tumour Society 15th Annual Conference 2018. Barcelona, Spain.

Oral Presentations:

1. **Al-Saig H**. Adjuvant endocrine therapy in breast cancer. General Practitioner Education evening 2018. Brisbane Australia
2. **Al-Saig H**. Post European Society for Medical Oncology Congress update. South East Queensland Oncology Group Meeting 2018. Brisbane, Australia
3. **Burge M**. Circulating tumor DNA analysis informing adjuvant chemotherapy in stage III colon cancer: a multicenter phase II/III randomized controlled study (DYNAMIC-III). Brisbane Cancer Care Conference 2018. Brisbane, Australia
4. **Burge M**. Enhancing immunotherapy in colorectal cancer: an RBWH study. Brisbane Cancer Care Conference 2018. Brisbane, Australia
5. Burtress B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyri A, Basté Rotllan N, Neupane P, Bratland A, Fuereder T, **Hughes BGM**, Mesia R, Ngamphaiboon N, Rordorf T, 15 Ishak WZW, Roy A, Cheng J, Jin F, Rischin D. KEYNOTE-048: Phase 3 study of first-line pembrolizumab (P) for recurrent/ metastatic head and neck squamous cell carcinoma (R/M HNSCC). European Society for Medical Oncology Congress 2018. Munich, Germany
6. **Bryant G**. Creating intelligence from patient experience: just a Qlik away? Health Services Research Association of Australia and New Zealand Pros and Cons of PROMs and PREMs conference 2018 (November). Sydney
7. **Campbell JS**. Capacity Building of Gynae Trial Sites. Australia New Zealand Gynaecological Oncology Group Annual Scientific Meeting 2018. Brisbane, Australia
8. Cayce E, **Inglis P**, **Kuchel A**, Stephens S. Keep the pineal gland operating and you will never grow old. Cooperative Trials Group for Neuro-Oncology 11th Annual Scientific Meeting 2018. Brisbane, Australia
9. Chan R, Bradford N, Walker R, Henney R, **Inglis P**. Improving Clinical practice for fertility preservation. 2nd Victorian Cancer Survivorship Conference 2018. Melbourne, Australia
10. **Cubitt A**. Clinical Trials History & Infrastructure. Where Have We Come From? Where Are We Going? Brisbane Cancer Care Conference 2018. Brisbane, Australia
11. de Bono J, **Goh J**, Ojamaa K, Gross-Gouil M, Piulats J, Drake Charles G, Hoimes CJ., Wu H, Qiu P, Poehlein C, Antonarakis ES. Keynote-199: Pembrolizumab For Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC). American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
12. **Eastgate M**. Trends in outcomes of resected intracranial metastatic melanoma across the pre and post era of modern systemic therapies. 27th Annual RBWH Healthcare Symposium 2018. Brisbane, Australia

Oral Presentations: (cont):

13. Fong L, Powderly J, Luke J, Hotson D, Sznol M, George S, Choueri T, Rini B, Hellmann M, Kummar S, Hernandez-Aya L, Mahadevan D, **Hughes B**, Markman B, Riese M, Brody J, Renouf D, Heist R, Goodwin R, Wiese A, Emens L, Willingham S, Kwei L, Laport G, Miller R. Refractory Renal Cell Cancer (RCC) Exhibits High Adenosine A2A Receptor (A2AR) Expression and Prolonged Survival Following Treatment With the A2AR Antagonist CPI-444. The Society for Immunotherapy of Cancer Conference 2018. Washington, USA
14. **Goh J**. Management of gBRCA/HRD mutation associated high-grade serous ovarian cancer. 27th Annual RBWH Healthcare Symposium 2018. Brisbane, Australia
15. **Goh J**. Genito-Urinary and Gynaecology. Brisbane Cancer Care Conference 2018. Brisbane, Australia
16. **Goh J**. Advances & trials in renal cell cancer care. Brisbane Cancer Care Conference 2018. Brisbane, Australia
17. **Goh J**. Advances and trials in Prostate Cancer therapy. Brisbane Cancer Care Conference 2018. Brisbane, Australia
18. **Hughes B**. HREC/QRBW/43659 – POPCORN: Pre-surgical evaluation of anti-PD1 with Denosumab in patients with operable stage 1-3A NSCLC. Cancer Care Services Research Retreat 2018. Brisbane, Australia
19. **Hughes B**. Head and neck cancer. Brisbane Cancer Care Conference 2018. Brisbane, Australia
20. **Hughes BGM**, Nowak AK, Grosso F, Steele N, Novello S, Popat S, Greillier L, John T, Leighl NB, Reck M, Pavlakakis N, Sørensen JB, Planchard D, Ceresoli GL, Mazières J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti GV. Nintedanib+pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): phase II biomarker data from the LUME-Meso study. Australian Lung Cancer Conference 2018. Sydney, Australia
21. **Hughes BGM**, Vansteenkiste J, Reungwetwattana T, Nakagawa K, Cho BC, Cobo Dols M, Cho EK, Bertolini A, Bohnet S, Zhou C, Lee KH, Nogami N, Okamoto I, Leighl N, Hodge R, McKeown A, Brown AP, Rukazenkova Y, Ramalingam SS. Central Nervous System (CNS) response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): data from the phase III FLAURA study. Australian Lung Cancer Conference 2018. Sydney, Australia
22. Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, Barnes E, Hovey E, Ellingson B, **Lwin Z**. Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG) (2018) Co-operative Trials Group of Neuro-oncology Annual Scientific Meeting 2018. Brisbane, Australia
23. Kok PS, Stockler MR, Lesterhuis WJ, **Hughes BGM**, Brown C, Kao SCH, Karikios D, John T, Pavlakakis N, O'Byrne K, Yip S, Lam WS, Briscoe K, Karapetis CS, Nowak A. DREAM - A phase 2 trial of DuRvalumab with first line chemotherapy in Mesothelioma: Final result. Clinical Oncology Society of Australia Annual Scientific Meeting 2008. Perth, Australia
24. Moore J, Dunn N, Tran T, **Wyld D**. Is survival improving for patients diagnosed with small intestinal neuroendocrine tumours in Queensland? Clinical Oncology Society of Australia Annual Scientific Meeting 2018. Perth, Australia
25. Nowak A, Kok PS, Lesterhuis WJ, **Hughes BGM**, Brown C, Kao SCH, Karikios D, John T, Pavlakakis N, O'Byrne K, Yip S, Lam WS, Briscoe K, Karapetis CS, Stockler MR. DREAM - A phase 2 trial of DuRvalumab with first line chemotherapy in Mesothelioma: Final result. The International Association for the Study of Lung Cancer World Conference on Lung Cancer 2018. Toronto, Canada
26. Nowak AK, Lesterhuis WJ, **Hughes BGM**, Brown C, Kok PS, O'Byrne K, John T, Pavlakakis N, Kao SCH, Yip S, Lam WS, Karikios D, Langford A, Stockler M. DREAM: A Phase II study of DuRvalumab with first line chemotherapy in Mesothelioma: First Results. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
27. Nowak AK, Lesterhuis WJ, **Hughes BGM**, Brown C, Yeung A, Kok PS, Yip S, Lam WS, Kao S, Karikios D, John T, Pavlakakis N, Stockler M on behalf of ALTG (Australasian Lung Cancer Trials Group). DREAM - A phase 2 trial of DuRvalumab with first line chemotherapy in Mesothelioma with a safety run in. International Mesothelioma Interest Group 2018. Ottawa, Canada
28. Oza A, Coleman RL, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JL, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, **Goh JC**, O'Malley DM, Banerjee S, Goble S, Cameron T, Ledermann JA. Effect of Prior Bevacizumab Therapy in Patients with Platinum-Sensitive Recurrent Ovarian Carcinoma in the Phase 3 Study ARIEL3. International Gynecologic Cancer Society 17th Biennial Meeting 2018. Kyoto, Japan
29. Pavlakakis N, Novello S, Nowak AK, Grosso F, Steele N, Popat S, Greillier L, John T, Leighl NB, Reck M, Sørensen JB, Planchard D, Ceresoli GL, **Hughes BGM**, Mazières J, Socinski M, von Wangenheim U, Barrueco J, Morsli N, Scagliotti GV. Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib+pemetrexed/cisplatin (PEM/CIS) vs placebo+PEM/CIS in chemo-naïve patients with malignant pleural mesothelioma (MPM). Australian Lung Cancer Conference 2018. Sydney, Australia
30. Puztai T, **Cubitt A**, Keller J. How do we measure activity? Cancer Care Services Research Retreat 2018. Brisbane, Australia
31. **Roberts N**. Early insights into implementing patient reported outcomes measures (PROMs) into a busy healthcare setting 27th Annual RBWH Healthcare Symposium 2018. Brisbane, Australia
32. **Roberts N**. Using Patient Reported Outcome Measures in Routine Patient Care. Blood Congress 2018. Brisbane, Australia
33. Shaw AT, Lee SH, Ramalingam SS, Bauer TM, Boyer MJ, Costa EC, Felip E, Han JY, Hida T, **Hughes BGM**, Kim SW, Nishio M, Seto T, Ezh PI, Chakrabarti D, Wang J, Chang A, Fumagalli L, Solomon BJ. Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: phase 1b data from the JAVELIN Lung 101 trial. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
34. **Suder A**. Overview of bladder cancer. Brisbane Cancer Care Conference 2018. Brisbane, Australia
35. Tran Q, Schmidt A, **Lwin Z**, **Hughes BGM**. Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study. European Society for Medical Oncology Congress 2018 Munich, Germany
36. **Wyld D**, **Burge M**, Dumbra M, Callum J, Neale R, Beesley V. How the rare see their care: Perceptions of care and patient reported outcomes in people living with neuroendocrine tumours. 2nd Victorian Cancer Survivorship Conference 2018. Melbourne, Australia
37. **Wyld D**, **Burge M**, Dumbra M, Callum J, Neale R, Beesley V. Perceptions of care and patient-reported outcomes in people living with neuroendocrine tumours. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
38. **Wyld D**, **Wyld M**, Moore J, Tran N. Neuroendocrine neoplasms in the paediatric, adolescent and young adult population in Queensland, Australia. Australian Gastro Intestinal Trials Group Annual Scientific Meeting 2018. Brisbane, Australia.

Poster Presentations:

1. Le DT, Kavan P, Kim TW, **Burge ME**, Van Cutsem E, Hara H, McKay Boland P, Van Laethem J, Geva R, Taniguchi H, Crocenzi TS, Sharma M, Atreya CE, Diaz LA, Liang LW, Marinello P, Dai T, O'Neil BH. KEYNOTE-164: Pembrolizumab for patients with advanced microsatellite instability high (MSI-H) colorectal cancer. *Journal of Clinical Oncology*. 2018 May 20; 36, no.15_suppl. DOI: 10.1200/JCO.2018.36.15_suppl.3514 **Poster and Discussion**
2. Aghajanian C, Coleman RL, Oza AM, Lorusso D, Oaknin A, Dean AP, Colombo N, Weberpals JI, Clamp AR, Scambia G, Leary A, Holloway RW, Fong PCC, **Goh J**, O'Malley DM, Banerjee SN, Wride K, Cameron T, Ledermann JA. Evaluation of Rucaparib in Platinum-Sensitive Recurrent Ovarian Carcinoma (rOC) in Patients With or Without Residual Bulky Disease at Baseline in the ARIEL3 Study. Abstract 5537. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
3. **Ahern E.** et al, An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. Medical Oncology Group of Australia Annual Scientific Meeting 2018. Adelaide, Australia
4. Allen MJ, Schmidt A, **Lwin Z, Hughes BGM**. Hospital admissions due to immune-oncology therapy associated toxicity: A retrospective analysis at two tertiary oncology centres. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
5. Banerjee SN, Tang M, O'Connell R, Clamp AR, Lord R, Mullassery VM, Hall M, Gourley C, Bonaventura T, **Goh J**, Sykes P, Grant PT, McNally O, Sjoquist K, Alexander L, Carty K, Paul J, Edmondson RJ, Friedlander M. PARAGON – a phase 2 study of Anastrozole (An) in patients with estrogen receptor (ER) and/ progesterone receptor (PR) positive recurrent/metastatic granulosa cell tumors/sex-cord stromal tumors (GCT) of the ovary – ANZGOG 0903. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
6. Barnett C, Sommerville R, Lin C, **Hughes B**, Taheri T. CXCR4 and PD-1 Expression in Head and Neck Cancer with Perineural Spread. 28th Annual Meeting North American Skull Base Society 2018. Orlando, USA
7. Bryant G, **Eastgate M, Wyld D, Burge M, Thaker D**, Busato M. Colorectal cancer patient reported outcomes: putting theory into practice. Clinical Oncology Society of Australia Annual Scientific Meeting 2018. Perth, Australia
8. **Bryant G, Wyld D, Burge M, Thaker D, Busato M & Eastgate M**. Colorectal cancer patient-reported outcomes: putting theory into practice. Clinical Oncology Society of Australia 2018 Annual Scientific Meeting. Perth, Australia
9. **Bryant G, Thaker D, Wyld D, Leach J, Wheatley H & Garth V**. Implementing a highly accessible model of screening and assessment in geriatric oncology: our experience. Clinical Oncology Society of Australia 2018 Annual Scientific Meeting. Perth, Australia
10. Bryant G, **Thaker D, Wyld D**, Leach J, Wheatley H, Garth V. Implementing a highly accessible model of screening and assessment in geriatric oncology: Our experience. Clinical Oncology Society of Australia Annual Scientific Meeting 2018, Perth, Australia.
11. Dulfkar A, **Lwin Z**, Pinkham E, Foo J, Hides J, Pinkham M, Naumann F. 'Active Patients' Tailored Exercise as Intervention in People with Glioma. Princess Alexandra Hospital Symposium 2018. Brisbane, Australia
12. Dulfkar A, **Lwin Z**, Pinkham E, Foo J, Hides J, Pinkham M, Naumann F. Feasibility of an Individualised Exercise Intervention During and After Treatment in Patients with Glioma: A Case Report Translational Research Institute Symposium 2018. Brisbane, Australia
13. Dulfkar A, Koh E-S, **Lwin Z**, Hovey E, Dhillion H, Arundell J, Pinkham E, Foo J, Hides J, Pinkham M, Naumann F. Baseline functional status in post-operative glioma patients prior to adjuvant radiation: relevance to participation in a supervised exercise programme. Co-operative Trials Group of Neuro-oncology Annual Scientific Meeting 2018. Brisbane, Australia
14. **Eastgate MA**, Atkinson V, Khattak MA, Roy AC, Haydon AM, Mueller C, Dunkelmann T, Brignone C, Triebel F. Pushing the accelerator and releasing the brake: A phase I dose escalation study evaluating a LAG-3 fusion protein (eftilagimod alpha), together with pembrolizumab in unresectable or metastatic melanoma. American Society of Clinical Oncology 2018. Chicago, USA
15. **Eastgate M, Wyld D, Dumbrava M**, Brown T. Dietary patterns and preferences/attitudes of cancer patients regarding sources of information about the diet during cancer treatment. 27th Annual RBWH Healthcare Symposium 2018 Brisbane, Australia
16. Fingrut W, Yelamanchili R, Thawer A, Chan D, **Wyld D**, Singh S, Lo D. Ontario oncologists' perspectives on addressing potential barriers in the management of patients with neuroendocrine tumours. North American Neuroendocrine Tumour Society Annual Multidisciplinary NET Disease Symposium 2018. Seattle, USA
17. **Goh JC**, Baron-Hay S, Bonaventura T, Buck M, Dean A, Friedlander M, Gao B, Mileschkin L, Oehler MK, Steer C, Nguyen V, Goble S, Grechko N, Monk BJ, Kristeleit RS. ATHENA (GOG-3020/ENGOT-ov45): a Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study of Rucaparib + Nivolumab Following Front-Line Platinum-Based Chemotherapy in Ovarian Cancer. Clinical Oncology Society of Australia Annual Scientific Meeting 2018. Perth, Australia
18. Goodman S, Patford S, Ladwa R, Smith J, **Wyld D**, Pattison DA. Validation of Abbreviated 177Lu-DOTATATE Renal and Lesional Dosimetry Protocol using Quantitative SPECT. 12th Congress of the World Federation of Nuclear Medicine and Biology 2018. Melbourne, Australia
19. Grosso F, Nowak AK, Steele N, Novello S, Popat S, Greillier L, John T, Leighl NB, Reck M, Pavlakakis N, Sorensen JB, Planchard D, Ceresoli GL, **Hughes BGM**, Mazieres J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti GV. Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma: Phase II biomarker data from the LUME-Meso study International Mesothelioma Interest Group 2018. Ottawa Canada
20. Guccione L, Murray A, Gough K, Michael M, Khasraw M, Price T, Pavlakakis N, **Wyld D**, Ransom D, Kong G, Leyden S, Leyden D, Rogers M, Schofield P. Living with a rare and complex cancer diagnosis: Describing the experiences, information and supportive care needs, psychosocial status and characteristics of patients with newly diagnosed Neuroendocrine Tumours. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
21. **Hughes BGM**, Mersiades A, Livingstone A, Jurkovic H, O'Connor J, Stockler M, Badillo F, Leighl N. BR-34 – a randomized trial of durvalumab and tremelimumab plus or minus/- platinum-based chemotherapy in patients with high-risk, metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC). Australian Lung Cancer Conference 2018. Sydney, Australia
22. Itchins M, Alexander M, John T, Kao S, **Hughes BGM**, Lee A, Hayes SA, Harvie R, Howell VM, Clarke SJ, Millward M, Solomon B, Pavlakakis N. Retrospective combined cohort analysis of the pattern of care and survival in advanced ROS1 rearranged non-small cell lung cancer (NSCLC). The Australian experience. World Conference on Lung Cancer 2018. Toronto, Canada
23. Itchins M, Alexander M, John T, Kao S, **Hughes BGM**, Clarke S, Millward M, Solomon B, Pavlakakis N. Retrospective combined cohort analysis of the pattern of care and survival in advanced ROS1 rearranged non-small cell lung cancer (NSCLC). The Australian experience. Australian Lung Cancer Conference 2018. Sydney, Australia

Poster Presentations (cont):

24. Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, Barnes E, Hovey E, Ellingson B, **Lwin Z**. Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG). Society of Neurooncology Annual Scientific Meeting 2018, New Orleans, USA
25. Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, Barnes E, Hovey E, Ellingson B, **Lwin Z**. Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG). Clinical Oncology Society of Australia Annual Scientific Meeting 2018. Perth, Australia
26. Khasraw M, McDonald K, Yip S, Verhaak R, Heimberger A, Hall M, Barnes E, Hovey E, Ellingson B, **Lwin Z**. Nivolumab and Temozolomide (TMZ) vs TMZ alone in newly diagnosed elderly patients (pts) with Glioblastoma (GBM) (NUTMEG): Trial in progress European Association of Neurooncology 2018. Stockholm, Sweden
27. Khasraw M, McDonald KL, Rosenthal M, **Lwin Z**, Ashley DM, Wheeler H, Barnes E, Koh E-S, Foote MC, Buckland M, Swanson R, Hall M, Yip S, Oostendorp M, Simes J. A randomized phase 2 trial of veliparib and radiotherapy and temozolomide in patients with unmethylated MGMT glioblastoma: Feasibility and safety outcomes (the VERTU study). American Society of Clinical Oncology 2018. Chicago, USA
28. Kisiel N, Ladwa R, Smith J, Lee K, Ramsay S, Bhatt M, Nocher S, **Burge M**, **Wyld D**, Pattison D. Renal function influences renal absorbed dosimetry, haematologic toxicity and early withdrawal from 177Lu-DOTATATE treatment. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
29. **Kuchel A**, McGrath K, **Wyld D**, **Burge M**, **Eastgate M**. Use of adjuvant chemotherapy and outcomes after preoperative long course chemoradiation in rectal cancer – a 2 year Royal Brisbane experience. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting 2018. Brisbane, Australia
30. Kulkarni S, Laurie S, Goss G, Perrone F, **Hughes BGM**, Stockler M, Blais A, Zibdawi L, Vera-Badillo FE, Leighl NB. BR-34 Clinical Trial in progress- A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with high-risk, metastatic (stage IV) squamous or non-squamous non-small cell lung cancer (NSCLC). World Conference on Lung Cancer 2018. Toronto, Canada
31. Lee K, Debowski M, Goodman S, Bhatt M, Ramsay S, Pattison D, Francis L, **Wyld D**. Renal tubular injury presenting after 177Lu-DOTATATE peptide receptor radionuclide therapy with high renal dosimetry. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
32. **Lee SF**, Jeffree R, **Eastgate M**. Trends in outcomes of resected intracranial metastatic melanoma across the pre- and post-era of modern systemic therapies. Co-operative Trials Group of Neuro-oncology Annual Scientific Meeting 2018. Brisbane, Australia
33. **Lee S**, **Wyld D**, **Eastgate M**, **Cubitt A**, **Hingston L**, **Burge M**. Prospective evaluation of modified FOLFIRINOX for metastatic or locally advanced pancreatic cancer. Australian Gastro-Intestinal Trials Group Annual Scientific Meeting 2018. Brisbane, Australia
34. **Lee SF**, **Wyld D**, **Eastgate M**, Brown T. Dietary patterns and attitudes in cancer survivors. 2nd Victorian Cancer Survivorship Conference 2018. Melbourne, Australia
35. **Lee S**, **Wyld D**, **Brown T**, **Eastgate MA**. Dietary patterns and attitudes in cancer patients. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
36. Liede A, Hernandez RK, Wade SW, Bo R, **Ahern E**, et al. An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. American Society of Clinical Oncology Annual Meeting 2018. Chicago, USA
37. **Lwin Z**, Kirby E. I'm the handbrake.... the role of informal carers in glioma. Co-operative Trials Group of Neuro-oncology Annual Scientific Meeting 2018. Brisbane, Australia
38. McGahan W, Waterhouse M, O'Connell D, Merrett N, **Wyld D**, Goldstein D, Neale RE. The use of serum CA19-9 to guide selective uptake of staging laparoscopy in patients with pancreatic cancer. Royal Australasian College of Surgeons Annual Scientific Congress 2018. Sydney, Australia
39. Michael M, Pook DW, Ganju V, Link E, Toner GC, Hicks RJ, Matera A, Thompson M, Cullinane C, Campbell I, **Burge M**, Karapetis CS. The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
40. Moor RJ, Roberts KE, Mason R, Gunawan B, Feng S, Hong JH, Von Itzstein M, **Hughes BGM**, **Lwin Z**, Jain VK, Bigby KJ, Azer MWF, Sanmugarajah J, O'Byrne JJ. Immune-related adverse events and nivolumab outcomes in non-small cell lung cancer patients: A multi-institutional, retrospective cohort study. American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
41. O'Byrne K, Mauti L, Rivalland G, Klingbiel D, Kao S, Schmid, Nowak A, Gautschi, **Hughes B**, Bartnick T, Pavlakis N, Bouchaab H, Rothschild S, Russell P, Savic-Prince, Thapa B, Pless M, von Moos R, Metaxas Y, John T. Real world outcomes for patients treated with pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM). International Mesothelioma Interest Group 2018. Ottawa, Canada
42. Pavlakis N, Grosso F, Steele N, Nowak AK, Novello S, Popat S, Greillier L, Reck M, John T, Taylor P, Leighl NB, Ceresoli GL, Sorensen JB, Planchard D, **Hughes BGM**, Mazières J, Socinski M, Buchner H, Barrueco J, Scagliotti GV. Association between progression-free survival (PFS) rate (PFSR) and overall survival (OS) in LUME-Meso, a study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
43. Popat S, Grosso F, Steele N, Nowak AK, Novello S, Greillier L, Reck M, John T, Taylor P, Leighl NB, Ceresoli GL, Sorensen JB, Pavlakis N, Planchard D, **Hughes BGM**, Mazières J, Socinski M, von Wangenheim U, Barrueco J, Norsli N, Scagliotti GV. Tumor burden (TB), treatment exposure (TE) and adverse events (AEs) in the combination and monotherapy phases of LUME-Meso, a study of nintedanib (N)/placebo (P) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance with N or P in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM). American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
44. Popat S, Novello S, Nowak AK, Grosso F, Steele N, Greillier L, John T, Leighl NB, Reck M, Pavlakis N, Sorensen JB, Planchard D, Ceresoli GL, **Hughes BGM**, Mazières J, Socinski M, von Wangenheim U, Barrueco J, Norsli N, Scagliotti GV. Phase II LUME-Meso study of first-line nintedanib + chemo in malignant pleural mesothelioma: additional efficacy analyses. International Mesothelioma Interest Group 2018 Ottawa, Canada
45. Ratnayake G, Shanker M, Roberts K, Mason R, **Hughes B**, **Lwin Z**, Jain V, Vagenas D, O'Byrne K, Chua B. Prior or Concurrent Radiotherapy and Nivolumab Immunotherapy in Non-Small Cell Lung Cancer. European Society for Medical Oncology Congress 2018. Munich, Germany

Poster Presentations (cont):

46. Rischin D, Migden MR, Chang A, Chung CH, Dunn L, Guminski A, Hauschild A, Hernandez-Aya L, **Hughes BGM**, Lewis KD, Lim AML, Modi B, Schadendorf D, Schmultz C, Booth J, Li S, Mohan KK, Stankevich E, Lowy I, Fury MG. Primary analysis of phase 2 results for cemiplimab, a human monoclonal anti-PD-1, in patients with metastatic cutaneous squamous cell carcinoma (mCSCC). American Society of Clinical Oncology 2018 Annual Conference, Chicago, USA
47. **Roberts NA**, Janda M, Alexander K, **Wyld D**. Describing patient Reported Outcomes measures (PROMs) Knowledge for the Multi-Disciplinary Team. 20th World Congress of Psycho-Oncology 2018. Hong Kong
48. **Roberts NA**, Janda M, Alexander K, **Wyld D**. Describing patient Reported Outcomes measures (PROMs) Knowledge for the Multi-Disciplinary Team. Cancer Care Services Research Retreat 2018. Brisbane, Australia
49. Sjoquist KM, Mileschkin LR, Ananda S, Shannon CM, Bowtell D, Yip S, Espinoza D, **Goh J**, Harrison ML, Plebanski M, Gebiski V, Stockler MR, Livingstone K, Tang M, Friedlander M. REZOLVE (ANZGOG-1101): a phase 2 trial of intraperitoneal (IP) bevacizumab (bev) for recurrent ascites in advanced, chemotherapy-resistant, epithelial ovarian cancer (CR-EOC). American Society of Clinical Oncology Annual Conference 2018. Chicago, USA
50. Socinski M, Rittmeyer A, Shapovalov D, Orlandi F, McCleod M, Soo R, Palmero R, Kozuki T, Migliorino MR, Koynov K, Berard H, **Hughes BGM**, Lin R, Graupner V, Sun SW, Kowanetz M, Hoang T, Lin W, Jotte R. Overall survival analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel vs carboplatin + nab-paclitaxel in 1L advanced squamous NSCLC (IMpower131). European Society for Medical Oncology Congress 2018. Munich, Germany
51. Van der Zwan W, **Wyld D**, Brabander T, Teunissen J, Kam B, MacFarlane D, Krenning E, Kwekkeboom D, de Herder W.A Randomized Controlled Study Comparing treatment of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEPNET) with 177Lu-DOTATATE Alone and in Combination with Capecitabine. European Neuroendocrine Tumour Society 15th Annual Conference 2018. Barcelona, Spain.
52. van Haeringen B, **Burge M**, **Wyld D**. Metastatic colorectal carcinoma: Prognostic clinical, pathological and molecular biomarkers and elucidating associations of high neutrophil: lymphocyte ratio. Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting 2018 Brisbane, Australia
53. Wan MH, Moore J, **Wyld DK**. Neuroendocrine Neoplasm Trends Over 32 Years in Queensland, Australia. Princess Margaret Cancer Conference. Accelerating Precision Medicine 2018. Toronto, Canada
54. **Wyld D**, **Burge M**, **Dumbrava M**, **Callum J**, Neale R, Beesley V. How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors. 2nd Victorian Cancer Survivorship Conference 2018. Melbourne, Australia
55. **Wyld D**, **Burge M**, **Dumbrava M**, **Callum J**, Neale R, Beesley V. How the Rare See Their Care: Perceptions of Care and Patient Reported Outcomes in People Living with Neuroendocrine Tumors. (Abstract 1980). European Neuroendocrine Tumour Society 15th Annual Conference 2018. Barcelona, Spain
56. **Wyld D**, Moore J, Parker K, Pattison S, Cockcroft R, Tran N, Lawrence B. Neuroendocrine neoplasms in the paediatric adolescent and young adult population in New Zealand and Queensland Australia. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
57. **Wyld D**, Moore J, Tran N, **Wyld M**. Neuroendocrine Neoplasms in the Paediatric, Adolescent and Young Adult Population in Queensland, Australia. The Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting 2018. Brisbane, Australia
58. **Wyld D**, Wan M, Moore J. Neuroendocrine neoplasm trends over 32 years in Queensland, Australia. Asia Pacific Neuroendocrine Tumour Society Annual Meeting 2018. Melbourne, Australia
59. Yelamanchili R, Thawer A, Chan D, Lo D, Singh S, Fingrut W, **Wyld D**. Insights into the practice patterns, challenges and the role of a shared care model in the management of neuroendocrine (NET) patients in the community. North American Neuroendocrine Tumour Society Annual Multidisciplinary NET Disease Symposium 2018. Seattle, USA
60. **You K**, Lau H, **Paxton Hall F**, **Eastgate M**, **Wyld D**, **Burge M**. Surgery with curative intent in metastatic colorectal cancer: Real world practice in Queensland, Australia. Australasian Gastro-Intestinal Trials Group Annual Scientific Meeting 2018. Brisbane, Australia.

Other Communications and Outputs:

Journal Abstracts:

1. Lee B, Lipton LR, Cohen J, Tie J, Javed AA, Li L, Goldstein D, Cooray P, Nagrial A, **Burge ME**, Tebbutt NC, Nikfarjam M, Harris M, Lennon AM, Wolfgang CL, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Gibbs P. Circulating tumor DNA as a prognostic biomarker in early stage pancreatic cancer. J Clin Oncol 36, 2018 (suppl; abstr e16206)
2. Wong WT, Broom A, Kirby E, **Lwin Z**. What lies beneath? Experiencing emotions and caring in oncology. Health (London). 2018 Sep 24;1363459318800168. doi: 10.1177/1363459318800168. [Epub ahead of print].

Press Programme:

1. Tran Q, Schmidt A, **Lwin Z**, **Hughes B**. Identifying barriers to physical activity in patients with lung cancer: an Australian pilot study European Society of Medical Oncology ASM, ESMO Press Programme. Munich, Germany; 19-23 October 2018.

Research Exhibition Event:

1. Broom A, **Lwin Z**, Kirby E, Kenny K, Plage S, Oliffe J, Parker R, **Wyld D**, Yates P. Photo Exhibition RBWH Picturing Cancer Survivorship" A collection of photographs from the 'changing landscapes of survivorship' study. Brisbane 5–31 Nov 2018.

Radiation Oncology



Assoc. Prof Graeme Dickie
Director Radiation Oncology
 Cancer Care Services RBWH

The culture of inter-disciplinary collaboration and technology to advance research remains strong for radiation oncology in 2018. The regular Research Core Group meeting helps guide the interests and co-ordinate medical, radiation therapist, physics and nursing streams. The aim and focus of the Radiation Oncology Research group is to promote, support and drive innovation, promote quality initiatives and ensure quality improvement projects deliver evidence-based practice, to ensure safe treatment delivery.

Physics and radiation therapy lead most of the investigator-initiated technical studies, with the supervision of higher degrees.

Our department collaborates with several national and international trial groups, including the Tran-Tasman Radiation Oncology Group, Australian Lung Trial Group, Australian and New Zealand Urogenital and Prostate trials group. For some studies with those groups, there is a requirement for independent QA for patient accrual, and our department has been able to meet those standards.

As new and emerging technologies are rapidly being assimilated into daily practice, the focus of research outcomes is to implement new technology in a scientific manner. Quality assurance and research into new technology is important to ensure, precision radiotherapy is delivered in a safe, efficient and cost-effective manner. Our department has expanded surface guided radiotherapy and has expanded deformable registration for the planning and dosimetry review situations.

The radiation oncology team has been successful in securing grants to proceed with several studies through the Herston Imaging and Research Facility and several projects are progressing through the implementation phase. Radiation Oncology

has also been successful in obtaining grants through the Herston Biofabrication Institute to expand 3-D printing in the field of radiation oncology in a research framework.

Radiation Oncology was instrumental in developing a research trials database to record research activity. This database has revolutionised the generation of research reports, facilitates centralised storage of data and has been expanded to include all sections of Cancer Care Services.

Supervised Post-Graduate Research Students

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Trent Aland	PhD, QUT (2013-2019)	Quality assurance of complex radiotherapy treatments	Tanya Kairn , Jamie Trapp
Diana Binny	PhD, QUT (2015-2019)	Optimizing patient plan deliveries by characterizing treatment planning systems in radiotherapy	Scott Crowe , Tanya Kairn , Jamie Trapp
Rae Blades	MApp Sci, QUT (2016-2019)	A cost-effectiveness analysis of a silicone gel (StrataXRT®) for prophylaxis and management of Radiation Induced Skin Injury (RISI) in head and neck cancer patients	Patsy Yates, Ray Chan , Steven McPhail
Georgia Brown	MSc, QUT (2017-2018)	Dosimetric impact of gating of modulated breast radiotherapy using an optical surface monitoring system	Scott Crowe , Tanya Kairn , Steven Sylvander
Athreya Sherma Buddhavarapu	MSc, QUT (2018)	Characterising the performance of the PerFraction patient-specific QA system	Scott Crowe , Francis Gibbons
Naasiha Cassim	MSc, QUT (2017-2018)	Dosimetric plan quality for treatments of multiple brain metastases	Scott Crowe , Tanya Kairn , Mark West, Yurissa Ikeda
Orrie Dancewicz	PhD, QUT (2014-2018)	Development and verification of a novel 3D dosimetry technique for tomotherapy	Scott Crowe , Jamie Trapp, Tim Markwell
Jemma Devereaux	Masters, QUT (2017)	DIBH (Deep Inspiration Breath Hold)-BREaST Trial. Breath Hold Respiratory Endurance and Spirometry Training	Lisa Nissin, Cathy Hargrave, Julie Burberry, Gregory Rattray

Supervised Post-Graduate Research Students (cont)

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Joanna Kapeleris	PhD QUT (2018-2020)	Circulating tumour cells	Chamindie Punyadeera, Lizbeth Kenny
Dr Timothy Liu	MPhil	Oral Squamous Cell Carcinoma with intermediate risk factors	Martin Batstone, Benjamin Chua
Johnny Morales	PhD, QUT (2011-2018)	Independent Monte Carlo analysis for stereotactic radiosurgery treatments	Scott Crowe, Jamie Trapp
Juliana Muller Bark	PhD, QUT (2018 – ongoing)	Non-invasive biomarkers in glioblastoma	Benjamin Chua, Chamindie Punyadeera, Arutha Kulasinghe, Bryan Day, Lindy Jeffree
Samuel Peet	PhD, QUT (2016-2020)	Out-of-field dose in contemporary radiation therapy	Scott Crowe, Tanya Kairn, Jamie Trapp
James Rijken	PhD, QUT (2017-2022)	Dosimetric accuracy for SABR spine radiotherapy treatments	Scott Crowe, Tanya Kairn, Jamie Trapp, Konstantin Momot
Sanphat Sangudsup	PhD, QUT (2018-2020)	Dosimetric impact of interplay effects on FFF VMAT by gel measurements	Scott Crowe, Jamie Trapp, Andrew Fielding
Emma Whittle	MSc, QUT (2017-2018)	Measurement of tissue-phantom ratios in small radiotherapy fields	Scott Crowe, Tanya Kairn, Shadi Khoei, Emma Spelleken
Liting Yu	PhD, QUT (2017-2022)	Developing new methods of dose evaluation for VMAT patient specific plans	Scott Crowe, Jamie Trapp, Tanya Kairn, Christian Langton

2018 Research Positions: Coordinators, Fellow, Adjunct and Honorary Positions

Name	Type of Fellowship	Research Program	University (years)
Scott Crowe	Adjunct Associate Professor	School of Chemistry, Physics and Mechanical Engineering	QUT (2015 – current)
Allison Dry	RT R&D Co-ordinator	Radiation Therapy	Queensland Health
Jennifer Edmunds	Clinical Trial Co-ordinator	Radiation Oncology	Queensland Health
Catriona Hargrave	State-wide RT Research Fellow. Joint appointment with QUT (School of Clinical Sciences, Faculty of Health)	Radiation Oncology / Radiation Therapy	QUT
Tanya Kairn	Adjunct Associate Professor	School of Chemistry, Physics & Mechanical Engineering	QUT (2013 – current)
Jacqui Keller	Manager, Clinical Trials	Radiation Oncology	Queensland Health
Trang Le	Clinical Trial Co-ordinator	Radiation Oncology	Queensland Health
Rob McDowall	Radiation Therapist Consultant	Radiation Oncology / Radiation Therapy	Queensland Health
Charmaine Micklewright	Research Assistant	Radiation Oncology	Queensland Health
Michelle Ralston	Advanced Radiation Therapist	Radiation Oncology / Radiation Therapy	Queensland Health
Lee Tripcony	Principal Scientist Statistics	Radiation Oncology / Statistics	Queensland Health
Christopher Walsh	RT R&D Co-ordinator	Radiation Therapy	Queensland Health

2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Rae Blades / Ray Chan	Melissa Doolan	A cost-effectiveness analysis of a silicone gel (StrataXRT®) for prophylaxis and management of Radiation Induced Skin Injury (RISI) in head and neck cancer patients
Dr Philip Chan	Paul Thomas (HIRF), Robyn Cheuk, Michelle Grogan, Graeme Dickie	Prognostic Value of Assessing Hypoxia in Tumours Using ¹⁸ F-MISO PET During a Course of Radiation Therapy – Proof of Concept Study
Dr Ben Chua	Zarnie Lwin, Bryan Day (QIMR)	Using molecular-guided PET/MRI imaging to target hypoxia in glioblastoma: a preclinical study to identify novel pathways and define molecular signatures associated with hypoxia and poor patient outcome

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Dr Ben Chua	Tristan Shaw	Diagnostic performance of 18-fludeoxyglucose positron emission tomography (FDG-PET) in evaluation of glioma
Jemma Devereaux	Jemma Blyth, Elena Blyth, Gregory Rattray, Catriona Hargrave, Lisa Nissin, Julie Burbery	DIBH (Deep Inspiration Breath Hold)-BREAST Trial. Breath Hold Respiratory Endurance & Spirometry Training
Graeme Dickie	Philip Chan, Rachael Wilks	Pulse Dose Rate Brachytherapy for cervix cancer, Royal Brisbane and Women's Hospital review
Tanya Grant (SPP)	Catriona Hargrave, Jemma Blyth, Allison Dry, Gene Blow (RBWH Cultural Capability Officer), Judy Graham (Ca. Council Qld, Gold Coast), Anna Gordon (Ca. Council Qld, Greater Brisbane)	Improving access to Culturally Safe Care in Radiotherapy for Indigenous Patients
Alice Grigg	Catriona Hargrave	Retrospective evaluation of cardiac reduction between free-breathing (FB) and Deep Inspiration Breath Hold (DIBH) radiation therapy for left-sided breast cancer patients
Dr Lindy Jeffree (RBWH)	Michael Fay (NMH), Jennifer Martin (UON), Paul Thomas (HIRF), Stephen Rose (CSIRO), Nicholas Dowson (CSIRO)	Evaluation of the role of valproate in the treatment of high grade glioma
Tanya Kairn	Scott Crowe, Craig Lancaster, Rachael Wilks, Nancy Yu	Review of optically stimulated luminescence dosimeter measurements from total skin electron radiotherapy treatments
Tanya Kairn	Scott Crowe, Rachael Wilks, Liting Yu, Craig Lancaster	Retrospective review of optically stimulated luminescence dosimeters from total skin electron radiotherapy treatments
Liz Kenny	Sarju Vasani (RBWH)	A Pilot Study of CXCR4 PET for nodal staging of resectable mucosal head and neck Squamous cell carcinoma (HNSCC), including correlation with histopathology immunohistochemistry, sputum and Circulating Tumour Cells
Charles Lin	Ben Chua, Liz Kenny, Michelle Nottage, Brett Hughes, Michele Teng, Paul Thomas	A prospective study investigating the efficacy and toxicity of definitive chemo-radiation and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma
Charles Lin	Charles Lin, Megan Carroll, Ryan Somerville, Sarah Grigg	Carcinoma of Head and Neck with Perineural spread: Outcomes After Skull Base Surgery and Adjuvant Radiotherapy
Alexander Livingstone	Darren Cassidy, Kirby Francis	Developing a Monte Carlo quality assurance check system for radiotherapy
Jasmine Meaghan (SPP), Dr. Catherine Bettington, Rob McDowall,	Dr Cathy Hargrave, Allison Dry, Jemma Devereaux	What anatomical sites will benefit most from contrast-enhanced computed tomography in Radiation Therapy Planning? A review of current literature and standards of practice
Candice Milewski	Scott Crowe, Rachael Wilks, Tanya Kairn	Evaluation of metal artefact reduction algorithms for radiotherapy
Kane Miller (SPP), Rob McDowall, Michael Gray	Dr Cathy Hargrave, Allison Dry	Literature review and potential dosimetric impacts of metal artefact reduction methods for radiation therapy CT planning scans
Anthony Pagidas, Adrian Celati	Jemma Blyth, Michelle Grogan, Allison Dry, Catriona Hargrave	Retrospective Evaluation of breast seroma changes during radiation therapy & the dosimetric benefits of performing a repeat CT scan
Samuel Peet	Alex Livingstone, Kirby Francis	Dashboard web system for radiation oncology process recording
Kate Stewart	Molly Mee (QUT), Marika Lathouras, Helen Truong, Dr Catriona Hargrave	Evaluation of a Deformable Image Registration Quality Assurance Tool for Head and Neck patients in the MIM Maestro software
Kate Stewart	Tsz-Wun Pinky Tiu, Vickie Lightfoot, Catriona Hargrave	Comparison of Deformable and Rigid Image Registration of PETCT for Head and Neck patients in the MIM Maestro System
Steven Sylvander	Scott Crowe, Kirby Francis, Orrie Danciewicz (Nuc. Med), Tanya Kairn, Timothy Markwell (Mater Centre), Jamie Trapp (QUT)	Applications of 3D printing in radiation oncology medical physics
Helen Truong (SPP), Christopher Walsh, Richelle Hopkinson	Dr Cathy Hargrave, Allison Dry	Retrospective analysis of Catalyst reference image and radiographically defined radiotherapy treatment isocentres
Liting Yu	Scott Crowe, Tanya Kairn, Kirby Francis	Novel quality assurance metrics for radiotherapy dose verification measurements

2018 Collaborative Research Activity involving RBWH Research Group / Department

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Prof Stephen Ackland, (Calvary Mater Newcastle Hospital)	Mathew Burge (CCS MO), Graeme Dickie (CCS DRO)	A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer (SPAR)
Prof Sherene Loi (PMCC)	Robyn Cheuk (CCS DRO) Michelle Grogan (CCS DRO)	TROG 17.05 A randomised phase II trial comparing the efficacy of single fraction or multi-fraction SABR (Stereotactic ablative body radiotherapy) with Atezolizumab in patients with advanced Triple negative breast Cancer (AZTEC)
Michael D. Jenkinson PhD (University of Liverpool)	Catherine Bettington (CCS DRO)	ROAM – TROG 15.02 Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial
Dr Arjun Sahgal (CCTG)	Ben Chua (CCS DRO)	SC24: TD 17.06A Phase III Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) Versus Conventional Palliative Radiotherapy (CRT) For Patients With Spinal Metastases – S Siva and M Foote
Jamie Trapp (QUT)	Scott Crowe (CCS DRO) Tanya Kairn (CCS DRO)	Development of three-dimensional gel dosimetry solutions for radiation therapy
Jamie Trapp (QUT)	Scott Crowe (CCS DRO) Tanya Kairn (CCS DRO)	Investigation of issues surrounding small field dosimetry in radiation therapy
Jamie Trapp (QUT)	Scott Crowe (CCS DRO) Tanya Kairn (CCS DRO)	Evaluating dosimetry near non-water equivalent implants and prostheses
Vincent Grégoire (EORTC)	Liz Kenny (CCS DRO)	NIMORAL – TROG 14.03 (1219-ROG-HNCG) A blind randomized multicenter study of accelerated fractionated chemo-radiotherapy with or without the hypoxic cell radiosensitizer nimorazole (Nimoral), using a 15-gene signature for hypoxia in the treatment of squamous cell carcinoma of the head and neck
Danny Rischin (PMCC)	Liz Kenny (CCS DRO)	HPV - TROG 12.01 A randomised trial of Weekly Cetuximab And Radiation Versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma
Chamindie Punyadeera (QUT)	Liz Kenny (CCS DRO)	SPLIT Study A simple saliva test to diagnose head and neck cancer at an early stage – head and neck cancer detection is a spitting distance away
Prof Rajiv Khanna (QIMR)	Liz Kenny (CCS DRO)	P2191 Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies
Chamindie Punyadeera (QUT)	Liz Kenny (CCS DRO)	JNJ Saliva Study Developing an Oral Rinse Method to Detect Human Papillomavirus
David Pryor	Charles Lin (CCS DRO)	TROG 16.03: a multi stage multi centre international randomised trial of Conventional Care or Radioablation (stereotactic body radiotherapy) for Extra-cranial oligometastatic disease in lung, breast and prostate cancer (CORE)
Shankar Siva	Charles Lin (CCS DRO)	TROG 15.03 Focal Ablative STereotactic RADiosurgery for Cancers of the Kidney – a Phase II Clinical Trial (FASTRACK II)
Shankar Siva	Catherine Bettington (CCS DRO)	TROG 13.01 Stereotactic Ablative Fractionated Radiotherapy versus Radiosurgery for Oligometastatic Neoplasia to the Lung: a Randomised Phase II Trial (SAFRON II)
Scott Williams and Paul Nguyen (NHMRC)	Philip Chan (CCS DRO)	ENZARAD Randomised phase 3 trial of enzalutamide in androgen deprivation therapy with radiation therapy for high risk, clinically localised, prostate cancer
Kumar Gogna (RO Mater)	Catherine Bettington (CCS DRO)	SPLIT COURSE A single arm, prospective Phase II study of Split-Course Pelvic Radiotherapy for Locally Progressive, Castrate Resistant Prostate Cancer
Margot Lehman (PAH)	Philip Chan (CCS DRO)	P LUNG – TROG 11.03 A randomised phase III trial of High Dose Palliative Radiotherapy (HDPRT) versus concurrent Chemotherapy HDPRT (C-HDPRT) in patients with good performance status, locally advanced / small volume metastatic NSCLC not suitable for radical chemo-radiotherapy
Peter Graham (SGH)	Robyn Cheuk (CCS DRO)	STARS – TROG 08.06 A randomised comparison of anastrozole commenced before and continued during adjuvant radiotherapy for breast cancer versus anastrozole and subsequent anti-oestrogen therapy delayed until after radiotherapy. (STARS – Study of Anastrozole and Radiotherapy Sequencing)
Boon Chua (PMCC)	Liz Kenny (CCS DRO)	DCIS – TROG 07.01 A randomised phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast
L. Mileschkin (PMCC)	Robyn Cheuk (CCS DRO)	PORTEC – 3 – TROG 08.04 ANZGOG A Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma.
Maria Pearse (Auckland City Hospital)	Charles Lin (CCS DRO)	RAVES – TROG 08.03 Radiotherapy Adjuvant versus Early Salvage. A phase III multi-centre randomised trial comparing adjuvant radiotherapy (RT) with early salvage RT in patients with positive margins or extraprostatic disease following radical prostatectomy

2018 Collaborative Research Activity involving RBWH Research Group / Department (cont)

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Michael Poulsen (RO Mater)	Graeme Dickie (CCS DRO)	MP3 – TROG 09.03 A Phase II Efficacy Study of Chemo-radiotherapy in PET Stage II and III Merkel Cell Carcinoma of the Skin
Gail Ryan (PMCC)	Roger Allison (CCS DRO)	TROG 06.01 Primary chemotherapy with Temozolomide vs. Radiotherapy in patients with Low Grade Gliomas after stratification for genetic 1P loss: a phase III Study
Australasian Lung Cancer Trials Group	Brett Hughes (CCS), Phillip Chan (CCS)	NIVORAD – a randomised phase 2 trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy

2018 Research Awards and Achievements

Recipient	Award	Event
Rae Blades	Scholarship	2018 Research Postgraduate Scholarship – RBWH Foundation
Tanya Grant	Best SPP Paper: improving access to Culturally Safe Care in Radiotherapy for Indigenous Patients	ASMIRT Queensland RT Weekend MEETS Country AIR conference, 'Technology in the Tropics', 20-21 Oct 2018, Townsville

2018 Research Grants – Awarded

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Chamindie Punyadeera, Liz Kenny , Jean Paul Thiery, Brett Hughes, Majid Warkiani, Arutha Kulasinghe	CCS DRO, DMO	Circulating tumour cells: clinical applications in head and neck cancers	Cancer Australia	\$199,919	\$599,756 (2018-2020)
A/Prof Scott Crowe (CI), Dr. Graeme Dickie , Dr. Philip Chan , Dr. Catherine Bettington , Lee Heseltine , Steven Sylvander , A/Prof Tanya Kairn	CCS DRO	Improving radiation oncology via the application of 3D printing	MNHHS Program (Clinical / Resarch) for the Herston Biofabrication Institute	\$158,000	\$474,500 (2018-2021)
Chamindie Punyadeera, Liz Kenny , Chris Perry, Ken O'Byrne, Ian Vela, Arutha Kulasinghe	CCS DRO	Circulating tumour cells in head and neck cancer	Garnette Passe and Rodney Williams Memorial Foundation	\$119,994	\$239,988 (2018-2020)
Charles Lin	CCS DRO	A prospective study investigating the efficacy and toxicity of definitive chemoradiotherapy and immunotherapy (CRIO) in locally and/or regionally advanced cutaneous squamous cell carcinoma	Astra Zeneca	\$52,750	\$211,000.15 (2017-2021)
Marina Reeves, Sandra Hayes, Wendy Denmark-Wahnefried, Jennifer Muller, Elizabeth Eakin, Liz Kenny , Catherine Shannon	CCS DRO	Optimising Survivorship: a pilot study evaluating the feasibility, safety and preliminary efficacy of an exercise and dietary intervention for women with metastatic breast cancer	National Breast Cancer Foundation	\$99,918	\$197,179 (2017-2018)
Chamindie Punyadeera, Liz Kenny , Ken O'Byrne, Erik Thompson, Steve Mattarollo, Arutha Kulasinghe	CCS DRO	Circulating Tumour Cells as Biomarkers to Identify Head and Neck Cancer Patients For PD1 Therapy	Translational Research Unit (TRI) Spore Grant	\$40,000	\$80,000 (2017-2018)
Steven Sylvander	CCS DRO (Medical Physics)	Catalyst optical surface monitoring system	New Technology Grant	\$22,000	\$72,000 (2017-2018)
Graeme Dickie	CCS DRO	QCOG Cancer Clinical Trial Data Manager Grant	Queensland Clinical Oncology Group	\$68,000	\$68,000 (2018)

2018 Research Grants – Awarded (cont)

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Benjamin Chua , Bryan Day, Stephen Rose, Paul Thomas , Lindy Jeffree , Yi-Chieh Lim, Po-ling Inglis , Zarnie Lwin , Jacqui Keller	Radiation Oncology	Using molecular-guided PET/ MRI Using molecular-guided PET/ MRI imaging to target hypoxia in glioblastoma: a preclinical study to identify novel pathways and define molecular signatures associated with hypoxia and poor patient outcome	HIRF seed research funding	\$0	\$66,498 (2017-2019)
Lizbeth Kenny	Radiation Oncology	CXCR4 PET for nodal staging of resectable mucosal head and neck squamous cell carcinoma (HNSCC)	HIRF seed research funding	\$28,008.75	\$56,017.50 (2017-2019)
Samuel Peet	CCS DRO (Medical Physics)	Out-of-field dose in contemporary radiation therapy	RBWH Foundation	\$36,864	\$36,864 (2018)
Nancy Yu	CCS DRO (Medical Physics)	Developing new methods of dose evaluation for VMAT patient specific plans	RBWH Foundation	\$36,864	\$36,864 (2018)

2018 Research Publications

Journal Articles:

- Binny D, **Kairn T**, Lancaster CM, **Trapp JV**, **Crowe SB**. Photon Optimizer (PO) versus Progressive Resolution Optimizer (PRO): a conformality and complexity based comparison for Intensity Modulated Arc Therapy plans. Med Dosim 2018; 43;3:267-275. doi: 10.1016/j.meddos.2017.10.003
- Binny D, **Lancaster CM**, Byrne M, **Kairn T**, Trapp JV, **Crowe SB**. Tomotherapy treatment site specific planning using statistical process control. Physica Medica 2018; 53;32-39. doi: 10.1016/j.ejmp.2018.08.003
- Boase NRB, Smith S, Masters K-S, Hosokawa K, **Crowe S**, Trapp J. Xylenol orange functionalised polymers to overcome diffusion in Fricke gel radiation dosimeters. Reactive and Functional Polymers 2018;132;81-88. doi: 10.1016/j.reactfunctpolym.2018.09.011
- Chamunyonga C, Burberry J, Caldwell P, Rutledge P, Fielding A, **Crowe S**. Utilising the Virtual Environment for Radiotherapy Training system to support undergraduate teaching of IMRT, VMAT, DCAT treatment planning, and QA Concepts, Journal of Medical Imaging and Radiation Sciences 49(1): 31-38, 2018
- Crowe SB**, Pross Z, Nilsson S, **Dawes J**, **Kairn T**, **Lancaster CM**. Characterisation of the radiological properties of a brachytherapy moulding material. Australas. Phys. Eng. Sci. Med. 2018 Sep; 41;3:731-737. doi: 10.1007/s13246-018-0673-4
- Denham JW, Joseph D, Lamb DS, Spry NA, Duchesne G, Matthews J, Atkinson C, Tai KH, Christie D, **Kenny L**, Turner S, Gogna NK, Diamond T, Delahunt B, Oldmeadow C, Attia J, Steigler A. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial. Lancet Oncol. 2018 Dec 19. pii: S1470-2045(18)30757-5. doi: 10.1016/S1470-2045(18)30757-5. [Epub ahead of print]
- Diaz ME, Debowski M, Hukins C, Fielding D, Fong KM, **Bettington CS**. Non-small cell lung cancer brain metastasis screening in the era of positron emission tomography-CT staging: Current practice and outcomes. J Med Imaging Radiat Oncol. 2018 Jun;62(3):383-388. doi: 10.1111/1754-9485.12732. Epub 10 May 2018
- Kapeleris J, Kulasinghe A, Warkiani ME, Vela I, **Kenny L**, O'Byrne K, Punyadeera C. The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer. Front Oncol. 2018 Aug 14;8:311. doi: 10.3389/fonc.2018.00311
- Kulasinghe A, Kapeleris J, Kimberley R, Mattarollo SR, Thompson EW, Thiery JP, **Kenny L**, O'Byrne K, Punyadeera C. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer. Cancer Med. 2018 Dec;7(12):5910-5919. doi: 10.1002/cam4.1832. Epub 2018 Nov 22
- Kulasinghe A, Schmidt H, Perry C, Whitfield B, **Kenny L**, Nelson C, Warkiani ME, Punyadeera C. A Collective Route to Head and Neck Cancer Metastasis. Sci Rep. 2018 Jan 15;8(1):746. doi: 10.1038/s41598-017-19117-9
- Lim Y, Fukuma N, Totsika M, **Kenny L**, Morrison M, Punyadeera C. The Performance of an Oral Microbiome Biomarker Panel in Predicting Oral Cavity and Oropharyngeal Cancers. Front Cell Infect Microbiol. 2018 Aug 3;8:267. doi: 10.3389/fcimb.2018.00267
- Liu T, **Chua B**, Batstone M. Post-Operative Radiotherapy for Oral SCC with Histologic Risk Factors: Are We Over-Treating?, J Oral Maxillofac Surg. 2018 Jul;76(7):1565-1570. doi: 10.1016/j.joms.2018.01.014. Epub 2018 Jan 31
- Moroney LB, Helios J, Ward EC, Crombie J, Pelecanos A, Burns CL, Spurgin AL, Blake C, **Kenny L**, **Chua B**, Hughes BGM. Helical IMRT with concurrent chemotherapy for oropharyngeal SCC: A prospective investigation of acute swallowing and toxicity patterns. Head Neck. 2018 Sep;40(9):1955-1966. doi: 10.1002/hed.25182. Epub 2018 May 13
- Nair S, Tang KD, **Kenny L**, Punyadeera C. Salivary exosomes as potential biomarkers in cancer. Oral Oncol. 2018 Sep;84:31-40. doi: 10.1016/j.oraloncology.2018.07.001. Epub 2018 Jul 13
- Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, **Kenny L**, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D. Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: the Randomized Phase III TROG 05.01 Trial. J Clin Oncol. 2018 May 1;36(13):1275-1283. doi: 10.1200/JCO.2017.77.0941. Epub 2018 Mar 14

Journal Articles (cont):

16. Poulsen M, Macfarlane D, Veness M, Estall V, Hruby G, Kumar M, Pullar A, **Tripcony L**, Rischin D. Prospective analysis of the utility of 18-FDG PET in Merkel cell carcinoma of the skin: a Trans Tasman Radiation Oncology Group Study, TROG 09:03. *J Med Imaging Radiat Oncol*. 2018 Jun;62(3):412-419. doi: 10.1111/1754-9485.12705. Epub 2018 Feb 5
17. Rijken J, Jordan B, **Crowe S**, **Kairn T**, Trapp J. Improving accuracy for stereotactic ablative radiotherapy treatments of spinal metastases. *J App Clin Med Phys* 2018 Sep; 19;5:453-462. doi: 10.1002/acm2.12395
18. Rijken J, **Kairn T**, **Crowe S**, Muñoz L, Trapp J. A simple method to account for skin dose enhancement during treatment planning of VMAT treatments of patients in contact with immobilisation equipment. *J App Clin Med Phys* 2018; 19;4:239-245. doi: 10.1002/acm2.12394
19. Schmidt H, Kulasinghe A, Allcock RJN, Tan LY, Mokany E, **Kenny L**, Punyadeera C. A Pilot Study to Non-Invasively Track PIK3CA Mutation in Head and Neck Cancer. *Diagnostics (Basel)*. 2018 Nov 29;8(4)
20. Shanker M, **Chua B**, **Bettington C**, Foote M, Pinkham M. Re-irradiation for recurrent high-grade gliomas: a systematic review and analysis of treatment technique with respect to survival and risk of radionecrosis. *Neuro-Oncology Practice*, doi: 10.1093, 14 June 2018
21. Spelleken E, **Crowe SB**, Sutherland B, Challens C, **Kairn T**, Accuracy and efficiency of published film dosimetry techniques using a flat-bed scanner and EBT3 film, *Australasian Physical and Engineering Sciences in Medicine* 41(1): 117-128, 2018
22. Tang KD, **Kenny L**, Frazer IH, Punyadeera C. High-risk human papillomavirus detection in oropharyngeal cancers: comparison of saliva sampling methods. *Head Neck*. 2018 Dec 23. doi: 10.1002/hed.25578. [Epub ahead of print]
23. Vasani SS, Youssef D, **Lin C**, Wellham A, Hodge R. Defining the low-risk salvage laryngectomy – a single-center retrospective analysis of pharyngocutaneous fistula. *Laryngoscope Investig Otolaryngol*. 2018 Mar 23;3(2):115-120. doi: 10.1002/lio2.144. eCollection 2018 Apr.

Book Chapters / Letters:

1. **Kairn T**. Patient rotation during linac-based photon and electron radiotherapy. *J Med Imag Radiat Oncol*. 2018 Aug; 62;4:548-552. doi: 10.1111/1754-9485.12757.

2018 Conference Presentations – Invited Speaker, Oral and Poster

Invited Speaker:

1. **Kairn T**. Sharing clinical medical physics work via the scientific literature. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October, 2018
2. **Kairn T**. The pros, cons, implications and future exploration needed in novel patient rotation systems for radiation therapy. Australian MR in Radiotherapy Meeting, Wollongong, Australia, November 2018
3. **Kenny L**. Radiation Oncology and Interventional Oncology: a Marriage Made in Heaven. Radiological Society of North America (RSNA), Chicago. November 2018
4. **Kenny L**. Interventional Oncology. Royal Australian and New Zealand College of Radiologists (RANZCR). Canberra, Australia. October 2018
5. **Kenny L**. Oration at UQ School of Medicine, Brisbane, Australia. December 2018
6. **Kenny L**. The impact of quality assurance on cancer outcomes: why IASIOS is necessary Cardiovascular and Interventional Radiological Society of Europe (CIRSE). Lisbon, Portugal. September 2018
7. **Kenny, L**. IO or SBRT: When and where. European Congress of Interventional Oncology (ECIO) Vienna, Austria, April 2018
8. **Kenny, L**. SABR, Conventional Radiotherapy or nothing at all – which choice when. European Congress of Interventional Oncology (ECIO) Vienna, Austria, April 2018
9. **Kenny L**. Quality Assurance in Interventional Oncology: It's not just about the kit". Asian Pacific Congress of Cardiovascular and Interventional Oncology. Auckland New Zealand. 10 March 2018.

Oral Presentations:

1. Binny D, **Lancaster CM**, Byrne M, **Kairn T**, Trapp JV, **Crowe JB**. Investigating effects of planned MLC distribution on tomotherapy delivery using Statistical Process Control. Accuray Symposium, Brisbane Australia, May 2018
2. Binny D, **Lancaster CM**, **Kairn T**, Trapp JV, **Crowe JB**. Radiotherapy quality assurance using statistical process control. World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
3. **Chua B**, Dowthwaite S, Panizza B, O'Neill J, Porceddu S, Jackson J. Primary trans-oral surgery and risk adapted radiotherapy for early tonsillar SCC. ANZHNCS ISMR Joint Meeting to be held in Melbourne, Australia, 26-28 July 2018
4. **Crowe S**. The performance of metal artefact reduction algorithms, in comparison to Megavoltage CT imaging. Accuray Symposium, Brisbane Australia, May 2018
5. **Crowe SB**, **Dick A**, **Livingstone A**, **Kairn T**, **Sylvander SR**. Observations made while commissioning a Womed T300 superficial unit using ACPSEM working group recommendations. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
6. **Crowe SB**, **Sylvander S**, **Kairn T**. Radiotherapy dose measurements using a fluorescing quinine solution. World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
7. **Crowe SB**, Whittle E, Jones C, **Kairn T**. Measurement of tissue-maximum ratio and percentage depth-dose profiles in small fields. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
8. **Devereaux J**. Inspiring Spirometry – The Royal Experience. CEC Breast Seminar, Spirometer PAH Russell Strong Auditorium, 24 March 2018
9. **Devereaux J**. Inspiring Spirometry – The Royal DIBH Experience. RBWH Symposium, RBWH Education Centre, 10-13 September 2018.
10. **Dickie G**. How do you assess an optimal plan? Accuray Symposium, Brisbane Australia, May 2018
11. **Dry A**. TSETS: Total Skin Electron Therapy: RBWH Experience, Qld. Continuing Education Committee (CEC), Russell Strong Auditorium, PAH, 21 July 2018

Oral Presentations: (cont):

12. **Dry A.** Preparing for Interviews: Expectations. Qld. Early Careers Seminar, Des O'Callaghan Auditorium, Mater, Raymond Terrace, 28 July 2018
13. **Dry A.** Overview of Radiation Therapy with Breast Case Study: psych-social implications. Qld Cancer Council, Gregory Terrace, 5 September 2018
14. **Dry A.** Overview of Radiotherapy. CIRCS Supporting the Cancer Patient with their oral health forum, Brisbane Australia, June 2018
15. **Grant T (SPP).** Improving access to Culturally Safe Care in Radiotherapy for Indigenous Patients: Where Are We Now? ASMIRT Queensland RT Weekend MEETS Country AIR conference, Technology in the Tropics, Townsville, 20-21 October 2018
16. **Grant T (SPP).** Improving access to Culturally Safe Care in Radiotherapy for Indigenous Patients: Where Are We Now? Qld Continuing Education Committee (CEC), Grab Your Soapbox. Princess Alexandra Hospital, 10 November 2018
17. **Grant T, Nguyen H.** Generating the abscopal effect with Radiation Therapy and checkpoint inhibitor immunotherapy. ASMIRT, Canberra, 15 March 2018
18. **Kairn T, Crowe SB, Peet SC.** Linac leakage dose received by patients treated using non-coplanar radiotherapy beams. World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
19. **Kairn T.** Suitability of vendor-recommended small field output factors in a post-TRS-483 world. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
20. **Kairn T, Yu L, Wilks R, Lancaster C, Crowe SB.** In vivo measurements of skin dose from total skin electron therapy treatments. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
21. **Meaghan J (SPP).** Contrast-Enhanced CT and Dual-Energy CT for Radiotherapy Patients, ASMIRT Queensland RT Weekend MEETS Country AIR conference, Technology in the Tropics, Townsville, 20-21 October 2018
22. **Meaghan J (SPP).** Contrast-Enhanced CT and Dual-Energy CT for Radiotherapy Patients, Qld Continuing Education Committee (CEC), Grab Your Soapbox, Princess Alexandra Hospital, 10 November 2018
23. **Miller K (SPP).** Quality Improvement Project Investigating Potential Dosimetric Impacts of Metal Artefact Reduction Methods, ASMIRT Queensland RT Weekend MEETS Country AIR conference, Technology in the Tropics, Townsville, 20-21 October 2018
24. **Miller K (SPP).** Quality Improvement Project Investigating Potential Dosimetric Impacts of Metal Artefact Reduction Methods, Qld Continuing Education Committee (CEC), Grab Your Soapbox, Princess Alexandra Hospital, 10 November 2018
25. **Lancaster C.** Level III audits of TomoTherapy systems. Accuray Symposium, Brisbane Australia, May 2018
26. **Lathouras M.** Is TomoTherapy a viable option for treating Breast Cancer? Accuray Symposium, Brisbane Australia, May 2018
27. **McCoola B.** Improving Outcomes in Radiation Therapy: Proven Practices in paediatrics applied to other patient groups. CAHRLI, Shining Lights Symposium, Brisbane Australia, June 2018
28. **McCoola B.** AYA (Adolescent and Young Adults) You Can Centre (Sony Foundation). State-wide Research and Development Radiation Therapy Video Conference, 9 July 2018
29. **Milewski C, Peet SC, Sylvander SR, Crowe SB, Kairn T.** Optimising a radiotherapy optical surface monitoring system to account for the effects of patient skin contour and skin colour. World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
30. **Milewski C, Wilks R, Kairn T, Crowe S.** The performance of metal artefact reduction algorithms, in comparison to megavoltage CT imaging. Accuray Symposium, Sofitel Brisbane Central, Brisbane, Australia, June 2018
31. **Pagidas A.** Radiation Therapy for Nasopharyngeal Carcinoma using Accuray TomoTherapy at the Royal Brisbane and Women's Hospital. Accuray Symposium, Brisbane Australia, May 2018
32. **Peet S, Kairn T, Lancaster C, Sylvander S, Trapp J, Crowe S.** Evaluating foetal dose in TomoTherapy treatments, Accuray Symposium, Brisbane Australia, May 2018
33. **Rattray G.** Now and Then: a review of the impact of introducing Tomotherapy at RBWH. Accuray Symposium, Brisbane Australia, May 2018
34. **Rijken J, Kairn T, Crowe S, Trapp J.** Optimal treatment planning conditions for SBRT of spinal and lung tumours. Asia-Oceania Congress of Medical Physics, Kuala Lumpur, Malaysia, 2018
35. **Shanker M, Chua B, Pinkham M, Bettington C.** Re-irradiation in recurrent high grade gliomas: an analysis of survival and radionecrosis outcomes. ESTRO, Barcelona Spain, April 2018
36. **Shaw T, Jeffery RL, Thomas P, Goodman S, Debowski M, Lwin Z, Chua B.** Diagnostic Performance of FDG-PET/CT in the Evaluation of Glioma. 11th COGNO Annual Scientific Meeting (ASM), Targeting survival: living well with brain cancer in the era of precision treatments. Brisbane, Australia, 7-9 October 2018
37. **Sylvander S.** Evaluating foetal dose in TomoTherapy treatments. Accuray Symposium, Brisbane Australia, May 2018
38. **Truong H (SPP).** It's What's on the Surface That Counts, ASMIRT Queensland RT Weekend MEETS Country AIR conference, Technology in the Tropics, Townsville, 20-21 October 2018
39. **Truong H (SPP).** It's What's on the Surface That Counts Qld Continuing Education Committee (CEC), Grab Your Soapbox, Princess Alexandra Hospital, 10 November 2018
40. **Walsh C.** Catalyst Surface Guided Radiation Therapy vs Image Guided Radiation Therapy for breast patients, CEC Breast Seminar, PAH Russell Strong Auditorium, 24 March 2018
41. **Walsh C.** Catalyst: Surface Guided Radiotherapy for DIBH Breast Treatments. RBWH Symposium, RBWH Education Centre 10-13 September 2018
42. **Yu L, Kairn T, Crowe SB.** Retrospective audit of patient specific quality assurance results obtained using helical diode arrays, World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018.

Poster Presentations:

1. **Cassim N**, Biggerstaff K, Ikeda Y, Skidmore C, **Wilks R**, **Crowe SB**, **Kairn T**. Level III audit of two stereotactic radiosurgery treatment planning and delivery systems. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
2. **Crowe SB**, **Kairn T**. Calibration seed sampling for iodine-125 prostate brachytherapy. World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
3. **Kairn T**, **Crowe SB**. Application of data mining to clinical protocol design: Are breath-hold techniques beneficial for prone breast radiotherapy patients? (ePoster), World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
4. **Kairn T**, **Crowe SB**. Development of an experience-based end-to-end test. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
5. **Kairn T**, **Crowe SB**. Producing inserts for a commercial motion phantom using 3D printing. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
6. **Kairn T**, Ikeda Y, Schlect D, **Crowe SB**. Retrospective review of brain dose from stereotactic radiosurgery treatments of brain oligometastases. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
7. **Kairn T**, **Peet SC**, **Yu L**, **Crowe SB**. Long-term reliability of optically stimulated luminescence dosimeters (ePoster), World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
8. **Kairn T**, **Stephens H**, **Crowe SB**, **Peet S**. Optically stimulated luminescence dosimeters as an alternative to radiographic film for performing head-wrap linac leakage measurements (ePoster), World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018
9. Ratnayake G, Shankar M, Roberts K, Mason R, Hughes BGM, Lwin Z, Jain V, O'Byrne KJ, **Chua B**. Prior or Concurrent Radiotherapy and Nivolumab Immunotherapy in Non-Small Cell Lung Cancer. ESMO 2018 Congress, Munich, Germany, 19-23 October 2018
10. Stephens S, Kuchelb A, **Cheuk R**, Alexander H, Robertson T, Rajah T, Tran Q, Inglis P. Pineal germinoma: a 13-year Queensland experience. Cooperative trials group for neuro-oncology (COGNO) ASM, Sydney, Australia, 27-28 October 2018
11. Whittle E, **Crowe S**, Khoei S, Spelleken E, **Kairn T**. Conversion of PDDs to TMRs for small radiotherapy fields. Engineering and Physical Sciences in Medicine, Adelaide, Australia, October 2018
12. Zolfaghari S, **Crowe SB**, Papworth D, West M, **Kairn T**. Stereotactic radiosurgery for multiple brain metastases: a dose-volume study (ePoster), World Congress on Medical Physics and Biomedical Engineering, Prague, Czech Republic, June 2018.

Other Communications and Outputs:

'Cancer Preceptorship for Primary Health Care Providers', 21st July 2018. **A Dry; C Walsh; J Devereaux; D Bryant; M Lathouras; J Outhwaite; K Miller; J Meaghan; H Truong.**

Catalyst article in Cancer Care News: **J Blyth.**

Haemophilia Centre



Dr Jane Mason
A/Director Haemophilia
Cancer Care Services RBWH

The Queensland Haemophilia Centre (QHC) has a strong focus on collaborative research, both with other departments within RBWH and with Haemophilia Centres nationally through the framework of the Australian Haemophilia Centre Directors Organisation (AHCDO). The QHC is also actively involved in global pharmaceutical sponsored multicentre clinical trials examining novel haemophilia therapies. In 2018, we were an active site in a multicentre phase 3 randomised trial evaluating a longer acting intravenous factor VIII therapy (Adynovate) and a multicentre phase 3 study evaluating the efficacy of a factor VIII mimetic (Emicizumab) given via monthly subcutaneous injection.

QHC staff contributed data and wrote the manuscript for the national study of factor VIII and factor IX prophylaxis in severe and moderate haemophilia A and B, an AHCDO collaborative project which represented the first major publication to come out of the Australian Bleeding Disorders Registry (ABDR).

We completed a retrospective study evaluating our local “fixed dose subcutaneous DDAVP” protocol for patients with mild Haemophilia A. This project demonstrated adequate factor VIII responses for this administration protocol. These local data were shared with the AHCDO group and have led to the commencement of a national collaborative multi-site project comparing DDAVP responses to fixed subcutaneous DDAVP dosing to historic intravenous protocols (aimed to be completed in early 2019).

The QHC established an “Acquired Haemophilia A” state wide working group and entered detailed clinical data in the Australian Bleeding Disorders Registry (ABDR) for all patients in QLD with Acquired Haemophilia A diagnosed over the previous 5-year period. This case series is one of the largest of its kind and provided important insight into the demographic, clinical features and patient outcomes of this very rare and challenging disease.

The QHC participated in a collaborative project lead by the RBWH Orthopaedic Department which was published in July 2018 and demonstrated a good functional outcome and high patient satisfaction in total hip and knee arthroplasty procedures in Haemophilia patients carried out at RBWH over a 20-year period with use of our local haemostatic protocols. These data are useful to effectively counsel our patients with haemophilic arthropathy of the risks, benefits and likely functional outcome of these major orthopaedic procedures.



2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Jane Mason	Stewart Hunt, John Casey, Joel Collins, Jason Conn, Joshua Richmond, Tzu Yang Wang, Matthew Hourigan, Anthony Mills, Jane Royle	Acquired Haemophilia A: 5 years of Queensland experience
Jane Mason	Beryl Zeissink, Alex Connolly, Simon McRae, Jacoba von Wielligh, John Rowell	Does a fixed “single vial” dose of 15 micrograms of subcutaneous desmopressin (SC-DDAVP) produce adequate biologic responses for persons with mild haemophilia A?

2018 Collaborative Research Activity involving RBWH Research Group / Department

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Sponsor: Hoffmann-La Roche	John Rowell, Beryl Zeissink, Jane Mason, Alex Connolly	A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Emicizumab Given Every 4 Weeks in Participants With Hemophilia A (HAVEN 4)
Sponsor: Shire	John Rowell, Beryl Zeissink, Jane Mason, Alex Connolly	Phase 3, Prospective, Randomized, Multi-center Clinical Study Comparing the Safety and Efficacy of BAX 855 Following PK-guided Prophylaxis Targeting Two Different FVIII Trough Levels in Subjects With Severe Hemophilia A

2018 Research Publications

Journal Articles:

1. **Mason JA**, Aung HT, Nandini A, Woods RG, Fairbairn DJ, **Rowell JA**, et al. Demonstration of a novel Xp22.2 microdeletion as the cause of familial extreme skewing of X-inactivation utilizing case-parent trio SNP microarray analysis. *Molecular genetics & genomic medicine*. 2018;6(3):357-69
2. **Mason JA**, Parikh S, Tran H, **Rowell J**, McRae S. Australian multicentre study of current real-world prophylaxis practice in severe and moderate haemophilia A and B. *Haemophilia*. 2018;24(2):253-60
3. **Mediawake H**, Robertson J, Beggs J, **Mason J**. Anaphylaxis Following Human Prothrombin Complex Concentrate in a Child with Lupus Anticoagulant Hypoprothrombinemia Syndrome: a Cautionary Tale. *TH Open*. 2018;02(01): e25-e7
4. **Anderson JA**, **Mason JA**, **Halliday B**. Clinical outcomes and patient satisfaction following total hip and knee arthroplasty in patients with inherited bleeding disorders: a 20-year single-surgeon cohort. *Haemophilia*. 2018;24(5):786-91.

2018 Conference Presentations – Invited Speaker, Oral and Poster

Invited Speaker:

1. **Mason JA**. Acquired Haemophilia A: 5 years of Queensland Experience. *Blood*. 2018. Brisbane.



Allied Health Professions – Research related to Cancer Care Services



Dr Clare Burns
Advanced Speech Pathologist
Speech Pathology Department
Allied Health Services

Allied Health Professions have continued to lead and actively contribute to Cancer Care Services research in 2018. Our program of research is diverse, incorporating multidisciplinary teams within the streams of Radiation Oncology, Medical Oncology, Haematology/BMT. Our research has continued to be patient-focused, covering the continuum of survivorship from pre-treatment, during treatment, recovery and rehabilitation, and beyond. Examining outcomes through a patient, carer, and health service lens, we have developed and evaluated new and innovative practices and service delivery models delivering improved patient care and service benefits.

During 2018, we have continued to maintain and develop new research collaborations within RBWH, Queensland Health and external departments incorporating leading academic and clinical research centres across Australia. Our research has been funded through grants and scholarships from RBWH Foundation and Allied Health Practitioner Research Scheme and key achievements for this year include prizes to Claire Blake (Leadership in Education), Laura Moroney (CAHRLI New Researcher Award), and Dr Clare Burns and Speech Pathology Led Telehealth Service (Metro North Research Excellence Award).

Finally, Allied Health Professions have demonstrated their ongoing commitment to building research capacity and capability throughout 2018 with senior staff actively supporting and supervising a growing number of research higher degree students. As many of these students are also RBWH clinical staff, it enables opportunity for direct translation of these research outcomes within Cancer Care Services.

Supervised Post-Graduate Research Students

Name (RBWH staff in bold)	Current Studies (e.g. PhD, Masters etc.) University (duration)	Research Project Title	Supervisors (RBWH staff in bold)
Emilie Croisier	PhD, UQ (2018-2021)	Nutritional outcomes of gynaecology patients undergoing pelvic radiotherapy: understanding the patient experience and dietary recommendations for symptom management	Judy Bauer, Teresa Brown
Joanne Hiatt	PhD, UQ (2017-2023)	Nutrition throughout head and neck cancer treatment: patient experience and adherence, barriers and enablers to enteral feeding recommendations	Merrilyn Banks, Teresa Brown , Judy Bauer
Sarah Andersen	PhD, UQ (2015-2019)	Investigating nutrition support during allogeneic stem cell transplantation	Judy Bauer, Merrilyn Banks , Olivia Wright
Laura Moroney	PhD, UQ (2015-2019)	Dysphagia and related toxicities in head and neck patients undergoing Helical Intensity Modulated Radiotherapy (H-IMRT) +/- chemotherapy	Liz Ward, Jane Crombie, Clare Burns
Sarah Wilson	MPhil, UQ (2018-2022)	Assessment of dysphagia following laryngectomy	Bena Cartmill, Clare Burns
Jasmine Foley	PhD, UQ (2018-2021)	A statewide model for enhanced access to speech pathology specialist outpatient services for patients following head and neck cancer care	Liz Ward, Clare Burns , Rebecca Nund, Laurelie Wall

2018 Research Positions: Coordinators, Fellow, Adjunct and Honorary Positions

Name	Type of Fellowship	Research Program	University (years)
Teresa Brown	Research Coordinator, Associate Lecturer	Nutrition in cancer care	University of Queensland (2018-current)
Clare Burns	Honorary Lecturer	School of Health and Rehabilitation Sciences	University of Queensland (2017-current)
Maree Grier	Adjunct Lecturer	School of Psychology	University of Queensland (2018-current)

2018 Current RBWH Research Group / Department Led Research Activity

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Robyn Scheer	Nicole Andrews, Erin Molloy	The effect of limb position on leg circumference measurements in patients diagnosed with lower limb lymphoedema
Robyn Scheer		The Lymphoedema Arm Measurement Study – Winter vs Summer
Claire Blake	Teresa Brown, Rainbow Lai (UQ), Laura Moroney (SP), Jennifer Helios (SP), Brett Hughes (Cancer Care), Liz Kenny (Cancer Care), Anita Pelecanos (QIMR), Judy Bauer (UQ)	Nutrition outcomes and toxicities from tomotherapy in head and neck cancer patients
Claire Blake	Teresa Brown, Laura Moroney (SP), Jennifer Helios (SP), Brett Hughes (Cancer Care), Liz Kenny (Cancer Care), Anita Pelecanos (QIMR)	Enteral Nutrition outcomes and toxicities from tomotherapy in head and neck cancer patients
Claire Blake	Merrilyn Banks, Mark Appleyard (Gastroenterology)	Cost effectiveness of Dietitian-led PEG service
Claire Blake	Teresa Brown	Evaluation of pre-treatment model of care in patients with head and neck cancer
Claire Blake	Elise Treleaven, Ally di Bella, Teresa Brown, Adrienne Young, Jenni Leutenegger (Cancer Care), David Wyld (Cancer Care)	Implementation of patient-led malnutrition screening in the cancer care ambulatory setting
Joanne Hiatt	Teresa Brown, Merrilyn Banks, Judy Bauer (UQ)	Patient Experience of Nutrition Care across three treatment modalities for the management of head and neck cancer
Sarah Andersen	Merrilyn Banks, Glen Kennedy (Cancer Care), Teresa Brown, Nicholas Weber (Cancer Care), Judy Bauer (UQ)	Does early proactive enteral nutrition improve outcomes post allogeneic stem cell transplantation – a randomized comparison to standard care
Sarah Andersen	Merrilyn Banks, Glen Kennedy (Cancer Care), Teresa Brown, Nicholas Weber (Cancer Care), Judy Bauer (UQ)	Investigating the effect of enteral and parenteral nutrition on the gastrointestinal microbiome post allogeneic transplantation
Sarah Andersen	Merrilyn Banks, Glen Kennedy (Cancer Care), Teresa Brown, Nicholas Weber (Cancer Care), Judy Bauer (UQ)	Staff perceptions, barriers and enablers to enteral feeding during allogeneic stem cell transplantation
Sarah Andersen	Merrilyn Banks, Glen Kennedy (Cancer Care), Teresa Brown, Nicholas Weber (Cancer Care), Judy Bauer (UQ)	Nutrition support during allogeneic transplantation in Australian adult bone marrow transplantation units
Sarah Andersen	Madison Jefferis (UQ), Cameron Curley (Cancer Care), Teresa Brown, Judy Bauer (UQ)	Investigating the effect of malnutrition on clinical outcomes post allogeneic stem cell transplantation
Teresa Brown	Aaron Chan (UQ), Kathleen Dwyer, Merrilyn Banks, Brett Hughes (Cancer Care), Judy Bauer (UQ), Charles Lin (Cancer Care), Liz Kenny (Cancer Care), Jane Crombie (Speech Path), Ann-Louise Spurgin (Speech Path)	Revalidation of swallow and nutrition guidelines in tomotherapy
Teresa Brown	Ray Chan (PAH), Angela Byrnes, Rebecca Fichera, Alex Molassiotis (Hong Kong), Patsy Yates (QUT), Gillian Nasato (Cancer Care), Elise Button (Cancer Care), Andrea Marshall (Griffith), Liz Isenring (Bond University), David Wyld (Cancer Care), Melissa Eastgate (Cancer Care) Nicole Gavin (Cancer Care)	A patient-family-centred intervention to promote nutrition in advanced cancer patients: a pilot randomised controlled trial
Teresa Brown	Louise Cooney (PAH), Louise Elvin-Walsh (PAH), Eliza Kern, Suzie Ahern, David Smith (QIMR), Liz Kenny (Cancer Care), Brett Hughes (Cancer Care), Sandro Porceddu (PAH), Ingrid Hickman (PAH), Bena Cartmill (PAH)	Comparison of nutrition and clinical outcomes in H&N cancer patients following reactive and proactive nutrition support approaches
Emilie Croisier	Teresa Brown, Judy Bauer (UQ), Philip Chan (Cancer Care), Jeff Goh (Cancer Care), Alice Grigg (Cancer Care)	Retrospective observational cohort study to assess the clinical and nutritional outcomes of gynae-oncology patients undergoing pelvic radiotherapy
Laura Moroney	Elizabeth Ward (UQ), Jane Crombie, Jennifer Helios, Clare Burns, Ann-Louise Spurgin, Liz Kenny Brett Hughes (Cancer Care), Clare Blake	Dysphagia and related toxicities in head and neck patients undergoing Helical Intensity Modulated Radiotherapy (H-IMRT) +/- chemotherapy
Laura Moroney	Laura Moroney, Jennifer Helios, Elizabeth Ward (UQ), Jane Crombie, Anita Pelecanos (QIMR), Clare Burns, Ann-Louise Spurgin, Claire Blake, Liz Kenny (Cancer Care), Ben Chua, Brett Hughes (Cancer Care), Tracy Comans (UQ)	Implementation of the Head and Neck Cancer Low Risk Speech Pathology Pathway

2018 Current RBWH Research Group / Department Led Research Activity (cont)

RBWH Research Group/Department Lead Researchers	Collaborative Researchers	Research Project Title
Clare Burns	Elizabeth Ward (UQ), Claire Blake , Liz Kenny (Cancer Care) , Rachael Villiers (CQHHS), Mia Hemingbrough, Tracy Comans (UQ), Kerrie-Anne Frakes (CQHHS), Phil Greenup (QH)	Implementation of a telepractice service providing specialist swallowing, nutrition, and communication intervention for patients with head and neck cancer
Leonie Naumann	Jennifer Paratz , Hildegard Reul-Hirche , Michelle Cottrell , Clare Burns , Anna Finnane, Tracy Comans, Trevor Russell	A telehealth model for education and monitoring of early lymphoedema detection and shoulder dysfunction in patients after breast cancer surgery: a pilot cohort study

2018 Collaborative Research Activity involving RBWH Research Group / Department

Collaborative Lead Researchers	RBWH Researchers	Research Project Title
Judy Bauer (UQ)	Teresa Brown , Merrilyn Banks , Brett Hughes (Cancer Care), Charles Lin (Cancer care), Liz Kenny (Cancer Care), Louise Campbell (Qld PET Service)	Comparison of body composition methods in head and neck cancer patients undergoing chemoradiotherapy – PET-CT vs BIA
Melissa Eastgate (Cancer Care)	Shu Fen Lee (Cancer Care), David Wyld (Cancer Care), Teresa Brown	Patient perceptions of diet and cancer – survey of cancer care patients
Nicole Gavin (Cancer Care)	Glen Kennedy (Cancer Care), David Patterson (Infectious Diseases), Claire Rickard (Griffith Uni), Sarah Andersen , Elise Button (Cancer Care), Rebecca Lippiatt (Cancer Care)	Exploring changes in gastrointestinal tract microbiome and their influence on mucosal barrier injury laboratory confirmed bloodstream infection in patients diagnosed with high risk features of acute myeloid leukaemia
Nicole Gavin (Cancer Care)	Glen Kennedy (Cancer Care), Claire Rickard (Griffith Uni), Patrick Harris (UQ), Sarah Andersen , Elise Button (Cancer Care), Rebecca Lippiatt (Cancer Care)	Improving central-line associated bloodstream infection diagnosis in malignant haematology patients with parenteral nutrition (Improving CLABSI Trial)
Nicole Kiss (Deakin University)	Anna Boltong (Cancer Council), Merran Findlay (RPA), Belinda Steer (Peter mac), Jenelle Loeliger (Peter Mac), Teresa Brown , Liz Isenring (Bond), Judy Bauer (UQ)	Australian cancer clinician's awareness, perceptions and practices regarding to cancer-related malnutrition and sarcopenia
Haryana Dhillon (University of Sydney), Joanne Shaw (University of Sydney), David Kissane (Monash University), Danette Langbecker (UQ), Kim Hobbs (Westmead Hospital), Laura Kirsten (Nepean Cancer Care Centre), Lisa Beatty (Flinders Centre for Innovation in Cancer), Lisa Vaccaro (University of Sydney), Carrie Lethborg (St Vincent's Hospital, Melbourne)	Maree Grier	Adjustment Working Group for the PoCoG Transforming Psychosocial Care of Patients in Australia: Implementation of a Comprehensive Training and Service Delivery Program

2018 Research Awards and Achievements

Recipient	Award	Event
Claire Blake	Leadership in Education	CAHRLI, 20 th June 2018
Shu Fen Lee, Melissa Eastgate, David Wyld, Teresa Brown	Best poster	2 nd Victorian Cancer Survivorship Conference, 8-9 th February, Melbourne
Clare Burns	The National Foundation of Swallowing Disorders Award	Dysphagia Research Society, Annual Scientific Meeting, 17 th March 2018
Clare Burns	Research Translation Award	Queensland Health Speech Pathology Advisory Committee Annual Awards September 2018
Clare Burns and Speech Pathology Led Telehealth Team	Highly Commended – Health Service and Implementation Research	MNHHS Research Excellence Awards, 22 nd May 2018
Laura Moroney	CAHRLI New Researcher Award	CAHRLI Symposium, 20 th June 2018

2018 Research Grants – Awarded

Investigators (RBWH staff in bold)	RBWH Research Groups/ Departments	Project Title	Granting Body	Amount in 2018	Total Amount (years)
Claire Blake, Ally di Bella, Teresa Brown, Adrienne Young , Jenni Leutenegger (Cancer Care), David Wyld (Cancer Care)	Nutrition and Dietetics; Cancer Care	Implementation of patient-led malnutrition screening in the cancer care ambulatory setting	RBWH Foundation Diamond Grant	\$20,000	\$40,000 (2018-2019)
Joanne Hiatt	Nutrition and Dietetics	Nutrition throughout head and neck cancer treatment: patient experience and adherence, barriers and enablers to enteral feeding recommendations	RBWH Scholarship	\$36,864	\$36,864 (2018)
Ray Chan (Cancer Care), Alex Molassiotis (Hong Kong), Patsy Yates (QUT), Gillian Nasato (Cancer Care), Teresa Brown , Elise Button (Cancer Care), Andrea Marshall (Griffith), Liz Isenring (Bond University), David Wyld (Cancer Care), Melissa Eastgate (Cancer Care) Nicole Gavin (Cancer Care)	Cancer Care Services, Nutrition and Dietetics	A patient-family-centred intervention to promote nutrition in advanced cancer patients: a pilot randomised controlled trial	RBWH Foundation Diamond Care Grant	\$40,000	\$40,000 (2018)
Sarah Andersen	Nutrition and Dietetics	Does early proactive enteral nutrition improve outcomes post allogeneic stem cell transplantation – a randomized comparison to standard care	RBWH Scholarship	\$36,864	\$36,864 (2018)
Sarah Andersen	Nutrition and Dietetics	Energy expenditure in patients undergoing allogeneic stem cell transplant: are we feeding them enough?	RBWH PPTF Research and Training Capital Funding Grant	\$39,167	\$39,167 (2018)
Clare Burns	Speech Pathology, Nutrition and Dietetics, and Cancer Care	Implementation and evaluation of a telehealth service providing specialist speech pathology and nutrition and dietetics intervention for patients with head and neck cancer	Post-Doctoral Fellowship Grant - RBWH Research Foundation	\$40,000	\$40,000 (2018)
Laura Moroney	Speech Pathology and Cancer Care	Dysphagia outcomes in head and neck cancer patients undergoing tomotherapy	RBWH Foundation PhD Scholarship	\$36,864	\$36,864 (2018)
Leonie Naumann, Jennifer Paratz, Hildegard Reul-Hirche, Michelle Cottrell, Clare Burns , Anna Finnane (UQ), Tracy Comans(UQ), Trevor Russel (UQ)	Physiotherapy Department	A telehealth model for education and monitoring of early lymphoedema detection and shoulder dysfunction in patients after breast cancer surgery: a pilot cohort study	Health Practitioner Research Scheme	\$29,929	\$29,929 (2018/2019 FY)

2018 Research Publications

Journal Articles:

1. **Di Bella, A**, Blake, C, Young, A, Pelecanos, A, & Brown, T. (2018). Reliability of Patient-Led Screening with the Malnutrition Screening Tool: agreement between Patient and Health Care Professional Scores in the Cancer Care Ambulatory Setting. *Journal of the Academy of Nutrition and Dietetics*. doi: 10.1016/j.jand.2017.11.023
2. **Moroney, L. B**, Helios, J, Ward, E. C, Crombie, J, Pelecanos, A, Burns, C. L, Spurgin A. L, Blake, C., Kenny, L, Chua, B, Hughes, B. G. M. (2018). Helical intensity-modulated radiotherapy with concurrent chemotherapy for oropharyngeal squamous cell carcinoma: a prospective investigation of acute swallowing and toxicity patterns. *Head Neck*. doi: 10.1002/hed.25182
3. **Moroney, L. B**, Helios, J, Ward, E. C, Crombie, J, Burns, C. L, Yeo, S. Q, Pelecanos, A, Spurgin, A. L, Blake, C, Kenny, L, Chua, B, & Hughes, B. G. M. (2018). Radiotherapy for cutaneous head and neck cancer and parotid tumours: a prospective investigation of treatment-related acute swallowing and toxicity patterns. *Support Care Cancer*. doi:10.1007/s00520-018-4352-5
4. **Burns C** & Wall L. Using telepractice to support the management of Head and Neck Cancer: key considerations for speech-language pathology service planning, establishment, and evaluation. *Perspectives of the ASHA Special Interest Groups*, (2018) 2(13), 139-146. doi:10.1044/persp2.SIG13.139

Journal Articles (cont):

5. Steele M, Janda M, Vagenas D, Ward L, Cornish B, Box R, Gordon S, Matthews M, Poppitt S, Plank L, Yip W, Rowan A, **Reul-Hirche H, Obermair A**, Hayes S. Normative inter-limb impedance ratios: Implications for early diagnosis of uni- and bilateral, upper- and lower-limb lymphoedema. *Lymphatic Research and Biology*, (2018) Published Online: 2 Oct 2018 <https://doi.org/10.1089/lrb.2017.0082>
6. Gane EM, Steele ML, Janda M, Ward LC, **Reul-Hirche H**, Carter J, Quinn M, **Obermair A**, Hayes SC. The Prevalence, Incidence, and Quality-of-Life Impact of Lymphedema After Treatment for Vulvar or Vaginal Cancer. *Rehabilitation Oncology*, (2018) 36(1), 48-55. DOI: 10.1097/01.REO.0000000000000102.

2018 Conference Presentations – Invited Speaker, Oral and Poster

Invited Speaker:

1. **Andersen S**. Investigating Enteral Nutrition During Allogenic Stem Cell Transplantation. Australasian Society of Parenteral and Enteral Nutrition, Sydney, December 2018
2. **Burns C.L.** & Ward E.C. Application of Telepractice in Speech Pathology Management of Head and Neck Cancer. Webinar Series – Veterans Affairs, USA, December 2018.

Oral Presentations:

1. **Collins A, Burns C**, Ward E, Comans T, **Blake C**, Kenny L, Greenup P, Best D. Home based telehealth service for swallowing and nutritional management following head and neck cancer treatment. Speech Pathology Australia, Adelaide, 29th May 2018
2. **Fox, S**. It's a strange thing to say, that a disease like this could be empowering: a qualitative study of head and neck cancer survivors. University of Queensland Social Work Research and Practices Day Program, June 2018
3. **Fox, S**. Working with grief and loss: disrupting theory to make way for skills development. Australian and New Zealand Social Work and Welfare Education and Research (ANZSWER) Symposium, September 2018.

Poster Presentations:

1. **Andersen S**, Weber N, Kennedy G, **Brown T, Banks M**, Bauer J. Investigating tolerance and clinical outcomes of early enteral nutrition versus parenteral nutrition support during allogeneic transplantation. European Society for Blood and Marrow Transplantation, Lisbon, Portugal. March 2018
2. Lee SF, Eastgate M, Wyld D, **Brown T**. Dietary patterns and attitudes in cancer survivors. 2nd Victorian Cancer Survivorship Conference, February 2018
3. Dhillon HM, Vaccaro L, Langbecker D, Beatty L, **Grier M**, Hobbs K, Kirsten L, Kissane D & Shaw J. (2018). Prevalence and management of adjustment disorder in cancer patients, In: 20th World Congress of Psycho-Oncology, Hong Kong, (137-137). 29 October – 2 November 2018. Oxford, United Kingdom: John Wiley & Sons.